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Abstract 
For almost two decades it is claimed that cell-based therapies will 
revolutionize the field of medicine. Albeit major scientific breakthroughs that 
present cells as the active ingredient of a clinical therapy are succeeding each 
other at increasing speed, today only few of these research successes are able 
to materialise their full clinical potential and develop into a widely available 
commercial cell-based treatment. Besides the remaining scientific challenges 
(e.g. mechanisms of action), costly product development, and a complex 
regulatory and reimbursement landscape, it is hypothesised that the lack of 
automated, controlled and cost-effective production strategies forms a major 
hurdle towards a wide-spread clinical translation of cell based therapies. The 
objective of this work was therefore to create enabling tools and knowledge 
for monitored and controlled large-scale stem cell production, with the 
ultimate goal of facilitating the manufacturing process of qualitative and cost-
effective cell-based therapies. 
Flask-based cell expansion processes are currently still the gold standard 
culture vessels, despite the disadvantage of their limited scale-up and 
automation potential. In a first phase, the translation from flask-based cell 
production processes to a bioreactor-based process was investigated, without 
adversely influencing the quality of the cells. Two commercial large-scale 
bioreactor types were evaluated for their ability to produce qualitative batches 
of cells for an autologous cell-based advanced therapy medicinal product 
(ATMP) that is being developed for the treatment of large bone defects at the 
Prometheus (KU Leuven) lab. The first bioreactor that was evaluated was the 
Xpansion® Multiplate Bioreactor System from Pall Life Sciences in 
combination with the Ovizio iLine S imaging system. It was shown that the 
growth dynamics of the cells in the bioreactor closely matched the dynamics 
as observed in the standard flask. Both cultures resulted in the same cell 
density at the time of harvest (17 500 cells/cm2 in the 5.6 L bioreactor with a 
30 600 cm2 culture surface and 17 300 cells/cm2 in the tissue flasks with a 
175  cm2 culture surface).  
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The second scale-up study evaluated the Quantum® Cell Expansion System 
from Terumo BCT. This hollow fibre bioreactor was able to support 
expansion processes starting from very low cell seeding densities, therefore 
resulting in a more efficient expansion process compared to the standard 
flask-based process (average expansion factor of 16.4 in the bioreactor 
compared to 3.0 for the flasks). Both bioreactors were able to yield the 
clinical amount of cells (around 350 million human periosteum derived cells 
or hPDCs) required for the ATMP under development at Prometheus. After 
the bioreactor-based cell expansion processes, the cultured cells performed 
similarly to the cells from a standard flask in a standard set of in vitro and in 
vivo characterisation assays. Additionally, an interactive tool for the objective 
comparison of multiple cell expansion strategies was developed, based on a 
visualisation of 73 different cell expansion processes in 5 types of culture 
vessels for 7 different types of mesenchymal stem cells. 
In parallel to the bioreactor-based scale-up, this work investigated how data 
measured during these bioreactor processes can be utilised to non-invasively 
monitor critical process parameters in real-time, and then utilise this 
information for process control strategies that enable more informed process 
decisions, ultimately leading to an improved product quality. A monitoring 
strategy was developed for the quantification of the number of cells (as low as 
1 x 105 cells) in a perfusion bioreactor based on a data-based model on 
oxygen data from a single sensor under dynamic perfusion conditions. Also a 
real-time imaging-based monitoring strategy was developed for the 
determination of the ideal time to inhibit the enzymatic cell harvest reaction at 
the end of an expansion step in 2D culture vessels.  
In conclusion, this work shows that the scale-up of human periosteum derived 
progenitor cells for their use in a cell-based therapy is feasible by making use 
of automated bioreactor processes. Additionally, new methods were 
developed to monitor and control critical process parameters during bioreactor 
culture by making use of process data and data-based models.  
v 
 
 
 
Samenvatting 
Al ruim 20 jaar wordt beweerd dat cel-gebaseerde therapieën een revolutie 
zullen teweegbrengen op geneeskundig gebied. Hoewel de grote 
wetenschappelijke doorbraken die voorstellen om cellen als actief bestanddeel 
van een therapie te gebruiken elkaar steeds sneller opvolgen, slagen tot op 
vandaag slechts enkele van deze onderzoeksuccessen er in om hun volledig 
klinisch potentieel waar te maken en door te groeien tot een 
alomtegenwoordige commerciële cel gebaseerde behandeling. Naast de 
overige wetenschappelijke uitdagingen (bijvoorbeeld de exacte 
actiemechanismen), de dure productontwikkeling en de complexe situatie 
inzake regelgeving en terugbetalingen van cel-gebaseerde therapieën, wordt 
verondersteld dat het gebrek aan geautomatiseerde, gecontroleerde en kost-
effectieve productiestrategieën een belangrijke hindernis vormen voor de 
wijdverspreide klinische translatie van dit soort therapieën. Dit werk streeft 
daarom naar de ontwikkeling van tools en kennis voor het monitoren en 
controleren van stamcelproductie op grote schaal, met als ultieme doel het 
faciliteren van de vervaardiging van kwalitatieve en kost-effectieve cel-
gebaseerde therapieën. 
Ondanks hun beperkt opschaal- en automatisatiepotentieel is celexpansie in 
celcultuurflessen momenteel nog steeds de meest gangbare 
productietechnologie. In de eerste fase werd de translatie van een 
celcultuurfles gebaseerd productieproces naar een bioreactor gebaseerd proces 
onderzocht, zonder dat daarbij de eigenschappen van de cellen nadelig 
beïnvloed werden. Twee grootschalige commerciële bioreactor types werden 
geëvalueerd voor hun capaciteit om kwalitatieve celdosissen te produceren 
voor een geavanceerd autoloog cel gebaseerd medicinaal product (ATMP) dat 
momenteel ontwikkeld wordt in het Prometheus lab (KU Leuven) voor de 
behandeling van grote bot defecten. De eerste bioreactor die werd geëvalueerd 
was de Xpansion® Multiplate Bioreactor System van Pall Life Sciences in 
combinatie met het Ovizio iLine S beeldvormingssysteem. Het werd 
aangetoond dat de groeidynamiek van de cellen in de bioreactor dicht 
aanleunt bij de dynamiek die werd geobserveerd in de standaard 
celcultuurflessen. Beide culturen resulteerde op het moment van de oogst in 
vi 
dezelfde celdensiteit (17 500 cellen/cm2 in de 5.6 L bioreactor met 30 600 cm2 
cultuuroppervlak en 17 300 cellen/cm2 in de cultuurflessen met 175 cm2 
cultuuroppervlak). 
De tweede studie met betrekking tot opschaling evalueerde het Quantum
®
 
celexpansiesysteem van Terumo BCT. Deze holle vezel bioreactor was in 
staat om expansieprocessen te onderhouden waarbij van een zeer lage zaai 
densiteit gestart werd. Hierdoor werd een efficiënter expansieproces bekomen 
in vergelijking met het standaard proces op basis van celcultuurflessen 
(gemiddelde expansiefactor van 16.4 in de bioreactor vergeleken met 3.0 voor 
de flessen). Beide bioreactoren waren in staat om de klinische hoeveelheid 
cellen te producen nodig voor de ATMP die wordt ontwikkeld in het 
Prometheus lab (ongeveer 350 miljoen humane periostale voorlopercellen of 
hPDCs). Na de bioreactor gebaseerde expansieprocessen presteerde de cellen 
gelijkaardig aan de cellen uit de traditionele fles gebaseerde processen in een 
standaard set van in vitro en in vivo karakterisatie experimenten. Bijkomend 
werd een interactieve tool ontwikkeld voor de objectieve vergelijking van 
meerdere celexpansiestrategieën die gebaseerd is op een visualisatie van 73 
verschillende celexpansieprocessen in 5 verschillende expansietechnologieën 
voor 7 verschillende types mesenchymale stam cellen. 
In parallel met de bioreactor gebaseerde opschaling werd in dit werk ook 
onderzocht hoe de data van deze bioreactorprocessen gebruikt kan worden om 
op niet-invasieve wijze kritische procesparameters op te volgen in real-time. 
Van deze informatie kan daarna verder gebruik gemaakt worden door 
procescontrolestrategieën die beter geïnformeerde procesbeslissingen toelaten 
en uiteindelijk leiden tot een verbeterde productkwaliteit. Een 
monitoringstrategie op basis van een data-gebaseerd model en data van een 
enkele zuurstofsensor werd ontwikkeld voor het kwantificeren van het aantal 
cellen (met een ondergrens van 1 x 105 cellen) in een perfusiebioreactor onder 
dynamische perfusiecondities. Ook werd een real-time monitoringstrategie op 
basis van beeldvorming ontwikkeld voor het bepalen van het ideale tijdstip 
om de enzymatische oogstreactie aan het einde van de expansiestap te 
inhiberen voor 2D celcultuur opstellingen. 
In conclusie, dit werk toont aan dat de opschaling van humane periostale 
voorlopercellen mogelijk is voor het gebruik in cel-gebaseerde therapieën 
door gebruik te maken van geautomatiseerde bioreactorprocessen. Bovendien 
werden nieuwe methodes ontwikkeld om kritische procesparameters te 
monitoren en controleren tijdens bioreactorprocessen door gebruik te maken 
van procesdata en data gebaseerde modellen. 
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 Cell-based therapies 1.1.
Cell-based therapies aim to cure various unmet clinical conditions by utilising 
living cells as the active component of the treatment. While they are still in 
the early phase of their commercial development, cell-based therapies have 
the ability to reduce the burden of chronic, oncologic, neurodegenerative, 
genetic and age-related conditions. Especially since the discovery of the 
induced pluripotent stem cells (IPS) (Takahashi et al., 2007), it is generally 
assumed that cell-based treatments will revolutionise the medical field. While 
the term ‘cell-based therapies’ is often considered a synonym for the 
regenerative medicine field that aims at the regeneration of the function of 
defective tissues and organs (Mason and Dunnill, 2008), the scope of cell-
based therapies is broader. For example, tissue engineering strategies where 
cells are combined with biomaterials and growth factors to replicate the 
anatomical and physiological nature of the original tissue are considered cell-
based therapies, but also the exploitation of the immunomodulatory properties 
of certain cells for example in graft-versus-host treatments (Nauta and Fibbe, 
2007), as well as gene editing of cells for immunotherapies (e.g. chimeric 
antigen receptor T cell technology) (Kalos et al., 2011) are included under the 
cell-based therapy umbrella. Conveniently, all the cell-based strategies are 
regulated under the same European legal framework (Regulation EC No 
1394/2007) under the common term of Advanced Therapy Medicinal 
Products (ATMPs).  
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A classification of cell-based therapies can be made based on the source of the 
cells; allogeneic or autologous (Mason and Dunnill, 2009) (Figure 1.1). This 
concept has a significant repercussion on the use of the cells, the advisable 
production strategy and business model.  
 
Figure 1.1: Illustration of the difference between allogeneic and autologous strategies for cell-
based therapies.  
For an allogeneic therapy the cells from one donor are used for many different patients and 
economies of scale are extremely important for the cost-effective cell processing. For an 
autologous therapy the donor and patient are the same person, requiring very efficient scaled-
out cell processes that are able to handle donor-related variability. Figure from (Brandenberger 
et al., 2011) 
The first option is to source the cells from a “universal donor” from which the 
cells are used to treat multiple patients in allogeneic cell-based therapies, 
allowing an off-the-shelf business model similar to the one of a traditional 
biopharmaceutical product such as monoclonal antibodies. Additionally, the 
allogeneic production and quality control processes benefit from economies of 
scale. However, the need for immunosuppression is a disadvantage for 
allogeneic therapies. A second strategy therefore is the autologous therapy, in 
which the donor and the patient are the same person. This approach results in 
a personalised therapy where product variability needs to be taken into 
account to a much higher degree since the biological input material for the 
production process changes from donor to donor. Autologous therapies have 
the advantage that they do not require donor matching or immunosuppression, 
and the production processes inherently scaled to the demand. However, the 
supply chain and quality controls for personalised cell-based therapies are 
much more complicated, and certain diseases that compromise the quality of 
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the donor cell material itself can likely not be cured by autologous therapies. 
Although not used exclusively as a cell source, stem cells are often of great 
interest for cell-based therapies since they have the ability to self-renew and 
can differentiate into multiple types of mature tissues.  
Initial cell-based therapy ventures yielded limited but encouraging economic 
successes. For example the autologous in vitro expanded chondrocytes used 
by Tigenix (Belgium) in the ChondroCelect cell-based therapy for the 
treatment of joint surface defects in the cartilage of the knee was the first cell-
based therapy approved by the European Medicine Agency (EMA). To date 
Holocar (by Chiesi Farmaceutici), an autologous in vitro expanded cell-based 
product for the treatment of physical or chemical burns of the cornea, is the 
first and only commercial therapy using stem cells that is approved by the 
EMA. There are multiple patients treated with stem cells in Europe under 
“hospital exemption” where experimental cell-based therapies are used 
outside the formally authorized clinical trials. In the EU member states in 
2012 there were in total 60 official exemptions of the standard market 
authorisation track, of which 16 were granted in Belgium (European 
Comission, 2012). Additionally, there are multiple companies making use of 
cells by providing high-throughput drug screening and toxicity testing assays 
based on the biological response of (stem) cells on certain chemical 
compounds.  
Although estimates differ significantly depending on the source of the study, 
the market value of stem cell products (taking into account both cell-based 
therapies and drug screening applications) was estimated in a recent report to 
be around $12 billion in 2014 and predicted to reach around $26.6 billion by 
2020 (Mordor Intelligence, 2016). These estimates are based on the large 
pipeline of potential commercial cell-based therapies that are currently 
showing promising results in clinical trials. Heathman et al. (2015) report that 
in 2015 there were 1 342 active clinical trials for cell-based therapies, of 
which 444 used hematopoietic cells and 382 used mesenchymal stem cells. 
The evolution of the number of active clinical trials with mesenchymal stem 
cells, as illustrated in Figure 1.2, suggests that in the near future cell-based 
therapies will be at the forefront of modern medicine.  
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Figure 1.2: Evolution of the number of active clinical trials with mesenchymal stem cells.  
As reported in (Heathman et al., 2015a; Squillaro et al., 2015; Trounson et al., 2011). 
References were aggregated based on similarity of selection criteria and data source 
(ClinicalTrials.gov). 
 
 Large-scale production of cell-based therapies 1.2.
One thing all cell-based therapies have in common is the need for 
reproducible and  high quality batches of cells. As cell-based therapies are 
rapidly evolving beyond the laboratory scale, the demand for the production 
of cells at an industrial scale is rapidly increasing. Unfortunately, only a 
limited amount of cells can be sourced from living donors. For example, 1 mL 
of human bone marrow provides approximately 1 000 mesenchymal stem 
cells (Fennema et al., 2009), while cell-based therapies and other applications 
such as cell-based drug screening platforms generally require much more 
cells. Typically, single cell doses for cell-based therapies range between 107 
to 109 cells (Jung et al., 2012; Simaria et al., 2014a). An interesting example 
regarding the scale and frequency of the required cell numbers is the 
allogeneic cell-therapy by Osiris Therapeutics, Prochymal, as a treatment 
against acute graft-versus-host disease. The therapy is based on in vitro 
expanded mesenchymal stem cells. Patients are treated by repeated 
intravenous injection of 2 x 106cells/kg/dose, twice a week for four weeks, 
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reporting 82% of the patients with positive response in phase III trials (Martin 
et al., 2010). Hence, it is clear that sequences of cell expansion steps are 
required to multiply the small number of cells taken originally from the donor 
biopsy to the amounts required for clinical application. Given that currently 
the majority of cell based-therapies remain in the early phases of the clinical 
trials (as seen in Figure 1.2) where only relatively small production volumes 
are required, it is hypothesised that the scale-up of cell-based therapy 
production is one of the major hurdles in translating promising cell-based 
therapies from the lab to an economically viable product (Davie et al., 2012). 
The large-scale production of living cells is a multi-disciplinary attainment at 
the interface of  biology and engineering. It might therefore not be a surprise 
that it is a daunting task to design cost-effective cell production processes that 
are able to robustly deliver potent cells for clinical applications. However, the 
biopharmaceutical industry has overcome similar challenges for the 
production of monoclonal antibodies and other therapeutic products by 
making use of cells as biological production units. The production of these 
‘biologics’ by yeasts, and later by mammalian cells, also started off slowly 
with modest production titers. Now it represents a market with a value of 
around $ 1 425 billion per year (Marketsandmarkets, 2015). Many lessons can 
be learned from its evolution towards the mature industry it has become in 
only a couple of decades (the first monoclonal antibody was produced in 
1975, the first licence for clinical use was granted in 1986 (Liu, 2014)).  
Some of the current cell expansion technologies are inspired on the 
conventional bioprocesses for the bioreactor or fermentor-based production in 
the biopharmaceutical industry. However, it is clear that the production of 
cells for cell-based therapies requires its own distinct developments. One 
important difference is that for biologics the product can be purified and 
isolated without the need to recover the living cells, contrary to the production 
of the cells themselves for cell based-therapies. Additionally, in contrast to the 
standardised non-human cell lines used for the production of biologics (e.g. 
suspension cultures of Escherichia coli, Chinese hamster ovary or CHO cells), 
the human (stem) cells generally are sourced from many different donors with 
various growth characteristics, are anchorage dependent, and can potentially 
start to (de)differentiate during culture. Although all cell expansion processes 
share similar foundations, there is currently not a single process blueprint that 
can be applied because many different cell types and clinical applications are 
involved that all require fine-tuned culture conditions and protocols. 
On top of the manufacturing challenges from the technical side, cell-based 
products for clinical applications also need to comply to stringent rules for 
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quality control and regulatory requirements. Since the produced cells are used 
eventually in clinical applications where the patient’s life might be at stake, 
the monitoring and control of process and product characteristics is 
paramount. Considering that the inherent biological complexity and 
variability of the living product is challenging the standard regulatory 
framework of the traditional pharmaceutical sector, multiple directives have 
been written by the European Medicines agency (EMA) the US Food and 
Drug Administration (FDA) that guide manufacturers towards a better 
controlled production in order to receive market authorisation. However, in 
practice the implementation of these directives is challenging due to the lack 
of appropriate tools for monitoring and controlling bioprocesses. Preferably a 
continuous verification of cell potency, identity, purity and safety is required 
during culture and it is up to the manufacturing process to assure the presence 
of these critical quality attributes (CQAs) at the moment of the administration 
of the product to the patient.  
As a way to implement more controlled manufacturing processes for the 
consistent quality of cell-based products as requested by the regulatory 
bodies, the use of quality assurance frameworks such as Process Analytical 
Technologies (PAT) and Quality by Design (QbD) are encouraged (Glassey et 
al., 2011; Kourti, 2006; Read et al., 2010). The main goal of QbD is to clearly 
define the interdependency of critical process parameters and their effect on 
the CQAs (by means of statistical and other data-sciences tools such as 
Design of Experiment or DoE) with the ultimate aim of determining a 
parameter space or “design space” in which the desired product quality can be 
guaranteed. The design space is defined by the International Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human 
Use (ICH) as “the multidimensional combination and interaction of input 
variables and process parameters that have been demonstrated to provide 
assurance of quality” (ICH, 2009). In practice, this means that after the 
assessment and approval by the regulatory bodies of a design space, 
operations within this space are considered save and should result in adequate 
products, while operating outside of this space is not allowed without 
regulatory post-approval. 
This implies that processes for clinical-scale cell expansion require (i) the 
appropriate sensors and monitoring tools to define and verify the design space 
and its effect on the critical quality attributes of the product, preferably in an 
on-line (as in close to continuously measured) and non-invasive way 
(discussed in section 1.4), and (ii) the appropriate hardware that allows to 
control the large-scale processes within the design space. This control is often 
found in the form of automated bioreactors that use the sensor and monitoring 
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tools as feedback to optimise and control the environment of the cells as 
discussed in the next section. 
 Bioreactors for cell expansion 1.3.
The term ‘process intensification’ indicates efforts that, compared to the gold 
standard techniques used today, provide sizeable improvements in 
manufacturing and substantially decrease the equipment size over production 
capacity ratio (i.e. footprint) and resource utilisation, ultimately leading to 
more cost-effective technologies (Stankiewicz and Moulijn, 2000). As in any 
industry where process intensification is required, process engineers revert to 
increased automation and scale-up of processes. Since the start of the 
industrialisation of biology, bioreactors and industrial biotechnology have 
been going hand in hand for the automation and scale-up of bioprocesses. In 
addition, bioreactor technology is often implemented at critical process steps 
in order to reduce process variability and enhance process reproducibility. 
Bioreactors are described as instruments that “create a biosphere that as 
profoundly and adequately as possible provides the ideal environment for the 
biological reaction” (Mandenius, 2016). Within this general definition the 
term ‘ideal’ is rather ill-defined and might depend on the exact application of 
the bioreactor. In the context of bioprocess development for cell production 
there are two necessary conditions before the cell environment is considered 
‘ideal’ (but compared to the human body rather to be classified as ‘suitable’): 
(i) favourable physical conditions regarding mass balances (i.e. nutrient, waste 
and gas transport), energy balances (i.e. heat and shear stresses) and their 
evolution over time to maintain cellular function, (ii) operability in an 
industrial setting, i.e. providing process monitoring and control, optimising 
input of resources (work load, reagents, facility,..), decreasing contamination 
risk and facilitating regulatory approval. 
Bioreactor technology historically originates from the early food processing 
industry (e.g. beer, wine), and evolved to other fermentation-based production 
processes for biochemical components (e.g. alcohols, amino acids, polymers) 
and the large-scale production of antibiotics (Mandenius, 2016). Since the 
bioreactor-based protein manufacturing (e.g. insulin, erythropoietin and 
monoclonal anti-bodies) the biotech industrialisation is moving up a gear and 
over the second half of the 20th century immense production volumes are 
reached for which mammalian cell suspension cultures are used to produce 
biopharmaceutical products (Croughan et al., 2015). Not only the bioreactor 
technology surged, but many process monitoring and control strategies find 
their origins in this industry. Since the very end of the 20th century, the efforts 
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of harnessing the potential of the cells themselves (and not solely their by-
products) for the treatment of unmet clinical needs began. While previously 
the cells or their remnants were highly undesired regarding the purity of the 
clinical product, the use of the cells themselves in cell-based therapies 
preluded a paradigm shift for the design, monitoring and control of the 
bioreactors in which they are produced. 
In the pursuit for more cost-effective cell expansion processes there are three 
strategies that can be followed. Generally the choice depends on the clinical 
application and the specific cell type. Firstly, there is scale-out, which means 
increasing the production by doing more of the same, i.e. using more culture 
vessels. Secondly, there is scale-up, or increasing the available cell culture 
surface by increasing the size of the vessel. In parallel there is a continuous 
evolution towards an increased culture surface per volume, i.e. increasing the 
available surface per vessel in order to reduce the process footprint. This is 
often done by replacing the gas layers in culture vessels with active 
oxygenation and perfusion systems and/or increasing the available surface by 
going from planar culture systems to bended and more 3D-like or porous 
surfaces. Large gains in production can be made by combining these three 
strategies. 
The current gold standard for (anchorage dependent) cell expansion is still the 
planar plasma-treated polystyrene tissue culture flask. Cell culture flasks or T-
flasks (Figure 1.3A) are easy to use, and relatively cheap and versatile for 
small-scale processes. However, there are many disadvantage associated with 
their use. First of all do they require extensive manual open-vessel 
manipulation by highly trained operators in large and expensive 
contamination-free environments (i.e. clean rooms and incubators compliant 
with Good Manufacturing Practices or GMP). Additionally, cultures in T-
flasks will never be able to reach very high cell densities per volume due to 
their inherent design features with a low culture surface per total vessel 
volume. Cell factories or cell stacks (Figure 1.3B) are the scaled-up version of 
tissue flasks. Technically, by having one flask in which multiple horizontal 
layers of culture plastic and gas are alternated the number of open-vessel 
operation can be reduced. However, the increase in culture surface per volume 
is not significantly improved since there are still large gas layers in between 
the different levels in the flaks. In a more recent evolution, e.g. the hyperflask 
(or the larger scale hyperstack), the large gas layer above the culture medium 
is replaced by a very thin opening underneath the different layers of plastic 
that in turn is also designed to be O2 and CO2 permeable (Figure 1.3C). While 
this features saves ± 2.5 times the volume for the same amount of culture 
surfaces, using large numbers of any type of flask becomes impractical fairly 
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fast due to the clunky auxiliary peripheral devices required for filling and 
harvesting the flasks (Figure 1.3D). 
 
Figure 1.3: Evolution of flask-based planar culture vessels.  
A) Standard T-flask. B) Cell stacks C) Hyperstack in which the gas layer above the medium is 
made redundant by use of a O2 and CO2 permeable plastic D) Peripheral instruments for filling 
large numbers of cell stacks. 
By completely removing the gas layers in between the different polystyrene 
layers in a cell stack, and solving the resulting mass transfer problem with 
active oxygenation of the culture medium and a magnetic mixer to recirculate 
the oxygenated medium over all the layers of the vessel, the Xpansion 
bioreactor of Pall Life Sciences (Figure 1.4A, see Figure 4.3 in Chapter 4 for 
more details) optimises the available culture surface per volume even further. 
More importantly, by making use of external pumps and sterile connectors, 
the open processes required for flask-based cultures are avoided. Contrary to 
T-flasks, these bioreactor vessels are standardly equipped with temperature, 
pH and O2 sensors enabling the on-line control of the process. Additionally, a 
peripheral holographic microscope setup allows the visual off-line monitoring 
of 6 to 10 plates of the bioreactor. The largest Xpansion version, with 200 
layers, houses 122 400 cm2 culture surface in 21.9L culture medium. 
From here on an increase of the culture surface per volume is only possible by 
leaving the planar culture surfaces. For example the Terumo Quantum hollow 
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fibre bioreactor (Figure 1.4B, see Chapter 6 for more details) is able to culture 
cells in ±11 500 hollow fibres, making up 21 000 cm2 culture surface in a 
volume of only 500 mL. The hollow fibre bioreactor can be perfused with 
fresh or recirculated medium at two independent speeds either through the 
hollow fibre lumen or from the outside of the fibres. Additionally, it is a 
benchtop bioreactor with a small footprint that with the aid of peripheral 
sterile welding devices is able to work without the need for biosafety cabinets 
and incubators. Since the configuration of the fibres does not allow to monitor 
the cells visually, more innovative process monitoring approaches are 
required (see Chapter 7 for example). 
Another non-planar variation uses the surface of suspended microcarriers for 
cell expansion (Figure 1.4C). By growing the cells on small spherical particles 
(size around 200 μm) in suspension, very large culture volumes can be 
reached in vessels or bags with a relatively efficient culture surface per 
volume ratio. Additionally, monitoring tools are relatively easy to implement 
in these vessels or bags since they don’t have to be incorporated in the tubing 
of the perfusion system and even cell containing culture medium samples can 
be taken during culture for more elaborate quality control assays. A large 
variety of microcarrier-based culture systems exists, both in terms of vessel 
types, volumes and microcarrier composition. The microcarrier-based culture 
was not directly the focus of this doctoral work, although it is a very 
promising strategy for the scale-up of allogeneic cell-based therapies due to 
the large batch sizes that can be reached.  
A less common cell expansion strategy for human (stem) cells makes use of 
perfused packed beds or 3D scaffold structures from (macro)porous materials 
(Figure 1.4D, see Chapter 7 for more details). These 3D growth surfaces are 
able to significantly increase the available culture surface per volume, thereby 
optimising the process footprint. Since the curved surfaces of hollow fibre 
bioreactors or microcarriers are still having a relatively large radius compared 
to the cell size, these culture conditions do not differ that much from the 
planar culture technology. However, for the 3D surfaces that more closely 
resemble the natural environment of the cells, the cell behaviour is different 
(Braccini et al., 2005). For example the secretion of extra cellular matrix and 
pore bridging is often seen, making the recovery of the cells a primary 
concern (Sonnaert et al., 2015a). The 3D scaffold-based configuration makes 
these bioreactors particularly challenging for monitoring and therefore require 
novel monitoring approaches (see for example Chapter 7 and Sonnaert et al., 
2015b). 
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Figure 1.4: Bioreactor systems for (stem) cell expansion.  
A) Pall Life Sciences Xpansion® Multiplate Bioreactor System B) Terumo® BCT Quantum 
Cell Expansion System, a hollow fibre bioreactor C) GE Wave® bioreactor, a microcarrier 
bioreactor D) Illustration of a simple perfusion bioreactor design were the cells are cultured on 
3D scaffold structures E) Concept of the Octane bioreactor inside the Cocoon. 
Some bioreactors take the bioprocess optimisation, and more specifically the 
bioprocess integration, multiple steps forward. For example the Cocoon 
bioreactor developed by Octane (Canada) and currently under evaluation at 
Lonza as a platform for personalised cell therapy manufacturing platform, 
aims to fully automate the cell processes from the subsequent digest of the 
biopsy, (stem) cell isolation, cell expansion and seeding onto a biologically 
active carrier materials in a benchtop bioreactor system (www.octaneco.com).  
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Selecting the most appropriate technology during development is not always a 
straightforward task since there is no ‘one size fits all’ solution. An overview 
of some of the most popular cell expansion vessels and their culture 
characteristics is provided in Figure 1.6. A preliminary indication for the most 
appropriate expansion technology can be based on the autologous or 
allogeneic nature of the therapy. For autologous therapies, were the cell 
processes are not of a massive scale and often executed close to the patient 
due to the lack of appropriate means for cell storage, the decentralised 
(scaled-out) multi-centre production model is often the most feasible strategy 
(Foley and Whitaker, 2012; Hourd et al., 2014). These types of production 
models benefit more from compact and highly automated benchtop bioreactor 
systems as the Terumo Quantum bioreactor that can be operated next or the 
patient’s bedside by matter of speaking. For autologous decentralised 
production, process monitoring is critical in order to assure process 
consistency and comparability over the multiple sites and patients (Hourd et 
al., 2008). Allogeneic 
processes, where the 
‘economies of scale’ principle 
applies, focus more on the 
production of very large 
uniform batches of cells. With 
the current technology, these 
large volumes can only be 
reached in industrial size 
microcarrier suspension 
cultures (Figure 1.5) that are 
inspired on the production of 
biopharmaceuticals such as 
recombinant protein, 
vaccines, etc.(Simaria et al., 
2014b). 
As the scale of the cell production processes is increasing, the downstream 
processes (i.e. cell harvest, volume reduction, purification, storage and 
transportation) become more challenging (Hassan et al., 2015). Only recently 
the downstream process bottlenecks became the subject of process 
optimisation studies. For example Nienow et al. (2014) introduced a dynamic 
harvest methodology to retrieve expanded cells from microcarriers and the 
subsequent cryopreservation (Heathman et al., 2015d). More recently an 
integrated process for washing and filtration of stem cells after expansion was 
described (Cunha et al., 2015b; Cunha et al., 2016). 
Figure 1.5: 12000L bioreactors for the production of 
recombinant protein at Celltrion. Copyright© 2016 
Celltrion Inc. 
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Figure 1.6: Overview of different cell expansion units and their main characteristics.  
Data gathered from manufacturers’ specification sheets. Data on microcarriers from (Simaria et 
al., 2014b). 
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 Model-based bioprocess monitoring and control 1.4.
1.4.1. Monitoring cell expansion processes 
According to the European Medicines Agency’s (EMA) guidelines, Process 
Validation for pharmaceutical production is defined as “documented evidence 
that the process, operated within established parameters, can perform 
effectively and reproducibly to produce a medical product meeting its 
predetermined specifications and quality attributes” (ICH Expert Working 
Group, 2000). More recently, the EMA encouraged the use of ‘Continuous 
Process Verification (CPV)’ where process performance is continuously (or 
‘on-line’) monitored and the same type of performance evaluation is 
developed/used already during the product development phase, as this strategy 
facilitates scale-up, process comparability or reproducibility, and post-
approval change control in later stages of the product lifecycle (EMA, 2014).  
The goal of monitoring culture processes during cell therapy development and 
manufacturing is to assure a better replication and control of culture 
conditions over multiple cell-processing runs (Csaszar et al., 2013). In order 
for the monitoring strategy to support continuous process verification, on-line 
non-invasive monitoring tools are required, since these allow for up-to-date 
information to be obtained from the system at any time without manual 
interventions or time delays involved (which are typical for the more standard 
at-line process monitoring). Apart from the on-line or real-time nature of the 
measurements, the non-invasiveness (meaning that no probes or labels enter 
the closed culture environment) of the tool should be ensured if the process is 
running under GMP conditions, because otherwise the purity and sterility of 
the implanted cells will be more difficult to guarantee. In a second phase, on-
line monitoring enables intelligent real-time control of the culture parameters, 
resulting in an increased robustness of the process and clinical efficacy of the 
therapy. On-line non-invasive process monitoring techniques for cell therapy 
manufacturing can be roughly divided in three major classes as described 
below.  
Monitoring of physicochemical culture variables: Variables such as 
pH and dissolved O2 or CO2 concentration provide information on the 
(micro-) environment of the cultured cells. Often these variables can be non-
invasively monitored in real-time (on-line) by means of fibre-optic sensors, 
both for 2D and 3D cultures (Sart et al., 2014). On-line monitoring of these 
variables is critical for the bioreactor to maintain the suitable environmental 
conditions for cell expansion. However, these general environmental variables 
are not exclusively related to the biology of the cells and therefore only 
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provide limited or indirect information on the critical quality attributes of the 
cells themselves. An strategy to use O2 measurements to infer critical process 
information regarding cell growth will be discussed in more detail in Chapter 
7. 
Imaging technology: Image-based monitoring recapitulates the visual 
inspection that is currently done by a process operator. Current imaging 
technologies that are on-line and non-invasive (therefore excluding 
technologies using fluorescent labels or computed tomography) are only able 
to image 2D cell cultures on semi-transparent culture surfaces. The current 
state of the art in industrial-scale image-based bioprocess monitoring is the 
use of non-invasive holographic imaging (Ovizio) on large scale cell 
Xpansion bioreactors. This microscope is able to image and semi-
automatically analyse cell features on multiple heights in a multi-stack 2D 
bioreactors (see Chapter 5 for details). Traditional optical microscopes use a 
complex assembly of lenses and focusing requires mechanical movement of 
these optical elements, resulting in costly and bulky systems that are difficult 
to integrate in on-line monitoring systems for bioreactors. Therefore Imec 
(Belgium) and Prometheus (KU Leuven, Belgium) work together to integrate 
a lens-free holographic image-based technology with a very large field of 
view in cell culture systems to monitor cell growth and morphological 
changes during culture by using coherent light (i.e. a laser) and an imager to 
capture the light that is diffracted off the culture surface (see Figure 1.7 for a 
representative example of a capture with the lens-free microscope).  
Image-based monitoring provides direct feedback on the cellular phenotype 
and is therefore from a biological point of view an indispensable monitoring 
technique. However, translating images into objective quantitative process 
parameters is challenging and requires further development in image 
processing and data-based cell identification techniques. Additionally, the 
configuration of certain bioreactors (for example microcarrier or hollow fibre-
based designs) currently do not allow image-based monitoring. 
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Figure 1.7: Preliminary data generated by the IMEC-Prometheus collaboration on a LFI 
microscope.  
On the left the complete field of view is shown while on the right a more detailed zoom is 
provided, clearly indicating the exceptional combination of a large field of view and resolution. 
Bio-sensing: By analysing the (by-)products of cell metabolism, either 
being taken-up from the culture medium or secreted into the medium, the 
biological state of the cells can be derived indirectly. These techniques 
generally require sterile sampling from the culture medium and can be applied 
to 2D and 3D cultures. An advantage here is that the read-out (often in the 
form of spectra) represents information from the (internal) metabolism of the 
cells themselves. Since the metabolism is typically governing cell fate this 
data has therefore a higher informative value regarding in vivo potency 
compared to the two previous types of monitoring data. However, current 
technologies e.g. based on immunoassays, mass spectrometry, 
chromatography or spectroscopy are not yet available in cost-effective on-line 
setups, require large efforts in sample preparation (even requiring cell samples 
which is certainly not non-invasive) and often lack specificity in complex 
culture media with a high protein background. 
1.4.2. Model-based process control 
While it is common that measurements of physicochemical or environmental 
variables (e.g. pH, O2) are used as feedback for a controller that allows the 
bioreactor to maintain suitable conditions for expanding cells, it is much more 
challenging to obtain on-line and non-invasive information directly on the 
critical quality attributes (CQAs) of the cells themselves and use this 
information to directly control the features of the cultured cells, e.g. their 
growth characteristics, metabolic state, and ultimately in vivo potency. In the 
first place the challenge lies in developing the sensor hardware for the on-line 
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determination of these parameters as discussed previously. However, since 
more and more process data is collected, it is a promising approach to 
estimate the unmeasurable CQAs in real-time, based on (a combination of) 
indirect measurements that can be related to the CQA of interest. This is 
generally known as a ‘soft sensor’ method (de Assis and Filho, 2000; Kadlec 
et al., 2009), where the information of (multiple) indirect data streams is 
translated to interpretable process parameters. For example in Chapter 7, a 
method is described that exploits data from oxygen measurements and known 
changes in perfusion rates to derive precise on-line estimates on cell numbers 
in 3D scaffold-based cultures. In Chapter 6, the rate of change in lactate 
production of the cells is used to estimate the optimal time to start harvesting 
the bioreactor and in Chapter 5 the change in circularity of the cells is used as 
a predictor for the optimal time to stop the enzymatic harvest reaction.  
The examples above are all situations where, based on process measurements 
and consecutive interpretation of the data by a model, real-time process 
monitoring tools were developed for critical process features. Ultimately this 
‘model-based monitoring’ strategy, combined with a desired output trajectory 
can be used as the basis for ‘model-based control’ in which the measured 
process data and a model are used to determine or predict the most 
appropriate controller setting to reach the desired state of the process or the 
cells. Although more often used in fermentor bioreactors (Aehle et al., 2012; 
Kovarova-Kovar et al., 2000; Ławryńczuk, 2008; Ramaswamy et al., 2005) 
only limited examples of model-based control can be found in literature for 
stem cell bioreactors (Csaszar et al., 2012).  
In between process monitoring and the actual process control, models are 
required for ‘translating’ the raw monitoring data into interpretable process 
parameters that can be used to make informed process control decisions. 
There are some important considerations regarding the models used for this 
translation. In general, there are two opposing ends of the modelling 
spectrum: on the one had there are the data-based approaches where the 
model structure is completely based on the data (inductive). On the other hand 
there are the mechanistic approaches were a priori knowledge on the 
biological system is included (deductive) (Young, 1999). Modelling 
techniques used for the data-driven approach range from simple transfer 
function models (as used in Chapter 5 and 7) to principal component analysis, 
and neural networks. The mechanistic models often make use of conservation 
equations, stoichiometry and reaction kinetics.  
Mechanistic models may be superior in providing insight into the system 
under consideration since their parameters have a physical meaning. 
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However, they have a significant cost of development, are more difficult to 
parameterise, and are generally harder to compute in real-time which is often 
a requirement for process controllers. At the same time, the biological 
processes are often too complex to be described by mechanistic models and 
the experimental validation of these models quickly becomes too elaborate 
(for example the donor-related variability is near impossible to capture in a 
meaningful way without making use of data-driven methods). Data-based 
models on the contrary provide less insight into the system, but are more 
straightforward to develop and in situations where the data logging surpasses 
the speed of analysis they provide an ideal basis for online prediction and 
control (Papantoniou et al., 2014). In the cell expansion field and biotech in 
general, there is often abundant high quality process data available due to the 
GMP and quality control requirements, which is a clear advantage for data-
based approaches. On the other hand, biologists, doctors and regulatory 
bodies might be hesitant on the ‘black-box’ nature of the data-based models. 
Additionally, results from a data-based model can often not be extrapolated to 
cases outside of the initial scope of the data. While this PhD project focused 
on data-driven approaches, both modelling strategies can contribute to a more 
effective translation of cell-based therapies to the clinic. In addition, hybrid 
strategies exist, resulting data-based mechanistic models that are able in some 
cases to combine best of both worlds (von Stosch et al., 2014). 
 Challenges for widespread clinical use of cell-based 1.5.
therapies 
To summarise this introductory chapter, two main challenges for the 
widespread clinical use of cell-based therapies were identified. First, while 
there is an abundance of culture technology, there is a need for more 
integrated bioprocess designs that are able to produce cells for therapeutic 
products in a cost-effective and robust way. Secondly, there are not many 
sensors that are able to provide real-time feedback on the quality of the cells 
in the bioreactor. Therefore, novel monitoring strategies are required that 
allow on-line control of critical quality attributes of the cells in order to 
reduce process variability and improve in vivo potential of the cells. 
To date, the gold standard cell production strategy consists of a series of 
expansions steps in tissue culture flasks (see Figure 1.8 A). Human operators 
are required to perform the numerous manual manipulations to monitor and 
control the process, and generally there is only sparse feedback on the process 
(e.g. off-line manual verification of confluence level and morphology). The 
manual interventions and the lack of continuous feedback leads to high costs 
and variable process outcomes. Therefore, in this work it is hypothesised that 
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by translating the flask-based process to an integrated and controlled 
bioreactor-based process, in which online monitoring of critical process 
parameters allows continuous process control, will increase the robustness of 
the cell-based product (see Figure 1.8B). Since to date no monitoring systems 
exist that are able to directly measure the critical quality attributes of the cells, 
a model will be used to link process read-outs to critical quality attributes and 
subsequently derive the appropriate process inputs for a controlled process. 
 
Figure 1.8: A) Current gold standard cell culture process that makes use of tissue culture flasks 
and human operators. B) Concept of on-line monitored and controlled cell culture process. 
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The previous chapter attempts to familiarise the reader with the most 
important concepts, the state of the art and the challenges involved in large-
scale (stem) cell expansion for cell-based therapies. This chapter positions the 
work that was done during the doctoral research in this larger framework and 
addresses the thesis objectives. 
The common thread throughout this work is the need for a monitored and 
controlled expansion of progenitor cells suited for an autologous cell-based 
advanced therapy medicinal product (ATMP) that is currently being 
developed at Prometheus, the division of Skeletal Tissue Engineering of the 
KU Leuven. This ATMP makes use of ex vivo expanded human periosteal 
derived progenitor cells (hPDCs) for the clinical treatment of non-healing 
long bone defects (Lammens et al., 2012; Roberts et al., 2014). For the 
production of this cell-based product a small periost biopsy is taken from the 
patient, whereafter the stem/progenitor cells are enzymatically released and 
cultured in vitro for several weeks (10 to 12 population doublings). 
Ultimately, around 300 million cells are needed for implantation at the site of 
the bone defect, seeded on a calcium-phosphate based carrier in combination 
with a bioactive growth factor (BMP). Promising results were obtained in a 
series of large-scale pre-clinical experiments in which clinically relevant 
amounts of bone were formed in an orthotopic critical-size long bone defect in 
a large animal model (i.e. sheep). 
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In parallel with the scale-up of the hPDC production, data-based approaches 
were investigated that would allow to on-line monitor and control critical 
process parameters during these up-scaled expansion processes. The process 
monitoring and control approach was inspired on the data-based approach 
from the M3-BIORES (Measure, Model & Manage Bioresponses) lab. The 
main focus at M3-BIORES is to develop real-time model-based monitoring 
and control algorithms for biological processes taking into account the 
complex, individual, time varying and dynamic (CITD) nature of biological 
responses to the bioprocess environment. This approach is framed within the 
standard model-based control scheme as can be seen in Figure 2.1 (Brosilow 
and Joseph, 2002; Camacho and Bordons, 2007). The practical 
implementation of the control scheme varies widely, but in general it consists 
of a (biological) process, e.g. the cell expansion vessel in this case, and a 
model that is able to translate time-variant process data into interpretable 
information that is either used to report on the process status through a 
monitor, or that can be used to make informed process control decisions. 
With the clinical translation of the Prometheus ATMP in mind, this work 
focuses on two major hurdles for the development and widespread clinical 
translation of cell-based therapies in general: scale-up of cell expansion 
processes, and process monitoring and control under inherent biological 
variability. Pursuing the process scale-up and at the same time developing 
monitoring and control strategies leads to synergistic effects. While the 
additional data from the monitoring and control tools can be used to validate 
the process comparability, working in the large-scale clinical-grade 
bioreactors provides an instant reality check on the clinical applicability of the 
monitoring tool. The structure of this work reflects this interaction. Each 
bioreactor scale-up chapter (Chapter 4 and 6) is followed by a chapter on a 
data-based monitoring tool for this specific type of bioreactor (Chapter 5 and 
7). 
Objective 1: Provide a framework for benchmarking of cell expansion 
processes.  
Before the results of different cell expansion processes are compared in later 
chapters of this work, it is required to define how meaningful comparisons 
can be made. Especially since there are a large number of process parameters 
that contribute to the efficiency and cost-effectiveness of a cell expansion 
process (e.g. cell seeding densities, medium composition, culture vessels, 
medium volumes, etc.), in combination with multiple cell expansion strategies 
(scale-up vs scale-out, centralised production vs decentralised production), 
benchmarking of these processes is a challenging task. In Chapter 3 we 
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hypothesise that based on a selection of objective metrics (such as expansion 
factor, final cell yield, cell density at harvest, concentration of protein 
supplement ,etc.) it is possible to provide a framework for the comparison of 
cell expansion processes that is able to improve the general understanding of 
the critical process parameters that define a cell culture process, and in the 
future allow a more rational and integrated design of the cell expansion 
bioprocesses. 
Objective 2: Translate the standard flask-based expansion process for the 
autologous Prometheus ATMP to an automated and controlled 
bioreactor-based process.  
More and more technological developments (bioreactors, centrifuges, etc.) are 
becoming available for the large-scale production of stem cells, but the 
translation from the standard small-scale flask-based cell expansion to the 
large-scale bioreactor-based cell expansion is not straightforward. Challenges 
arise for example in how to retain the critical quality attributes of the cells 
during the process, matching the best available technology to a specific 
process strategy, and the effect of scale-up on the production cost and 
downstream processes. In other words, an integrated bioprocess design that 
takes into account cell quality, the required scale, up- and downstream 
workload and production costs is required. For the (pre-)clinical work that is 
undertaken in the Prometheus lab for the healing of long bone defects, it was 
hypothesised that the manual expansion of the human periosteum derived 
cells (hPDCs) can be translated to an automated bioreactor-based process 
without compromising the in-vivo bone healing potential of the cultured cells. 
Since the comparability between the bioreactor and flask-based process is 
critical (see Objective 3), a strong focus on evaluating the potency of the 
resulting cell quality is required, based on a quantitative in vivo bone-forming 
potency assay. Additional questions that were addressed are how the 
bioreactor-based expansion compares to the standard methods in terms of ease 
of use, cost of goods and scalability of production, thereby trying to connect 
the type of bioreactor to possible strategies for commercial cell processing. 
Objective 3: Incorporate cost-effective data-based monitoring and 
control strategies in the large-scale production processes in order to 
deliver cells with a more robust quality profile and assure process 
comparability. 
Cell expansion processes are still often operated as a ‘black box’, and thus in 
most cases result in sub-optimal and variable process outcomes. Functional 
24 Thesis objectives and research approach 
 
bioprocess control in cell expansion vessels, enabling direct control over the 
critical quality attributes of the cells such as proliferation rate, differentiation 
stage, etc., remains challenging due to inadequate on-line non-invasive 
monitoring tools. In addition, the living nature of the cell-based product 
introduces fluctuations in manufacturing outcomes while regulatory 
authorities desire a tight control of process performance. It is hypothesised 
that by skilfully utilising data that is generated by common process read-outs 
such as microscope images (Chapter 5) and oxygen sensors (Chapter 7), 
critical process parameters such as the level of confluence or the incubation 
time during cell harvest can be better monitored and controlled, while at the 
same time the inherent donor-related variability that is found in cell expansion 
processes can be taken into account (Chapter 6). The improved monitoring 
and control will ultimately lead to cells with a more robust quality profile. 
Additionally, the need for process comparability is, amongst others, critical 
for post-approval changes to the production processes of ATMPs, translation 
of processes to Contract Research Manufacturers or even just to verify the 
results of a scaled-up process as described in Objective 2. Especially for 
autologous therapies where decentralised manufacturing is a common strategy 
and donor-dependent variation is ubiquitous, comparability is key (Hourd et 
al., 2008). It is hypothesised that the data-based process monitoring tools can 
also be applied to facilitate the demonstration of comparability between 
different production methods, production batches or production sites, and 
even the comparability between different donors. 
 
In Figure 2.1 the core elements of the following chapters are situated in a 
general control scheme. At the beginning of every chapter this general control 
scheme will also be used to position the specific chapter within the framework 
of this PhD work. While Chapter 3 interactively summarises a large amount 
of expansion processes and introduces the framework for cell expansion 
process comparability, Chapter 4 and Chapter 6 both focus on the translation 
of a flask-based process to a large-scale bioreactor system. Chapter 5 and 7 
describe for each of the bioreactor types of the previous chapter an example of 
the use of data-based models. The models, in combination with process data, 
are utilised to monitor critical quality attributes of the process, based on which 
informed process control decisions can be made. 
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 Large-scale mesenchymal Chapter 3.
stem/stromal cell expansion: a 
visualisation tool for bioprocess 
comparison 
 
 
 
 
Adapted from: T. Lambrechts, M. Sonnaert, J. Schrooten, F. P. Luyten, J.-M. 
Aerts, I. Papantoniou. Tissue Engineering Part B: Reviews (2016) 
doi:10.1089/ten.TEB.2016.0111, [Epub ahead of print].  
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 Positioning within the context of the PhD project 3.1.
In Objective 1, as introduced in Chapter 2, it was stated that a framework for 
benchmarking cell expansion processes would improve the general 
understanding of the critical process parameters that define a cell culture 
process, and ultimately facilitate a more rational and integrated design of the 
cell expansion bioprocesses.  
This chapter therefore focuses specifically on the ‘process’ block of the 
general control scheme by analysing different strategies as described in 
literature for the large-scale expansion of mesenchymal stem cells. Processes 
using standard tissue culture flasks are included, as well as specialised 
bioreactor systems. An objective way of comparing the different processes, 
based on their input, output and process performance is introduced. 
 
Figure 3.1: Position of Chapter 3 in the general control scheme and the larger context of this 
work. 
 
 Abstract 3.2.
Large-scale and cost-effective cell expansion processes are a prerequisite for 
the clinical and commercial translation of cell-based therapies. A large variety 
of cell expansion processes are described in literature, utilising different cell 
types, culture vessels and medium formulations. Consequently there are no 
straightforward means for the comparison or benchmarking of these processes 
in terms of efficiency, scale or costs. The purpose of this study was to 
systematically review the available mesenchymal stromal cell (MSC) 
expansion literature and develop an interactive visualisation tool for 
comparing the expansion processes. By using this computational tool, process 
data could be concentrated, standardized and analysed in order to facilitate a 
more general understanding of the parameters that define a cell culture 
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process, and in the future allow rational selection or design of these 
bioprocesses. Additionally a set of bioprocess metrics were defined that 
assured the comparability between different processes. Currently the 
literature-based data repository holds 73 individual cell expansion processes 
on 7 different types of human mesenchymal stromal cells (MSC) in 5 different 
types of culture vessels. The visualisation tool allowed benchmarking of these 
processes against each other, serving as a reference point for cell expansion 
process efficiency. 
 Introduction 3.3.
The number of clinical trials for cell-based therapies has been constantly 
increasing over the last years. Approximately 400 of these trials use human 
mesenchymal stromal cells (MSCs) as a therapeutic cell source, and many 
other (stem) cell types are considered for clinical translation (Heathman et al., 
2015d; Trounson and McDonald, 2015). At the same time, the potential 
benefits that can be brought by cell-based therapy also seems to be recognised 
by industry since more and more cell-based companies arise (Culme-Seymour 
et al., 2013). It is expected that most cell therapy applications will require 
between 106 and 109 MSCs for a single dose (Jung et al., 2012; Simaria et al., 
2014a). Although the relatively low number of Phase III clinical trials and 
limited commercialisation has been partially attributed to manufacturing 
challenges associated with manual flask-based cell culture, the flask-based 
method is still the gold standard. Manual flask-based cell culture is labour 
intensive, requires sequential “open events” that are prone to contamination, 
and does not allow online monitoring and control of the microenvironment of 
the cells. At the same time the flask-based strategy is limiting the attainable 
cell density levels and the scale of operation due to the inherent design of the 
flasks with a low volume to culture surface ratio.  
The translation of clinically promising cell therapies to commercially 
successful products will require the conversion from manual cell culture 
processes to controlled bioprocesses that are able to guarantee the production 
of cell-based therapies with manageable cost of goods (COGs) and robust in 
vivo performance (Galipeau, 2013; Hourd et al., 2014; Kaiser et al., 2015; 
Salmikangas et al., 2015). Bioreactors have been shown to provide an 
improved cell culture environment by controlling nutrient refreshment and 
waste removal rates (Csaszar et al., 2013) while reducing complexity involved 
in bioprocessing (Leijten et al., 2015). From the translational perspective, 
bioreactors have been employed in order to provide efficiency in terms of 
cost, yield and scale. A growing body of literature examines the use of 
bioreactor systems with various designs for the expansion of human MSCs 
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and reflects on the concerns regarding large-scale MSC production, indicated 
by an increasing number of recent review papers (Cierpka et al., 2013; Kumar 
and Starly, 2015; Dos Santos et al., 2013). 
Existing literature and regulatory perspectives (Mendicino et al., 2014) 
discuss a very broad number of parameters that all affect bioprocess 
variability and efficiency at the same time. Their effects should therefore be 
taken into account when analysing and designing bioprocesses for the 
expansion of MSCs. These parameters can be classified as follows: 
Cell type and donor: There is a large variation of sources of adult progenitor 
cells, with the most common being bone marrow (Bianco et al., 2008), 
umbilical cord (Harris and Rogers, 2007), adipose (Ogura et al., 2014), 
synovium (De Bari et al., 2001b), periosteum (De Bari et al., 2001a). In 
addition, interdonor variability within the same cell type is also a factor that 
will affect translation to large-scale (Heathman et al., 2015b). Even from the 
very beginning of the process, the number of MSCs obtained from a biopsy is 
variable. For example, 1 mL of human bone marrow provides approximately 
1 000 MSCs (Fennema et al., 2009). While for adipose derived MSCs for 0.5–
2.0 × 106 cells per gram of adipose tissue the percentages of MSCs range from 
1 to 10% (Oedayrajsingh-Varma et al., 2006). Again here there is a large 
interdonor variability regarding cell yields from biopsies that affects 
translation, especially for autologous cell therapies.  
Type of culture vessel: Not only in the (multilayered) flask-based expansion, 
where the brand of culture plastic itself might already induce variability in cell 
yields (Sotiropoulou et al., 2006), also the large diversity of culture systems 
that has been reported to support MSC expansion contributes to the variety in 
bioprocess efficiency and variability. For instance microcarrier-based stirred 
tank reactors (Dos Santos et al., 2014), hollow fibre (Nold et al., 2013), wave 
bags (Timmins et al., 2009) and multiplate bioreactors (Lambrechts et al., 
2016a) have been successfully employed to generate large-scale batches of 
MSCs. 
Raw materials and reagents: There is a broad variety of media formulations 
for cell expansion that differ for example in protein source or glucose 
concentration. Since non-defined sources of protein such as Foetal Bovine 
Serum (FBS) and Human Platelet Lysate (HPL) introduce batch-dependent 
process variability and present a non-negligible risk for pathogen 
transmission, considerable effort goes to the development of defined xeno-
free medium formulations that support more efficient and less variable cell 
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growth (Heathman et al., 2015d; Tan et al., 2015). For a review on serum free 
media formulations see (Gottipamula et al., 2013).  
Process parameters: The operating conditions, for instance initial cell 
seeding density, media refreshment strategy, vessel geometry, type of 
impeller, mixing intensity and stress exposure, perfusion rates and dissolved 
oxygen tension vary for almost every process (Sart et al., 2013). The impact 
of the microenvironment in light of large scale MSC expansion is reviewed in 
(Ma et al., 2015). 
To add to this complex landscape, inconsistent metrics have been used to 
define bioprocess efficiency making comparison across research studies a 
rather challenging task. Therefore, there is need for a critical and systematic 
analysis of existing information in order to allow comparability, process 
benchmarking and improved understanding of bioprocess efficiency, to 
ultimately allow a more rational design of these bioprocesses.  
The first aim of this work was to analyse the performance of different 
expansion processes for MSCs. An exhaustive literature study was performed, 
currently resulting in a database of 73 individual cell expansion processes in 5 
different types of culture vessels (tissue culture flasks, hollow fibre 
bioreactors, microcarrier-based bioreactors, multiplate bioreactor and fixed 
bed bioreactors), 7 different types of MSCs and a wide range of media 
compositions. The scale of the processes in terms of final cell numbers ranged 
between 7.5x10
6
 and 1.1x10
10
 cells. Interactive visual process performance 
maps were created where the scale, expansion efficiency, cell type, culture 
method, load on downstream processing, medium formulation and population 
doubling time could be explored. Finally, based on scale-up studies carried 
out in our research group we provide a cross-system cost comparison using a 
specific adult progenitor cell type namely, human periosteum-derived cells 
(hPDCs, an MSC-like cell type that holds promise for skeletal regeneration 
and repair strategies) reaching yields of 3.5*108 cells per run.  
 Methods 3.4.
3.4.1. Database construction: 
A database of individual cell expansion processes was assembled based on a 
literature search for articles that have a detailed description of one or multiple 
cell culture processes. This database therefore not necessarily represents the 
current situation in industry. If multiple processes were described in one 
article, for example comparing different microcarrier densities or protein 
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sources, all described processes were included. The first criterion for a 
process to be included was that the article described processes for human 
mesenchymal stem cells (MSCs), as claimed by the authors. The second 
criterion was that the scale-up of the process was taken into consideration 
during data collection, with the aim of only including fairly optimised 
processes. However, scale-up was not necessarily the main goal of the article. 
Thirdly, precise information on critical process parameters, i.e. cell type, 
starting cell number at seeding, culture time, final cell yield, culture surface or 
microcarrier concentration, medium composition and exact type of culture 
vessel had to be included in the manuscript, either in text format, table or clear 
graphs. Unfortunately certain MSC expansion articles that were found failed 
to mention some of these critical parameters and were therefore not included. 
Finally, a cell quality read-out was required, either in terms of the 
International Society for Cellular Therapy (ISCT) criteria or a potency assay 
(Dominici et al., 2006), as long as it evaluated the influence of the process on 
relevant quality attributes of the specific cells. Although extremely important, 
(parts of the) processes that described “passage 0” (P0) results were excluded 
as the precise number of MSCs initially present within the biopsy is unknown. 
Most processes were situated between passage 1 and passage 6 (on the use of 
passage number as a metric, see below). Additional parameters that were 
collected in the database for their potential effect on the therapeutic 
effectiveness of the cells or indirect relation to the efficiency or cost of 
production, but that are therefore not explicitly used further in this work, are: 
brand of culture vessel, specific culture surface and coating, working volumes 
and refreshment rates, oxygen concentrations, maintenance of cell function or 
potency (yes/no) and bead-to-bead transfers in microcarrier culture (yes/no). 
3.4.2. Metrics for process comparison 
In order to allow a fair comparison between all the different processes in 
different culture vessels, specific metrics were calculated from the collected 
data of which the authors believe that they can provide objective comparison 
over multiple systems and cell types. For example, passage number is still 
often used to define the extent of cell growth. However, in contrast to the 
number of population doublings, this metric does not describe the 
proliferative precedent of the cultured cells. Similarly, in 2D culture the 
seeding and harvesting densities are generally stated as cells per cm2 of 
available culture surface. As the exact culture surface is generally less easy to 
quantify for different microcarrier types this metric cannot be used for 
comparing all different culture vessels. One metric that was therefore used 
often in this work is Expansion Factor or Expansion fold (EF) as this allowed 
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us to estimate how efficient the generation of cells during a certain process 
step was, irrespective of the available culture surface or the vessel volume. 
𝐸𝑥𝑝𝑎𝑛𝑠𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑜𝑟 𝑒𝑥𝑝𝑎𝑛𝑠𝑖𝑜𝑛 𝑓𝑜𝑙𝑑 (𝐸𝐹)
=
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 in vessel at harvest ∗ 𝑑𝑜𝑤𝑛𝑠𝑡𝑟𝑒𝑎𝑚 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑 ∗ 𝑠𝑒𝑒𝑑𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦
≈
𝑓𝑖𝑛𝑎𝑙 𝑐𝑒𝑙𝑙 𝑦𝑖𝑒𝑙𝑑
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑
 
As the downstream process efficiency (e.g. taking into account the amount of 
cells lost during harvest or volume reduction processes, before the actual 
count of the cell yield) is generally not separately quantified in literature, the 
enumerator was simplified to the reported final cell yield. Estimates for 
seeding efficiency are more often mentioned for microcarrier processes, but 
are generally not available for flask-based or hollow fibre processes. 
Therefore also the seeding efficiency was not taken into account for the 
expansion factor calculation in this work. If an expansion factor was provided 
in the article that took seeding efficiency into account, it was recalculated in 
order to not include the cells lost at seeding, therefore resulting in a simple 
“cells out” over “cells in” ratio. When using the expansion factor metric as a 
measure for expansion efficiency, starting from the total initial number of 
cells seeded is more accurate from a process efficiency point of view 
compared to using the number of cells that are effectively seeded. Taking into 
account the exponential growth of cells, losing even small amounts during 
seeding quickly becomes expensive as these lost cells do not contribute to the 
final yield. 
Reversely, to calculate the effective population doublings (PDs) and 
population doubling times (PDT) it is necessary to quantify and take into 
account the seeding efficiency as otherwise the apparent PDT seems longer 
than the effective PDT. Note that here the apparent PDT was calculated based 
on the initial and final cell number (as seeding efficiency and downstream 
process efficiency is generally not quantified in all articles) and therefore also 
includes lag phase and possible stationary phase at the end of the culture time: 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑑𝑜𝑢𝑏𝑙𝑖𝑛𝑔𝑠 𝑝𝑒𝑟 𝑝𝑎𝑠𝑠𝑎𝑔𝑒 = 𝑃𝐷 = 𝑙𝑜𝑔2(𝐸𝐹) 
𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑑𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 = 𝑃𝐷𝑇 =
𝑐𝑢𝑙𝑡𝑢𝑟𝑒 𝑡𝑖𝑚𝑒
𝑃𝐷
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The final volumetric cell density was calculated as the total number of cells 
harvested divided by the total medium volume (working volume) in the 
culture vessel. This metric was taken as a proxy for the load on downstream 
processes as it was considered that in relative terms larger cell numbers in 
smaller volumes are less cumbersome during volume reduction and possible 
purification steps. 
For the classification in low and high supplemented protein concentrations an 
arbitrary cut-off point at 5% was chosen. A medium composition with more 
than 5% Foetal Bovine Serum (FBS) or human Platelet Lysate was considered 
to be “high FBS” and “high HPL” respectively. Medium compositions with 
concentrations equal or lower than 5% FBS or HPL were considered to be 
“low FBS” and “low HPL” respectively. 
3.4.3. Cost calculations 
Cost calculations were based on the cell expansion processes required for 
large pre-clinical studies performed in the host lab (Prometheus, KUL) for the 
treatment of large bone defects with hPDCs. The calculated cost included 
labour costs for the operators at KU Leuven, disposable costs at list price and 
reagent cost at list price for the expansion of 20 million hPDCs to 350 million 
hPDCs. Other costs such as lab space, depreciation costs and utilities were not 
included. All processes were performed in DMEM high glucose supplemented 
with 10% irradiated FBS. The hollow fibres of the Terumo BCT bioreactor 
were coated with human fibronectin, while no fibronectin was used in the 
other culture vessels.  
3.4.4. Visualisations 
The visualisation tool was created with JavaScript and Google Charts and the 
visuals are generated automatically from the database that is hosted online. In 
this way the tool can be easily updated with new processes when new 
publications become available. The process performance maps shown in this 
article are static representations of the interactive visualisation tool. In the 
online version, the viewer is able to select processes per vessel type or per cell 
type. The authors would like to encourage the reader to open the following 
link (mtm.kuleuven.be/prometheus/processmap) in their browser in order to 
experience the interactive dataset visualisation.  
 Results and Discussion 3.5.
Based on data acquired through a literature search and subsequent data 
extraction, 73 individual bioprocesses were included in the visualisation tool. 
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The database included 7 different MSC types (Figure 3.2A), 5 different types 
of culture vessel (Figure 3.2B) and many different medium compositions that 
are roughly categorised based on protein source in Figure 3.2C. Although this 
data is based on research articles, the distribution of cell types used is 
comparable to the cell types used in recent clinical trials (e.g. 62% BM MSC 
and 15.4% ADSC as collected in (Heathman et al., 2015a), and 56% BM 
MSC and 12% ADSC as collected in (Sharma et al., 2014)).  
 
Figure 3.2: Overview of (A) cell types, (B) types of culture vessel, and (C) general source of 
protein supplement used for MSC expansion that are included in the database.  
MSC = Mesenchymal Stromal Cell, BM = Bone Marrow, ADSC = Adipose Derived Stem Cell, 
hPDC = human Periost Derived Cell, UC=Umbilical Cord, FBS = Fetal Bovine Serum, HPL = 
Human Platelet Lysate. 
3.5.1. Visualising process performance 
In order to present a complete overview of all the processes, an interactive 
tool was created where process performance maps can be plotted allowing a 
visual analysis of MSC culture expansion across studies. The interactive 
version of the visualisation tool can be accessed online at the following link 
(mtm.kuleuven.be/prometheus/processmap). For all process performance 
maps presented in this work the Y-axis represents the expansion factor for a 
single passage as an approximation of the expansion efficiency. The scale of 
each process is reflected by the X-axis that is indicating the final cell yield of 
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the passage. Figures 3, 4 and 5 provide additional information regarding cell 
density (cells/ml) at harvest represented by the size of the circles, while 
different colours are indicative of the specific MSC type.  
An interesting observation is that there seems to be a barrier on the process 
scale around a batch size greater than 1x109 cells that is not often exceeded in 
the scientific MSC expansion literature. This could indicate a technological 
barrier (i.e. size of bioreactor or load on downstream processes), or a current 
lack of market demand. For certain cell types and medium combinations this 
might also imply a biological barrier as certain MSC types undergo 
senescence after an extensive amount of population doublings (Larson et al., 
2010). 
With the interactive visualisation tool it is possible to categorize the process 
performance maps, for example based on the type of culture vessel. In the 
case of microcarrier based suspension culture (Figure 3.4) a “linear” 
correlation on the log-log plot (therefore actually an y=axb correlation) 
between the final cell yield and the expansion efficiency can be witnessed. 
This is surprising considering the wide range of process parameters that could 
affect the expansion factor and final yield in a microcarrier-based process, e.g. 
the type of microcarrier, microcarrier concentrations, energy dissipation rate. 
Contrary, in the case of multi-layered tissue flasks where there are much less 
process parameters that need to be optimised, a more scattered picture is 
observed in Figure 3.5. The multilayer flask-based processes seem to show 
both some of the most efficient processes as well as some of the least efficient 
processes for a certain scale, however average values are close to those 
observed in the microcarrier case. In recent work (Nienow et al., 2016) the 
relative performance of MSCs from different donors was reported to be the 
same for cell culture flasks and during experiments with the same cells on 
microcarriers.  
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Figure 3.3: Capture of an interactive process performance map on 73 different cell expansion 
processes.  
The y-scale indicates the expansion factor, the x-scale indicates the total cell yield, the colour 
of the dots indicates the specific MSC type. The size of the circle indicates final cell density 
(cells/mL) prior to the cell harvest step. 
 
Figure 3.4: Selection of the microcarrier-based MSC expansion processes present in the 
database.  
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The y-scale indicates the expansion factor, the x-scale indicates the total cell yield, the colour 
of the dots indicates the specific MSC type. The size of the circle indicates final cell density 
(cells/mL) prior to the cell harvest step. 
 
Figure 3.5: Selection of the multilayer flask-based MSC expansion processes present in the 
database.  
The y-scale indicates the expansion factor, the x-scale indicates the total cell yield, the colour 
of the dots indicates the specific MSC type. The size of the circle indicates final cell density 
(cells/mL) prior to the cell harvest step. 
In an alternative visualisation of the process performance map (Figure 3.6) it 
was chosen to use the same axis for scale and expansion efficiency (x and y 
respectively), but while the first version fousses on the technical side of the 
process by providing information on the type of bioreactor and load on 
downstream processes, here it was chosen to show more the biological side of 
the process. Therefore in this case, the color of the circle represents the 
amount and source of protein supplemented to the medium (i.e HPL, FBS or 
serum free medium) and the size of the circle represents the apparent 
population doubling time of the cells. The interactive format allows to sort the 
processes per cell type. It can be seen that the size of the circles was generally 
larger at the bottom of the map, indicating a longer population doubling time 
and therefore suggesting that the lower expansion factor of these processes 
could be attributed to a slower growth rate of the cells. Interestingly, both 
high and low protein content medium supplements were able to support very 
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efficient cell growth. HPL supplemented media result in relatively small 
circles, indicating fast population doubling times, and were therefore 
generally located at an average or higher expansion factor for a certain 
process scale. This indicates a more efficient cell growth in HPL 
supplemented medium which is often concluded from comparative studies 
between FBS and HPL containing media (Tan et al., 2015). Notwithstanding 
the clear benefits of serum-free cultures, from a process efficiency point of 
view certain serum-free processes reach an average expansion factor for a 
certain scale, while most of them currenlty resulted in a less efficient 
expansion process and therefore seemingly required further developments in 
order to accommodate every cell type – culture vessel combination (Tan et al., 
2016). 
 
Figure 3.6: Capture of an interactive process performance map on 73 different cell expansion 
processes.  
The y-scale indicates the expansion factor, the x-scale indicates the total cell yield, the colour 
of the dots indicates the source of protein supplements in the medium. The size of the circle 
indicates the population doubling time of the cells (larger bubbles indicate longer population 
doubling times). 
Another interesting observation that could be made from Figure 3.3 and 
Figure 3.6 together was that the 5 “best in class” processes that were able to 
show expansion factors above 100, all originate from the same research lab 
where a notable lower cell seeding density was used in multi-layered flasks 
(30 to 40 cells/cm2, compared to the average over het whole database of ± 
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3900 cells/cm2) in combination with relatively high concentrations of 
supplemented protein (10% HPL or FBS), and this for 2 different cell types 
(BM MSC and UC MSC). It is regularly stated in literature that lower seeding 
densities promote faster population doublings, therefore in turn allowing 
larger and more efficient expansion factors (Balint et al., 2015).  
3.5.2. Considering cost-effectiveness during bioprocess 
design 
Cost of Goods (COGs) and cost breakdown structures are generally not 
mentioned in articles on stem cell expansion and could therefore not be 
included in the database. However, there exists a need for more cost-effective 
production methods that yield large numbers of high-quality cells at a 
commercially viable price in order for cell therapies to be affordable for 
healthcare systems and reimbursement. Therefore a cost calculation from 
multiple standardised large-scale expansion processes as performed multiple 
times in the host lab for a forthcoming clinical trial was included in order to 
provide a COGs reference value for the different types of processes described 
in the database. The calculation specifically compared the expansion of 20 
million hPDCs to 350 million cells in high-glucose DMEM supplemented 
with 10% irradiated FBS in T175 tissue culture flasks, a hollow fibre 
bioreactor (Terumo BCT Quantum® Cell Expansion System, (Lambrechts et 
al., 2016b)) a multiplate bioreactor (Pall Integrity Xpansion, (Lambrechts et 
al., 2016a)) and in a spinner flask with CultiSpher-S microcarriers 
(unpublished results). Figure 3.7 illustrates the total cost per million of cells 
cultured in these vessels for the specific pre-clinical expansion process in the 
Prometheus lab. The reagent, disposable and labour axis provide the cost-
breakdown of the total cost. The average expansion factor axis represents the 
expansion factor that was obtained per vessel for the hPDCs, and is included 
since this significantly influences process efficiency and cost. For the final 
axis, the number of built-in sensors was used as a measure for the monitoring 
capability of the vessel, since these features are increasing the COGs but 
facilitate the clinical translation. 
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Figure 3.7: Cost breakdown structure. 
Cost breakdown structure of a standardized large-scale cell expansion process of 20 million 
hPDCs to 350 million cells in high-glucose DMEM supplemented with 10% irradiated FBS in 
T175 tissue culture flasks, a hollow fibre bioreactor (Terumo BCT Quantum® Cell Expansion 
system a multiplate bioreactor (Pall Integrity Xpansion), and in a spinner flask with CultiSpher-
S microcarriers. 
Since these processes were carried out by the same operators, with a common 
end-goal, and with the same cell type and medium formulation, the authors 
believe these cost calculations form a fair comparison between multiple 
systems regarding COGs and cost distribution specifically for the scale of 
operations at Prometheus KU Leuven. These estimations could represent a 
manufacturing scenario for early stages of an advanced-therapy medicinal 
product (ATMP) development and potentially up to clinical trial phase I. It 
should be emphasised that these data were generated in a university setting 
and therefore they could potentially differ from an industrial setting regarding 
labour costs as well as laboratory practice. Moreover, even though the 
cultured cells were expanded for pre-clinical trials, the process was not yet 
entirely compliant to cGMP (Current Good Manufacturing Practices) which 
would lead to increased costs, mainly for the manual culture processes, once 
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the setting is switched. Even so, it is expected that the trends between the 
different culture processes will remain relatively similar. It can be seen that 
closed-system bioreactors entail high COGs, mainly due to the current high 
cost of the disposables (expected to eventually drop as the market grows), 
whereas the labour costs are reduced due to partial automation of the process. 
At this scale, the tissue flask-based strategy is still competitive, while further 
scale-up will favour microcarrier-based production.  
An ongoing discussion exists in the bioprocessing field regarding the design 
of the most cost-effective bioprocess strategies for autologous and allogeneic 
cell production on the basis of “scale-out” or “scale-up”. While scale-out is 
simply doing more of the same (parallelisation of processes with the same 
dimensions), scale-up envisions a direct increase in volume or surface of the 
culture. In the case of an allogeneic therapy it seems that a scale-up strategy in 
which a transition from 2D (flask-based) culture towards microcarrier-based 
stirred tanks is the most attractive option, and there are bioprocess-economic 
models that support this strategy (Simaria et al., 2014a). The economics of 
allogeneic expansion for pluripotent stem cells (iPSCs and ESCs) have been 
recently modelled and described both for the upstream (Jenkins and Farid, 
2015) as well as for the subsequent downstream operations (Hassan et al., 
2015). However, this is not yet clearly addressed in the case of autologous 
large-scale expansion, where most likely a generic solution might not exist 
and optimal solutions might be case specific, based on inherent cell or donor 
properties as well as practical limitations (e.g. cells obtained from biopsies vs. 
cells required for therapy) (Hourd et al., 2014). The use of such deterministic 
models for the autologous case would therefore be a challenging task due to 
the inherent donor-related variability and uncertainty involved in these 
processes. 
3.5.3. Integrated bioprocess design: downstream processes 
MSC expansion (the “upstream” process) has gained considerable attention, 
addressing to a certain extent the scalability and GMP considerations. 
However, we are still far from whole-bioprocessing design. Downstream 
processing is only recently gaining attention as a result of the increasing 
volumes and batches of cells produced at the upstream stages. For example, 
the dynamic harvest of MSCs from microcarriers in suspension reactors was 
recently investigated providing scalable methodologies (Nienow et al., 2014), 
while in a follow up study the authors linked this process to the subsequent 
cryopreservation step (Heathman et al., 2015d). Dynamic harvest of single 
cells from fixed bed bioreactors was also recently described for the recovery 
of hPDCs that retained their regenerative potential in vivo (Sonnaert et al., 
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2015a) and the recovered viable cell fraction per step during the harvest and 
volume reduction proces in a multiplate bioreactor was described in 
Lambrechts et al. (2015). Downstream operations are gaining importance for 
stem cell bioprocessing, and initial discussion on separation techniques 
reviewed by Diogo et al. (2012) are now translated increasingly in research 
results. An increasing number of bioprocesses and methods for the 
clarification and volume reduction of MSC suspensions using membranes and 
tangential (Cunha et al., 2015a; Cunha et al., 2015b) or dead-end (Tostões et 
al., 2015) filtration have been recently described. Moreover the use of 
expanded bed chromatography for the washing of MSC suspension resulted in 
improved efficiency (Cunha et al., 2016). This shows the rapid evolution of 
the field in reaching a pipeline of unit operations for (autologous) MSC 
manufacturing, customized per application and from patient-to-patient. By 
developing similar data-based visualisation tools for downstream operations 
as was done here for the upstream process, a whole bioprocess design 
approach could be further exploited.  
3.5.4. Rational data-based bioprocess design 
As illustrated before by the large variety in the process maps, there is growing 
awareness on the need for standardization given the specialised and complex 
components involved in cell therapy research and development (Bravery and 
French, 2014). The lack of standardisation, or at least some degree of 
harmonisation, hampers a swift transition from the development phase that is 
often based on trial and error, to the translational stage that requires robust 
and cost-effective processes (Kinzebach and Bieback, 2013). For instance, the 
adoption of improved standards for stem cells entering clinic (Dolgin, 2014) 
was recently suggested. Regarding input cell material, recent literature has 
highlighted the need for standardised MSC lines as calibration tool (Deans, 
2015) or reference material (Viswanathan et al., 2014) while a systematic 
data-based approach and centralized manufacturing facilities able to conduct 
systematic comparability studies was advocated McKenna et al. (2014), 
highlighting the invasiveness of the immortalisation of the standardised MSC 
lines to the initial cell properties. Moreover in order to address the complex 
regulatory landscape, a cell therapy regulatory toolkit (online regulatory 
resource) was introduced for new ATMPs entering clinical trials for the EU 
and USA (Culme-Seymour et al., 2015). It is clear that a certain degree of 
standardisation would be helpful to move the field forward, however many 
cell-based therapies (in particular autologous therapies) will require 
personalised approaches where flexibility is required in order to allow 
customisation per patient or per therapy. Based on this work we propose and 
illustrate the potential of an in-silico data-based approach, where data related 
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to process performance and efficiency for MSC expansion could be 
concentrated, standardised and analysed based on objective quantitative 
criteria. This could help to obtain insights and conclusions regarding the 
translation of cell therapy and contribute towards efficient MSC bioprocessing 
and manufacturing. A similar data-based initiative was started recently by the 
FDA (Food and Drug Administration) to monitor manufacturing information 
of modified T-cells for cancer immunotherapies (CAR T) 
(http://www.raps.org/Regulatory-Focus/News/2016/03/16/24549/FDA-
Proposes-New-Databases-to-Monitor-CAR-T-Cell-Safety-Across-INDs/). The 
ultimate aim is to rationalize MSC production, i.e. standardising wherever 
possible, but allowing calculated flexibility where needed. However, it speaks 
for itself that process efficiency should not be pursued at the cost of biological 
functionality of the cells since a high expansion efficiency is not necessarily 
linked to therapeutic success. It would be extremely interesting to add a 
measure for the therapeutic potential of the cultured cells in this type of 
databases, however currently there are not often objectively quantifiably 
biomarkers available for the in vivo potential of stromal (or stem) cells, either 
due to a lack of the proper sensors and assays, or due to a limited 
understanding of the mechanism of action. Even if for a specific case a 
potency asasy is available, it is closely linked to the intended clinical 
application of the cells, therefore preventing a fair comparison across multiple 
processes.  
3.5.5. Future Challenges 
The authors will attempt to keep the current database updated when new 
relevant publications become available. Access to the database is available 
upon request for collaboration on further data analysis or the addition of new 
parameters. As more and more data is collected in the database, more in depth 
data mining techniques could allow for the extraction of data-driven strategies 
for bioprocess improvements. From the bioprocess design point of view, the 
incorporation of time-series data (Viazzi et al., 2015) or process parameters 
that quantitatively describe the dynamic culture environment (Lambrechts et 
al., 2014) could provide much more insightful information on the dynamics as 
well as the robustness of MSC bioprocesses. For example for stirred vessels, 
parameters such as energy dissipation rate, shear stress or oxygen transfer 
characteristics could provide readouts for shear stress and mass transport 
properties. Unfortunately, there are very few studies reporting on these 
readouts for dynamic MSC expansion. For instance Nienow et al. (2016) 
evaluated agitation conditions across a number of stirred reactors widely used 
for microcarrier-based MSC expansion. By providing this kind of information 
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an identification of optimal bioprocess operating conditions could be also 
achieved. 
From the cell quality attributes point of view, although ISCT criteria provide 
minimum cell identification criteria (Dominici et al., 2006), processes should 
be also linked to potency assays of increased sensitivity and functionality that 
could however be application specific. For instance, the performance of 
expanded cells in an in vivo setting is usually omitted and only seldom linked 
to its bioprocess history. There is still a need for predictive potency assays 
that correlate with in vivo activity, to ensure product comparability during 
manufacturing changes (Bravery et al., 2013). For most of the studies 
included in this paper the link with the impact of process conditions on MSC 
in vivo performance has been largely ignored, and only a handful of studies 
evaluated this.  
 Conclusion 3.6.
The steady increase in MSC production scales demonstrates the continuous 
maturation of the field. However there are considerable challenges to be faced 
for the successful transition from early preclinical to late commercial stage 
manufacturing. A major factor contributing to this challenge is that there is no 
typical, one-size-fits-all manufacturing solution. Therefore we present an 
interactive visualisation tool that provides an integrated perspective on MSC 
expansion that is able to increase the understanding of scale-up and 
commercialization of cell production processes. 
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 Positioning within the context of the PhD project 4.1.
This chapter is one of two ‘scale-up’ chapters were the translation of the 
Prometheus’ standard flask-based cell expansion process to a monitored and 
controlled bioreactor-based process is described. In this case a multiplate 
bioreactor is used. According to Objective 2 in Chapter 2, this translation 
should by all means not compromise the in-vivo bone healing potential of the 
cultured cells, as will be demonstrated here. Additionally, process monitoring 
data such as cell quantification by imaging or metabolic activity was used to 
assure process comparability to the standard flask-based culture as was 
envisioned in Objective 3 in Chapter 2. 
 
Figure 4.1: Position of Chapter 4 in the general control scheme and the larger context of this 
work. 
 
 Abstract 4.1.
In light of the large-scale expansion of human periosteum derived stem cells 
for the treatment of large bone defects, a multiplate bioreactor system (Pall 
Integrity Xpansion) in combination with an integrated holographic imaging 
platform (Ovizio iLine S microscope) was evaluated. The culture process was 
quantitatively characterized by imaging data, metabolite concentrations and a 
breakdown of the cell recovery fractions. The resulting cell quality was 
assessed based on the minimal criteria for mesenchymal stem cells, including 
viability on cell culture plastic, identity markers and tri-lineage differentiation 
potential. Additionally, an in vivo bone forming potency assay was used in an 
ectopic mice model that resulted in compelling bone formation (11.6% ± 
3.1% and 12.8% ± 3.3% for the bioreactor and control tissue culture flask 
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condition respectively). Therefore it was shown that the bioreactor is able to 
produce large quantities of cells, while maintaining satisfactory cell quality. 
 Introduction 4.2.
Currently, more than 1300 active clinical trials are reported using cell-based 
therapies to treat a wide variety of indications ranging from cardiovascular to 
neurological disorders, as well as skeletal disorders (Heathman et al., 2015a). 
Around 380 of these trials use mesenchymal stem cells (MSCs) as the 
therapeutic cell source. While most applications require between 107–109 
MSCs for a single dose (Dos Santos et al., 2014; Simaria et al., 2014a), cell 
expansion is traditionally carried out in 2D (monolayer) static culture set ups 
(e.g. tissue culture flasks or cell factories) that require extensive manual open-
process interventions for media exchange and cell harvest. The high labor and 
infrastructure costs associated with these techniques hamper the socio-
economic viability of the therapy after clinical translation. In combination 
with a lack of suitable potency assays related to the in vivo biological 
response of the cells (Bravery et al., 2013), the relatively low number of 
successful clinical translations of cell-based therapies are mainly attributed to 
the challenges associated with the production of the required cell numbers, 
while at the same time assure high and reproducible cell quality (Placzek et 
al., 2009; Rowley et al., 2012; Sharma et al., 2011; Simaria et al., 2014a). 
This highlights the rising need to develop and incorporate automated 
bioreactor systems for large-scale production of progenitor cells for clinical 
applications.  
Additionally, due to the inherent complexity of biologic processes, traditional 
cell culture processes that were designed by a rule-of-thumb approach are 
difficult to adapt to an efficient and robust clinical process that is able to 
deliver an efficacious product to every single patient. The full potential of 
cell-based therapies will therefore only be able to be harnessed by a cell 
culture process that is standardized, scalable and able to deliver clinically 
relevant cell numbers, while at the same time assure potent biological 
functionality in vivo (Glassey et al., 2011; Rodrigues et al., 2011; Want et al., 
2012). Recently, considerable effort is placed in developing such processes 
based on bioreactor systems, for example in the form of hollow fibre 
bioreactors (Hanley et al., 2014; Peters et al., 2013) and wave-rocking 
bioreactors for microcarrier-based expansion (Sutlu et al., 2010).  
In this work, a monitored multiplate bioreactor (Pall Integrity® Xpansion™ 
equipped with Ovizio iLine S microscope) was evaluated as a platform for the 
clinical-scale expansion of human periosteum derived stem cells (hPDCs) and 
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its ability to monitor the cell expansion process was evaluated. hPDCs are a 
promising source of progenitor cells for the treatment of skeletal defects. 
During the natural bone healing process they have been shown to be the main 
contributors to tissue regeneration (De Bari et al., 2001a; Eyckmans and 
Luyten, 2006), while after ex vivo expansion, they have been recently shown 
to possess improved bone forming capabilities compared to other MSC 
sources (e.g. bone marrow and synovium) when seeded on calcium phosphate 
carriers (Roberts et al., 2014). 
Using this multilayered bioreactor, limited changes to the classical planar cell 
culture process are required as opposed to, for example, microcarrier-based 
cell expansion where complex process variables need to be optimized (e.g. 
material/surface properties, hydrodynamics)(King and Miller, 2008). This is 
due to the fact that cells are seeded and cultured on a 2D cell culture surface 
similar to the conditions found in standard tissue culture flasks. In addition, 
the extensive quantitative bioreactor read-outs that can be obtained at-line, 
such as dissolved oxygen concentrations, pH and microscopic images, can be 
used to improve the control over the expansion process, ultimately leading to 
a more robust in vivo outcome (Thomas et al., 2008). 
The objective of this work is the development of a clinical scale bioreactor 
process for the expansion of hPDCs in the Xpansion bioreactor. The 
advantages of thorough process monitoring are illustrated and the synergy 
between the multiplate bioreactor and the mounted microscope is highlighted. 
In addition to the standard post-harvest in vitro cell characterization assays 
that were performed, an in vivo potency assay was implemented which is 
often lacking in bioprocess studies relevant to cell therapy applications.  
 Materials and Methods 4.3.
The experimental outline consists of 4 consecutive phases: (1) a pre-culture 
phase in tissue culture flasks in order to reach the amount of cells required for 
bioreactor seeding, (2) 7 days of bioreactor expansion with continuous 
monitoring of multiple process parameters, (3) cell harvest and concentration, 
and (4) post-harvest cell characterization in which the cells from the 
bioreactor are compared to a target quality profile of cells cultured in parallel 
in standard tissue culture flasks (Figure 4.2). The in vitro cell characterization 
is inspired on the International Society for Cellular Therapy (ISCT) minimal 
criteria for MSCs (Dominici et al., 2006), supplemented with a bone forming 
assay in order to assess the in vivo potency of the cells (Bianco et al., 2014). 
The bioreactor process was first evaluated and adapted to the needs of hPDCs 
in three small scale process development runs in the Xpansion-10. In a 
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following phase the process was translated to a larger scale bioreactor 
(Xpansion-50) that resembles the clinical-scale production.  
 
Figure 4.2: Overview of the general experimental outline with an initial tissue culture flask-
based pre-culture phase, followed by the Xpansion bioreactor culture.  
During the bioreactor culture the cell growth was monitored based on daily images from the 
Ovizio iLine S microscope and samples of the medium. Three standard tissue culture flasks 
were cultured in parallel as a positive control. Immediately after cell harvest and cell 
concentration the cell characterisation was initiated, including among others, an in vivo bone 
forming potency assay. 
 
4.3.1. Flask-based hPDC culture 
hPDCs were isolated from 4 different donors by means of enzymatic digestion 
of a periost biopsy as described by Eyckmans et al. (Eyckmans et al., 2010). 
Procedures were approved by the ethical committee for Human Medical 
Research (KU Leuven) and patient informed consent forms were obtained. 
The isolated cells were cultured in T25 flasks for the first passage in standard 
culture medium consisting of high glucose GlutaMAXTM Dulbecco’s 
modified Eagle’s medium (Life Technologies, Merelbeke, Belgium) 
supplemented with 10% irradiated fetal bovine serum (FBS; HyClone, 
Cramlington, UK), 1% sodium pyruvate (Invitrogen) and 1% antibiotic–
antimycotic (100 units/ml penicillin, 100 mg/ml streptomycin, and 0.25 
mg/ml amphotericin B; Invitrogen). Cells were further cultured in T175 flasks 
with a seeding density of 5 700 cells/cm2 and sub-cultured at ± 80% 
confluence. At passage 3, the cells from the 4 different donors were pooled all 
together and further expanded in T175 flasks up to passage 7 (approximately 
12 total population doublings). hPDCs generally maintain linear growth 
curves for over 30 population doublings (De Bari et al., 2006). At all 
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passages, cells were harvested by trypsinization for 10 min with TrypLE 
Express (Invitrogen). 
4.3.2. Bioreactor based hPDC culture 
The Pall Life Sciences Xpansion™® (Pall Life Sciences, Brussels, Belgium) 
is a multiplate bioreactor that houses from 10 to 200 hydrophilised 
polystyrene plates of ± 612 cm2 each (Figure 4.3). The plates are tightly 
packed around a central aeration column, that provides gas exchange 
controlled by an active gas flow controller. Based on the integrated 
temperature, dissolved oxygen and pH sensors, the culture conditions can be 
monitored and controlled (Castillo et al., 2013; Egloff and Castillo, 2012). 
Additionally, by making use of the holographic Ovizio iLine S microscope 
(Ovizio Imaging Systems, Brussels, Belgium), the cells inside the bioreactor 
can be visualized and critical process parameters such as cell density and 
morphological features can be non-invasively extracted in a quantitative way. 
After passage 7, the cells were transferred to the multiplate bioreactor with a 
total culture surface of 6 125cm2 (Xpansion-10) for the first 3 process 
development runs, and later to the Xpansion-50 with a total culture surface of 
30 600 cm2. The bioreactor and culture medium were pre-heated overnight in 
the incubator at 37°C in order to prevent gas bubble formation during filling. 
For each bioreactor run, at least 3 control tissue culture flasks were taken 
along as positive control for the cell expansion procedure and subsequent cell 
characterization. The control tissue culture flasks were seeded at the same 
initial seeding density as the bioreactors in order to compare growth kinetics. 
The inoculation densities of the bioreactor were corrected for the void 
volumes in the bioreactor (i.e. central aeration column and headspace) 
according to the manufacturer’s instructions to assure a similar density on the 
bioreactor plates as in the control tissue culture flasks. For the Xpansion-50 
bioreactor it was calculated that a little more than 85% of the cells from the 
inoculation volume will settle on the bioreactor plates. The seeding volume in 
the Xpansion-10 was 1.7 L, in the Xpansion-50 the volume was 5.7 L. After 
transferring the inoculation volume to the bioreactor, the bioreactor was 
incubated at 37°C for 7 days in parallel with the control flasks. The automated 
controller was only allowed to engage 9 hours after seeding in order to allow 
sufficient time for cell attachment, as the controller actions are accompanied 
by mixing of the medium. 
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Figure 4.3: Illustration of the bioreactor design.  
A) Bioreactor housing from bottom to top: bottom plate that fits on a magnetic stirrer which is 
installed in the incubator, magnetic impeller that drives the medium flow between the plates, 
cylindrical housing in which the polystyrene plates are tightly packed around the central 
aeration column, top plate with the connection to the gas flow rate controller, sensor probes, 
sampling lines and vent. The tubes for filling and draining the bioreactor are connected to the 
bottom plate of the bioreactor and shown on the sides. Note that the height of the housing is 
adapted to the number of plates for the different bioreactor scales. B) Stack of polystyrene 
plates inside the bioreactor housing. The red arrows indicate the medium recirculation through 
radial channels in the plates and through the aeration column. C) Close-up of central aeration 
column that provides gas exchange with the culture medium. D) Close-up of side view on three 
plates where the radial channels allow medium perfusion over the cells. The available culture 
surface per plate is 612 cm2 and the headspace between each plate is 1.6 mm, and this for every 
scale of the bioreactor. E) Close-up of bottom plate where the culture medium is recirculated by 
the impeller through the radial channels in the plates towards the top of the bioreactor. 
Illustration courtesy of Pall Corporation. 
 
The cells grown in the bioreactor were harvested after 7 days, together with 
the control flasks. First, after draining the culture medium, the bioreactor was 
rinsed once with pre-heated PBS (one bioreactor volume). A pre-heated 
diluted TryplE concentration was used (5 times diluted in PBS), supplemented 
with EDTA (ethylenediaminetetraacetic acid) to a final concentration of 1.8 
mM to harvest the cells from the bioreactor plates. This adapted harvest 
solution was optimized in T25 flasks based on a novel method that allows for 
the real-time quantification of the harvest kinetics by an imaging algorithm 
and the determination of cell yield and viability (Viazzi et al., in 
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preparation/press). For the bioreactor harvest a diluted harvest solution was 
preferred over the standard TryplE harvest as the final harvest volume is 
relatively large (5.6 L for the Xpansion-50, 21.9 L for example for the 
Xpansion-200). Therefore, to facilitate the downstream processing it was not 
chosen to neutralize this volume, as this would increase the volume even 
more, and spin down the harvested cells in the diluted TryplE solution.  
Right after adding the harvesting solution to the bioreactor, the vessel was 
moved to the microscope platform in order to visually assess cell detachment 
from the plates. In parallel, one of the control flasks was harvested with the 
same adapted harvest solution in order to assess the effectiveness of the 
solution and to have a reference for the required incubation time. Once all 
cells were circular and started to detach from the polystyrene plates, the vessel 
was mechanically shaken on the Xpansion harvest station to completely 
detach the cells. The cell suspension was subsequently drained from the 
bioreactor under constant agitation in order to keep the cells in suspension. 
The harvested volume was then reduced by spinning down the non-
neutralized cell-containing harvest solution. As a final step, the bioreactor was 
rinsed with PBS and placed under the Ovizio microscope again to check the 
harvest efficiency. 
As the cell harvest in the Xpansion bioreactor is a critical step in the process, 
the cell recovery efficiency was identified after each step in the entire process. 
As shown in section 4.3.1, cell density at the day of harvest was determined 
by the Ovizio microscope. This density was used as the reference (100%). 
Viable cells were counted on samples from the waste medium drained from 
the bioreactor at day 7, from the 1st PBS rinse, the non-neutralized harvest 
volume, the suspension after volume reduction and the 2nd PBS rinse after 
harvest based on trypan blue exclusion. 
Monitoring and control of cellular environment in the bioreactor 
Temperature, pH and dissolved oxygen concentration were continuously 
monitored at the top plate of the bioreactor. The pH and oxygen concentration 
were actively controlled by the injection of gasses (CO2, O2 and N2) through 
the central aeration column. pH was set-up to be controlled between 7.25 and 
7.56 for the runs in the Xpansion-10 bioreactor, and between 7.42 and 7.56 
for the Xpansion-50. These set points were based on observed culture 
conditions in standard tissue culture flasks. The dissolved oxygen 
concentration was set-up to be higher than 40% air saturation, with the main 
goal of preventing anoxic conditions in the bioreactor. The mixing of the 
culture medium is effectuated by a magnetic impeller at the bottom of the 
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bioreactor. The magnetic stirrer was automatically engaged (0.5 mm/s) during 
injection of gasses for pH or O2 control to assure sufficient mixing. When the 
gas controller was idle, the agitation rate in the Xpansion-10 runs was set up 
in a way that it would exhaustively mix the bioreactor volume at least every 4 
hours (i.e a mixing time of 20 min every 4 hours according to the 
manufacturers specifications). In the Xpansion-50 bioreactor continuous 
agitation was applied resulting at low linear speed (0.5 mm/s, 40 rpm) in order 
to mix the medium as much as possible. The bioreactor medium and control 
flask were sampled daily and lactate concentrations were determined 
immediately (Arkray Lactate Pro). The bioreactor was sampled via the 
sampling line, only after the bioreactor volume was mixed for at least 20 
minutes. Samples for lactate, glucose, glutamine and glutamate were also 
measured on frozen samples using a YSI 2950 Biochemistry Analyser 
(Ankersmid M&C, Wilrijk, Belgium).  
Metabolite analysis 
An estimation of the oxygen consumption rate during the exponential growth 
phase in the Xpansion-50 bioreactor run was determined based on the 
measured oxygen concentration in the bioreactor. As the perceived oxygen 
uptake rate is influenced by the supply of external gasses, only oxygen 
concentration data was used during time points at which the controller was 
inactive. Within the exponential growth phase 7 timeframes were selected 
with a length of 4 hours (i.e. approximately equally spread out between day 
1.5 and day 5), that were located at least 2 hours after gas injection or 
controller disconnection during imaging. The 4 hour timeframe was 
considered to have sufficient samples for a robust consumption rate 
calculation, while it is short enough to assume constant cell numbers. The 
midpoint of the 4h timeframe was used for a linear interpolation between 2 
daily cell density measurements from the Ovizio microscope. Based on the 
interpolated cell number, a cell specific oxygen consumption rate was 
calculated. This oxygen consumption estimation assumed a closed system, 
since the contact surface of the filter on the gas vent is negligible compared to 
the 5.7L volume of the Xpansion-50 bioreactor. 
The glucose and lactate consumption rates were calculated between 
consecutive daily samples and normalized to cell number to obtain cell 
specific consumption and production rates using the equation: 𝑞𝑀𝐸𝑇 =
∆𝑚𝑒𝑡/(∆𝑡. 𝑐𝑒𝑙𝑙), where ∆𝑚𝑒𝑡 (mM) is the change in metabolite 
concentration during the time period ∆𝑡(days) and 𝑐𝑒𝑙𝑙 (cells) the average 
number of cells during the same period. The metabolic ratios (qMET1/qMET2) are 
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calculated by dividing the average consumption or production rates of the 
same time period. 
Process monitoring by holographic imaging 
Cell growth in the bioreactor was monitored on a daily basis by disconnecting 
the gas and sensor lines, taking the bioreactor out of the incubator and placing 
it under the Ovizio microscope. The microscope set-up allows taking multiple 
holographic images per plate, and this for the upper ±10 plates. The OsOne 
software (Ovizio, Brussels, Belgium) allows to semi-automatically quantify 
the number of cells, the cell density on the plates and is able to provide 
specific morphological features per cell.  
4.3.3. Post-harvest cell characterization 
Growth kinetics 
Growth kinetics of the harvested cells was monitored via the PrestoBlue 
metabolic assay (Life Technologies, Merelbeke, Belgium) as described in 
Sonnaert et al. (Sonnaert et al., 2015b). Cells were seeded at 5700 cells/cm2 in 
a 12-well plate. Every day the normal growth medium was replaced by a 10% 
v/v PrestoBlue reagent supplemented growth medium. After 1 hour incubation 
(37°C, 95% RH, 5% CO2) the metabolic activity in the well was quantified by 
fluorescence measurements (Bio-Tek SynergyTM HT, Bad Friedrichshall, 
Germany) with an excitation wavelength of 540nm and an emission 
wavelength of 590nm on 100ml supernatant in a 96-well plate. A higher 
metabolic activity is indicated by higher fluorescent values. 
3-lineage in vitro differentiation potential 
Chondrogenic differentiation of the cultured hPDCs was assessed in a micro-
mass assay as described earlier (De Bari et al., 2001a). In short, 2x105 cells 
were re-suspended in 10 µL culture medium and seeded as micro-mass in a 
24-well plate. After 2 hours incubation (37°C, 5% CO2, 95% RH) 0.5 ml 
standard culture medium was added. After 24 hours, the medium was replaced 
by chondrogenic medium consisting of DMEM/F12 (Life Technologies), 2% 
FBS, 1% antibiotic–antimycotic, 1% ITS Premix (Corning), 100nM 
dexamethasone (Sigma), 10µM Y27632 (Axon Medchem), 50µg/ml ascorbic 
acid, 40µg/ml proline and 10ng/ml recombinant human transforming growth 
factor-β1 (Preprotech, London, UK). The chondrogenic medium was 
refreshed every other day. Micro-masses in normal culture medium were 
taken along as negative control. After 7 days of chondrogenic induction the 
micro-masses were fixed for 1 hour in ice cold methanol and stained at room 
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temperature for 1 hour with a 0.1% Alcian Blue solution in 0.1M HCL at pH 
1.2.  
Osteogenic differentiation was assessed by seeding the cells in 24-well plates 
at a density of 4 500 cells/cm
2
 in 0.5 ml standard culture medium. After 48 
hours the medium was replaced by standard culture medium supplemented 
with 100 mM dexamethasone, 50 µg/ml ascorbic acid and 10 mM β-
glycerolphosphate. The medium was refreshed 3 times per week for 21 days. 
Samples in standard culture medium were used as negative control. Cells were 
fixed prior to analysis in ice cold methanol for 1 hour and afterwards stained 
with a 2% Alizarin Red S solution in Baxter water.  
Adipogenic differentiation was investigated by seeding the cultured hPDCs in 
24-well plates at a density of 1x104 cells/cm2 in 0.5 mL standard culture 
medium. After 24 hours the medium was replaced by adipogenic medium 
consisting of αMEM (Life Technologies) supplemented with 10% FBS, 1% 
antibiotic–antimycotic, 1 µM Dexamethasone, 10 µg/ml human insulin 
(Sigma), 100 µM indomethacin (Sigma) and 25 µM 3-isobutyl-1-
methylxanthine (Sigma). Medium was refreshed 3 times per week. At day 14, 
cells were fixed in 10% formaldehyde for 20 minutes, rinsed shortly with 60% 
isopropanol and stained with Oil Red O. 
MSC phenotyping 
The expression of typical MSC cluster of differentiation (CD) markers 
(Dominici et al., 2006) and lack of expression for the haematopoietic markers 
on the harvested cells was evaluated based on a hMSC Phenotyping Kit 
(Miltenyi Biotec). The CD marker combinations used are CD90+-FITC (clone 
DG3), CD73+-APC (clone AD2), CD105+-PE (clone 43A4E1), CD14- (clone 
TUK4)/CD20- (clone LT20.B4)/CD34- (clone AC136)/CD45- (clone 5BI)-
PerCP. The non-specific isotype control stain panel included mIgG1-FITC, 
mIgG1-PE, mIgG1-APC, mIgG1-PerCP (clone IS5-21F5) and mIgG2-PerCP 
(clone S43.10). 6x105 cells per condition were washed in blocking solution 
(1%FBS in PBS) and the concentrated cell suspension was re-suspended in 
100 µL of stain solution (1:11 antibody dilution in blocking solution) for 10 
minutes at 4°C. After washing the aliquots with blocking solution again, the 
samples were analysed on a FACSCanto (BD Biosciences, San Jose, Ca, 
USA) equipped with FACSDiva acquisition software (BD Biosciences). 10 
000 total events were acquired. Data analysis was done in FlowJo V10 
(TreeStar Inc., Ashland, OR, USA). 
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In vivo bone forming potency assay and quantification 
One million cells in a total volume of 35 µL culture medium were seeded on 
35 mm3 clinical grade orthopaedic 3D matrices composed of calcium 
phosphate particles in an open collagen network (NuOss, ACE Surgical 
Supply Co.,Inc, Hannover, Germany) in triplicates per condition. The 
scaffolds were incubated overnight (37°C, 5%CO2, RH95%) before ectopic 
implantation on the back of nude mice (NMRI-nu/nu). Eight weeks later the 
mice were sacrificed, the scaffolds were retrieved, fixed overnight in 4% 
paraformaldehyde and preserved in PBS before scanning by X-ray computed 
tomography. All animal experiments and procedures were approved by the 
Animal Ethics Committee (KU Leuven). Animals were housed in accordance 
with the guidelines of the Animal Research Centre of KU Leuven. 
The volume of newly formed bone after 8 weeks of in vivo implantation was 
determined by nanofocus X-ray computed tomography (nanoCT) performed 
on a Phoenix NanoTom S (GE Measurement and Control) system equipped 
with a diamond-tungsten target and 0.5 mm aluminum filter. The applied scan 
settings were 60 kV X-ray voltage, 210 mA current, 500 ms exposure time, a 
frame averaging of 1 and image skip of 0. Images were reconstructed with 
Phoenix Datos|x CT software (GE Measurement and Control) and a 3 µm 
voxel size. The quantification of the bone volume was based on a 2-level 
automatic Otsu segmentation algorithm. The match of the segmented areas 
was confirmed visually for each sample. In case of mismatch, manual 
segmentation levels were determined based on the greyscale histogram of the 
whole sample. All image processing was performed in CTAn (Bruker micro-
CT). 
4.3.4. Statistical analysis 
Statistical analysis was performed using Matlab 2013a (The MathWorks, Inc., 
Natick, MA). Independent groups were compared by unpaired Student’s t-
tests, and considered statistically significant in case P-value <0.05. Error bars 
in figures represent standard deviation of mean. 
 Results and discussion 4.4.
4.4.1. Monitoring cell growth 
An example of a holographic image taken at the third plate from the top in the 
Xpansion-50 bioreactor at the final day of culture (day 7) where cells were at 
±80% confluence can be found in Figure 4.4A. Figure 4.4B shows the same 
image after analysis by the OsOne software, where cell perimeter is indicated 
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and counted cells are identified. The software was able to match the cell 
densities with a visual assessment of the original image. The microscope was 
therefore used to quantitatively monitor the bioreactor processes throughout 
the whole culture period in terms of cell number and homogeneity of cell 
distribution. Figure 4.4C shows the average cell density over the 7 days 
culture period, based on the analysis of daily pictures of the top 5 plates of the 
Xpansion-50 bioreactor.  
The Xpansion-50 bioreactor was seeded with a total of 160 million cells in a 
5.7 L seeding volume. Taking into account the void volume in the bioreactor 
this would theoretically result in a seeding density of 4 400 cells/cm2. The 
seeding density of the bioreactor was verified by the microscope (based on 
pictures at day 0 in Figure 4.4C) and was found to be around 4 500 cells/cm2. 
This was close to the theoretical seeding density and matched the density used 
to seed the control flasks (4 400 cells/cm2) (Figure 4.4D, day 0). Additionally, 
referring to the relatively small standard deviation on the microscope-based 
cell density estimate at day 0 in the bioreactor (Figure 4.4C), it can be stated 
that a homogeneous seeding density was achieved, which is important for an 
efficient cell expansion process. Over the 7 day culture period, a sigmoidal 
cell growth can be perceived with a 2 day lag period followed by an 
exponential growth phase, as is common after sub-culturing the hPDCs. The 
stagnation of growth at day 7 indicates confluence of the plates.  
 
60 Evaluation of a monitored multiplate bioreactor 
 
 
Figure 4.4: Monitoring cell growth  
(A) Holographic image at the third plate from the top in the Xpansion-50 bioreactor (B) Same 
image as in A with cell quantifications and signature data by OsOne software (C) Growth curve 
of hPDCs in Xpansion-50 bioreactor based on daily microscope-based quantification of the cell 
density (D) Cell density quantification in the control flasks based on manual counting after 
TryplE harvest. All error bars represent standard deviation of the mean. 
The cell density at the day of harvest was estimated to be around 17 500 
cells/cm2 in the bioreactor based on the data generated by the microscope. 
Given the 4 500 cells/cm2 and 7 day culture period, this corresponds to a 86h 
population doubling time of the cells. In the control flasks, the resulting cell 
density was 17 300 cells/cm2 based on manual cell counts after harvesting the 
flasks with TrypLE (corresponding to a 85h population doubling time of the 
cells). It can therefore be concluded that the growth kinetics and the level of 
confluence in the bioreactor and the control tissue culture flasks are 
equivalent. Population doubling times are comparable to the standard hPDC 
culture, however relatively high compared to typical values for MSCs in 
literature (Baksh et al., 2007; van Harmelen et al., 2004; Jin et al., 2013). It 
was demonstrated before that the continuous agitation in the bioreactor, 
resulting in continuous exposure of the cells to laminar flow (0.5 mm/s) 
would not damage cells, since hPDCs have been cultured regularly in 
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perfusion bioreactor at more intense flow conditions (Papantoniou et al., 
2013; Sonnaert et al., 2014). 
4.4.2. Monitoring metabolic activity 
Dissolved oxygen tension and pH were continuously monitored over the 7 
days of culture, and are shown in Figure 4.5. The short interruptions in the 
bioreactor sensor data are due to disconnecting the bioreactor from the 
controller in order to image the plates with the microscope. Small fluctuations 
in air saturation were caused by the injected air during pH control actions. 
Over the 7 day culture period the pH drops slightly. The dissolved oxygen 
concentration dropped gradually due to cell consumption (until around day 3 
in the Xpansion-10 runs, until day 5 for the Xpansion-50). Afterwards, the 
controller took action to maintain the dissolved concentration above the 40% 
air saturation set. The resulting average cell specific oxygen consumption rate 
during the exponential growth phase was 1.08  ± 0.22 x 10-17mol.s-1.cell-1. 
Although cell type and culture method dependent, this consumption rate is 
around one order of magnitude smaller compared to previously reported 
values in literature for MSCs (Kasper et al., 2010; Pattappa et al., 2011). 
When compared to a previous study on hPDCs specifically, i.e. a flow 
through perfusion bioreactor culture on 3D scaffolds (Lambrechts et al., 
2014), the oxygen consumption rate per cell (1.1 x 10-17 mol.s-1.cell-1) was 
very close to the amount perceived in this study.  
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Figure 4.5: On-line dissolved oxygen concentration (top) and pH (bottom) monitoring.  
A lower threshold of 40% air saturation was chosen, while for the pH a range between 7.25 to 
7.56, and 7.42 to 7.56 was chosen for the Xpansion-10 and Xpansion-50 runs respectively. 
Lactate, glucose, glutamine and glutamate concentrations were measured in 
daily medium samples both from the Xpansion-50 bioreactor and the control 
flask (Figure 4.6). In the Xpansion-10 bioreactor runs only lactate was 
measured, these production profiles showed similar trends as the Xpansion-50 
data (data not shown). Metabolite concentrations in the Xpansion bioreactor 
were similar compared to the tissue flask condition over the 7 days culture 
(Figure 4.6). However, slightly higher lactate concentrations were registered 
in the culture flask condition. The lactate concentration, both in the bioreactor 
and the control flasks, remained well below the growth inhibitory level for 
MSCs (35.4mM) determined by Shop et al. (2009) (Schop et al., 2009). 
Glucose consumption rates and lactate production rates are shown in Table 
4-I. As cell number quantification in the tissue flasks was done only at day 7 
of culture, the cell specific consumption rates and production rates in Table 
4-I for the control flasks are referring only to the last day in culture. The 
average cell specific rates for the bioreactor could be determined daily based 
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on the cell density estimates from the microscope. These rates were relatively 
constant over the culture period and an average is given in Table 4-I. For the 
sake of comparison with the control flasks, the rate at day 7 is also given for 
the bioreactor. The perceived lactate production and glucose consumption 
rates are in line with literature on other MSCs (Higuera et al., 2009).  
Table 4-I: Cell specific glucose consumption rates, lactate production rates and metabolic 
ratios. 
 
Bioreactor Tissue culture flask 
 
Day 7 Average Day 7 Average 
Glucose 
consumption 
(pmol.day
-1
cell
-1
) 
5.1 8.1 ± 0.34 3.4 n.a. 
Lactate production 
(pmol.day
-1
cell
-1
) 
9.2 13.9 ± 0.58 7.9 n.a. 
Ratio 
qLAC/qGLUC 
1.8 1.8 ± 0.37 2.3 2.5 ± 0.39 
Ratio qO2/qGLUC n.a. 0.11 n.a. n.a. 
 
The ratio of produced lactate over consumed glucose (qLAC/qGLUC), which is 
cell number independent, was equal to 2.54 ± 0.39 and 1.82 ± 0.37 for the 
tissue culture flask condition and bioreactor condition respectively, and 
remained stable over the whole culture. Although not significantly different, 
this qLAC/qGLUC ratio suggests that the energy production from glucose was 
more efficient in the bioreactor culture compared to the culture flask, and 
potentially indicates a different utilization of carbon sources. This difference 
might have been caused by the continuous mixing in the bioreactor that 
prevents built-up of diffusion gradients above the cell surface. The ratio of 
consumed oxygen over consumed glucose (qO2/qGLUC) in the bioreactor was 
equal to 0.11. This relatively low qO2/qGLUC ratio in non-hypoxic culture 
conditions, combined with the relatively high qLAC/qGLUC ratio suggested 
aerobic glycolysis as the preferred metabolic pathway during hPDC expansion 
(Cunha et al., 2015a; Sart et al., 2014). 
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Figure 4.6: Accumulated metabolite concentration in bioreactor and tissue culture flask (TCF) 
over the 7 day culture process.  
(A) Glucose and lactate, (B) glutamine and glutamate, continuous lines indicate bioreactor data, 
dashed lines indicate tissue culture flask data. Error bars represent standard deviation of the 
mean. 
Glutamate concentrations remained quasi constant, while the glutamine 
concentration needed around 2 days to reach a ±2 mmol/L level (Figure 4.6). 
The same trend was followed in both conditions, however the glutamine 
concentration was generally lower in the culture flask condition. 
Quantification of cell specific glutamine consumption rate is difficult in 
Glutamax (a more stable L-glutamine L-alanine dipeptide which gets 
hydrolysed by cell activity and is a therefore a steady source of glutamine, but 
which cannot be quantified by the medium analyser) supplemented media and 
without information on ammonia concentrations (the end product of natural 
glutamine decay). 
4.4.3. Bioreactor harvest and downstream processing 
The average total incubation time in the adapted harvest solution for the 
Xpansion was 38 ± 7 minutes. This was ±2 times longer than what was 
required for cell detachment in T175 flasks. It is hypothesized that the 
increase in required incubation time was due to a less effective first PBS rinse 
in the bioreactor, where the serum remnants might have partially inhibited the 
proteolytic trypLE reaction.  
Table 4-II indicates the recovered fraction of viable cells per step in the 
harvest process. The data is based on analysis of the third run in the 
Xpansion-10 bioreactor as this harvest procedure was the most exhaustively 
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analysed and had the furthest developed protocol. The cell count in the waste 
medium and 1st PBS rinse amounted up to nearly 10% of the total amount of 
the cells present on the plates at the time of harvest. However, these steps are 
generally also present in the harvest procedure in the traditional flask based 
process (not quantified in this study) and were therefore irrelevant regarding 
cell yield. More important, ± 82% of the cells were found back in the non-
neutralized harvest suspension. Cells within this fraction were collected by 
centrifugation (290 rcf) and used subsequently for post-harvest cell 
characterization. Another ± 6% of the cells was found in the 2nd PBS rinse and 
on the plates at the end of the harvest procedure. The total of all fractions add 
up to ± 104%. This overestimation is probably due to the fact that two 
different counting methods were used (manual cell counting and the Ovizio 
microscope based counts). Additionally, although prevented by all means 
possible, counting and sampling errors are inevitable in such large volumes 
with in some cases relatively low cell numbers present due to the high dilution 
factors.  
The final step in the harvest procedure was the volume reduction by 
centrifugation. Taking into account the ± 76% centrifugation efficiency 
gained in the non-neutralized harvesting suspension, in total a ± 63% final 
recovery efficiency of the cells present on the plates of the bioreactor was 
recorded in the third process development run in the Xpansion-10. Although a 
similar final cell density on the plates was reached in the Xpansion-50 and the 
same harvesting procedure was used, the final recovery efficiency in the 
Xpansion-50 bioreactor was around 45%. This reflects a final yield of 7 900 
cells/cm2. So, despite the high cell density gained in the Xpansion-50 
bioreactor growth, many cells were lost in the downstream processing for this 
specific run. While the final density here was almost 4 times the density as 
reported for hepatic progenitor cells in the Xpansion-200 (difficult to compare 
due to the different cell types) (Castillo et al., 2013), more effort is required 
on the downstream processing. Based on the recovery efficiencies listed here, 
most gain can be made mainly by improving the centrifugation efficiency. 
Exploration of alternative volume reduction bioprocesses such as the use of 
continuous centrifugation (Delahaye et al., 2014) or filtration systems (Cunha 
et al., 2015b) could also provide solution for a higher cell recovery. In light of 
this, it should be noted that in case of the Xpansion-50 it was the first time 
this research group was handling these sizes of harvest volumes. The authors 
are therefore convinced that by further development of the volume reduction 
and centrifugation process, the total cell yield can be improved significantly.  
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Table 4-II: Summary of recovered viable cell fraction per step during the harvest process 
relative to the optically determined number of cells on the day of harvest. The (*) indicates 
fractions determined by the microscope, the other fractions are based on cell counts. 
Step in harvest process % of cells counted  
Cell count on plates, 7 days of culture (*) 100% = reference 
Cell count in waste medium 3.20% 
Cell count in 1st PBS rinse 6.40% 
Cell count in non-neutralized harvest 
suspension 
82.40% 
Cell count in 2nd PBS rinse 6.10% 
Cell count of cells on plate after rinse (*) 6.20% 
Total 104.20% 
 
4.4.4. Post-harvest cell characterization  
After each bioreactor run, the harvested cells were subjected to a standard 
quality check and compared to the target quality profile as derived from the 
tissue culture flask condition. 
Growth kinetics of harvested cells 
Figure 4.7 represents the average growth curve (n=4) over 7 days as 
determined by the PrestoBlue assay for the harvested cells after being re-
seeded in 12-well plates. Growth kinetics of the harvested cells were similar 
for all bioreactor runs and up to day 7 no significant difference between the 
bioreactor condition and tissue culture flask condition was found. The lack of 
increased lag phase during initial culture days for the cells harvested from the 
bioreactor suggests that environmental stress during the bioreactor harvest 
procedure did not induce cell damage (Delahaye et al., 2014).  
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Figure 4.7: PrestoBlue-based average (n=4) growth curve of re-plated harvested cells in a 12-
well plate. Error bars represent standard deviation of the mean. 
In vitro 3-lineage differentiation 
After each bioreactor run the in vitro 3-lineage differentiation potential of the 
cells was assessed. Both cells from the bioreactor and tissue culture flasks 
were able to differentiate towards the adipogenic, osteogenic and 
chondrogenic lineage as shown in Figure 4.8. Both in bioreactor run 3 and run 
4, the in vitro chondrogenic differentiation was impaired compared to the 
tissue culture flask condition (Figure 4.8, bottom). It is hypothesized that this 
loss of in vitro chondrogenic potential was caused by an increased TrypLE 
exposure time as all other conditions were kept constant. It should be noted 
that in the case of the culture process being up-scaled with a flask or cell 
factory-based strategy the holding times of the cells will undoubtedly also 
increase. More importantly, the impaired in vitro chondrogenesis in run 3 and 
4 did not influence the outcome of the in vivo results, nor the CD marker 
expression as shown later. 
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Figure 4.8: Representative images of the in vitro 3-lineage differentiation assay for cells from 
the bioreactor, tissue culture flask and a negative control in normal medium shown in the left, 
middle and right column respectively.  
(top) Oil Red O staining after 2 weeks of adipogenic differentiation. (middle) Alizarin red 
staining after 3 weeks osteogenic differentiation. (bottom) Alcian Blue staining after 1 week 
chondrogenic differentiation in micro-mass culture. 
MSC phenotype 
Figure 4.9 on the left side indicates the simultaneous positivity for the 
standard MSC markers CD73, CD90 and CD105 for cells from the bioreactor 
and the control flask. On the right side the percentage of cells that are positive 
for at least one CD marker from the pool of hematopoietic markers CD45, 
CD20, CD14, CD34 are shown. Based on the flow cytometry data, cells 
harvested from the bioreactor showed a clear MSC like phenotype, that was 
close to identical the control flasks. Little variation between the different runs 
was perceived. 
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Figure 4.9: Percentage of simultaneous positivity for common MSC markers (CD73, CD90 
and CD105) and common hematopoietic markers (CD45, CD20, CD14, CD34).  
Error bars represent standard deviation of the mean. 
In vivo bone forming potential 
The in vivo performance for cells is a crucial aspect in the cell 
characterization process. As discussed by Bianco et al. (Bianco et al., 2014), 
the in vitro assays that are suggested by the ISCT (Dominici et al., 2006), and 
which were shown here (3.3.1-3: adherence to plastic, in vitro 3-lineage 
differentiation and (lack of) expression of certain CD markers) are of value as 
means to standardize MSC characterization. However, these assays are not 
necessarily reflecting the in vivo potency of the cells for specific indications. 
Therefore, in this work, an assay with a known mechanism of action was 
chosen, in order to assess the bone forming activity of the harvested cells in 
vivo (Chai et al., 2012a; Roberts et al., 2011). The amount of newly formed 
bone as quantified by nanoCT was normalized to the available volume in the 
scaffold (i.e. not taking into account the space occupied by the remaining 
calcium phosphate grains within the scaffold, see indications on Figure 4.10). 
All samples in both conditions resulted consistently in compelling ectopic 
bone formation in vivo. As quantified by the nanoCT analysis the average 
newly formed bone volume was 11.6% ± 3.1% and 12.8% ± 3.3% for the 
bioreactor and tissue culture flask respectively. Based on the boxplot it can be 
seen that the spread on the data is similar for both conditions, but the quartiles 
are closer for the bioreactor conditions. No statistical difference was found 
between the two conditions and the perceived quantities of newly formed 
bone corresponded to what was reported earlier in literature (Roberts et al., 
2011). It is interesting to note that while cells from run 3 and 4 showed 
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impaired chondrogenic differentiation potential, they were still able to form a 
compelling amount of bone in vivo. This stresses the need for potency assays 
that are able to assess relevant biological functions and illustrates a limitation 
of the ISCT minimal criteria (Bravery et al., 2013). However, as the time and 
resources required for in vivo assays are considerable, more cost-effective 
assays should be developed that might for example look at the secretome (e.g. 
trophic factors) (Mastri et al., 2012). 
 
Figure 4.10: NanoCT images and quantification of bone volume. 
(left top and bottom) Slides from the reconstructed nanoCT images, ”b” indicating remaining 
calcium phosphate grains from the implanted scaffold, “*” indicating newly formed bone 
tissue. The negative control consists of an implanted scaffold without cells. (bottom right) Box 
plot of the newly formed bone volume normalized to the available scaffold volume as 
determined by nanoCT imaging. Horizontal lines indicate first quartile, median and third 
quartile, whiskers indicate minimum and maximum, asterisk indicates average. 
Although technically challenging, upscaling planar tissue culture technology 
is attractive for autologous tissue culture strategies (or small batch sizes of 
allogeneic cells) since relatively small changes to the standard culture 
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conditions are required. In addition, the Pall Xpansion bioreactor specifically 
adds a significant level of automation and control to the planar culture 
process, while at the same time it is scalable between 6120 cm2 (Xpansion-10) 
and 122 400 cm2 (Xpansion-200). Based on the cell densities achieved in the 
Xpansion-50, the theoretical cell yield for hPDCs would be around 2x10
9
 cells 
in the Xpansion-200 (for bone marrow MSCs, which are smaller in size, this 
would be more close to 3x109 at a harvest density of 25 000 cells/cm2). 
Although this accounts already for a considerable cell yield, allogeneic cell 
therapy strategies will benefit from microcarrier or suspension culture 
technologies, as more favourable economies of scale can be reached due to 
the much larger culture surface to volume ratio (Jenkins and Farid, 2015; 
Rowley et al., 2012; Simaria et al., 2014a; Want et al., 2012). Discussing 
which culture system is better in terms of cell quality is challenging as this 
depends heavily on specific cell type, clinical indication and bioprocess 
design. Recent studies have shown that hMSC expansion on planar adherent 
surfaces could lead to gradual loss of their therapeutic potency with altered 
immune modulatory properties, low survival rate post transplantation, and 
changes in their secretory profile and therapeutic potential due to an 
increasing senescent subpopulation (Bara et al., 2014; Sepúlveda and Tomé, 
2014; Whitfield et al., 2013). However, similar effects could also occur during 
suspension culture under certain process conditions (Chen et al., 2011; Sart et 
al., 2013).  
 Conclusion 4.5.
In conclusion, the Xpansion bioreactor enabled the production of large 
amounts of progenitor cells, while maintaining equivalent cell quality 
compared to the standard flask-based culture. Importantly, it was shown that 
these cells retained their regenerative potential resulting in compelling in vivo 
bone formation. The efficiency of the culture process for this specific cells 
type reached a bottleneck at the downstream level, in particular during cell 
recovery. However, in addition to the integrated sensors and medium 
sampling possibilities of the bioreactor, the transparent stacked plate design in 
combination with the microscope offered excellent monitoring capabilities 
allowing to exactly pinpoint the root cause of the bottleneck. Consequently, 
future efforts will be directed towards optimizing the recovery efficiency 
during downstream processing. The large-scale production of progenitor cells 
under quantitative real-time process monitoring provides a tool for the 
translation to robust clinical implementation and facilitates the regulatory 
trajectory. 
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 Positioning within the context of the PhD project 5.1.
As the optimisation of the harvest procedure was found to have a large impact 
on the process efficiency in the multiplate bioreactor in Chapter 4, this 
Chapter focusses specifically on the use of imaging data from 2D cell culture 
surfaces (both tissue culture flasks and the multiplate bioreactor) for 
monitoring the cells detaching from the culture plastic during the enzymatic 
harvest of the culture vessel. The data collection, image analysis and data-
based model are run in real time, enabling prediction of the optimal time to 
stop the enzymatic reaction. This not only provides a quantitative measure for 
the process operators, the enhanced data-based process control also reduces 
the exposure of the cells to the proteolytic enzymes, which is beneficial for 
cell quality, as was the goal of Objective 3 in Chapter 2. 
 
Figure 5.1: Position of Chapter 5 in the general control scheme and the larger context of this 
work. 
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 Abstract 5.2.
Determining the optimal time to inhibit the enzymatic reaction during cell 
harvesting is crucial in order to successfully detach adherent cells from the 
substrate before irreversible cell damage is caused by prolonged cell exposure 
to the enzymes. This study aimed at developing a non-invasive methodology 
to determine objectively and automatically the optimal time-point to inhibit 
the enzymatic reaction during cell harvesting. The harvesting process was 
monitored under a microscope and image analysis was used to measure the 
cells’ morphology (circularity) from the images. System identification 
techniques were used to model the cells’ circularity in response to the 
harvesting solution and to quantify the time when the cells become circular 
and reach a plateau phase (inhibition time). ARX models (Auto Regressive 
model with eXternal input) were used to accurately model the process, both in 
culture flasks and in a bioreactor (R2 ≥ 0.98 and 0.95 respectively), and to 
quantitatively determine the inhibition time. ARX models were applied to 
predict the inhibition time in real-time. When the model parameters 
converged, the median error was 21 seconds (Min 0 second, Max 75 seconds). 
The error decreased monotonically as new data was collected. The developed 
approach was generic and could be applied both in flasks and in a clinical-
scale bioreactor. By automating decision-making, it will be possible to create 
standards and reproducibility that are necessary for large scale, robust and 
cost-effective cell cultures with reduced cell culture variability and consistent 
cell batches. 
 Introduction 5.3.
The basic principle of autologous tissue engineering therapies consists of the 
isolation of progenitor cells from the patient, expansion of these cells in vitro 
until the clinically required numbers of cells is obtained, and finally 
proceeding to in vivo implantation at the site of injury (Koc et al., 2000). In 
order to get a large scale population of cells, sub culturing is used to expand 
the cell culture. Cells that grow adherently to the dish or flask need to be 
detached and collected (or “harvested”) before being re-seeded and expanded 
(or “sub-cultured”) on new culture surfaces in order to promote further 
growth. Adherent cells can be harvested mechanically, but this process is 
labour-intensive and may result in cell membrane damage and cell loss. 
Moreover, this procedure cannot be applied in multi-layered cell culture 
vessels such as cell factories used for large scale cell expansion, or in recently 
developed bioreactor systems such as the Pall Life Sciences Xpansion® 
multiplate bioreactor. Therefore, enzymatic solutions are commonly used in 
76 Real-time characterisation of the harvesting process 
 
order to break the connection (proteolytic reaction) both between the cells and 
between the cells and the surface of the vessel (Carvalho et al., 2011). 
However, cells must not be over-exposed to these enzymes because they can 
damage the cell surface, resulting in apoptosis and cell death, compromised 
proliferation rate and limited in vivo potential (De Smedt et al., 2008; 
Sutradhar et al., 2010). 
The decision when to stop the proteolytic reaction is currently based on visual 
assessment by human operators that monitor the “roundness” of the cell via 
microscopy in order to determine the time-point of cell detachment (Masters 
and Stacey, 2007). As a result, the procedure is labour-intensive, highly 
operator-specific and prone to inter-operator variability and human error. 
Consequently current harvesting methods lack the standardisation and 
reproducibility that are necessary for large scale, robust and cost-effective 
production (Liu et al., 2010). Therefore, non-invasive, automatic monitoring 
systems are needed to guide operators throughout the cell culture process and 
in particular to improve and standardise the harvesting process with the 
ultimate goal of reducing cell culture variability and obtaining consistent 
batches of cells. 
However, cell monitoring poses particular engineering challenges. Since 
every living organism is individually different from each other, no single 
organism responds like the average of a group and since living organisms are 
time-varying, a single organism’s response to a stimulus might be different 
each time the stimulus is applied (Berckmans, 2008). Monitoring systems 
therefore have to cope with the variation between different individuals 
(individuality) and within the same individual (time-variance). Moreover, 
developing a general-purpose automated monitoring system for cells is 
complicated due to the different functioning principles of the available 
microscopes as well as due to the difference in cell density and cell types 
(Meijering, 2012). When using bright-field microscopy, image segmentation 
is also very challenging due to the low contrast between the cells and the 
background (Ali et al., 2012a). 
In order to determine the time-point of cell detachment it is furthermore 
necessary to monitor the cell harvesting in real-time and both the image-
processing and the modelling algorithm need to take this into account. 
Moreover, as the harvesting is a relatively short process, not many 
measurements can be used in order to determine and predict how the cells 
respond to the harvesting solution. 
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This study aimed at developing a non-invasive, automatic, on-line monitoring 
system that is based on a data-based (DB) modelling approach and uses non-
invasive imaging technology in order to predict the optimal time for cell 
harvesting. The monitoring system was designed to monitor on-line the cell’s 
response to changes in its micro-environment inflicted by a range of 
harvesting solutions in order to predict the optimal time-point to stop the 
proteolysis reaction and consequently to minimise the cells’ exposure to the 
harvesting solution. The hypothesis of this study was that the optimal time to 
harvest the cells is when the cells have become circular and almost no more 
changes in cell morphology can be detected. 
 
 Materials and Methods 5.4.
Two main experiments were performed in the present research. The first 
experiment was carried out on a small scale (i.e. tissue culture flasks, volume 
= 25 mL), the second experiment was carried out on a large scale (i.e. multi-
layer bioreactor, volume = 6 L). The details of both experiments are described 
hereafter in more detail.  
5.4.1. Small scale 
Cell line and cell culture 
After approval of the ethics committee for Human Medical Research (KU 
Leuven), human periosteum derived mesenchymal stem cells (hPDC) were 
isolated as described by Eyckmans and Luyten (Eyckmans and Luyten, 2006). 
The cells were cultured for up to seven passages in a mono-layer and in a 
culture medium consisting of high glucose Dulbecco’s modified Eagle’s 
medium (Invitrogen, Merelbeke, Belgium) supplemented with 10% fetal 
bovine serum (FBS, Gibco, Merelbeke, Belgium), 1% sodium pyruvate 
(Invitrogen) and 1% antibiotic-antimycotic (100 units/ml penicillin, 
100 mg/ml streptomycin, and 0.25 mg/ml amphotericin B; Invitrogen). At 
passage 8, cells were seeded in T25 tissue culture flasks (Greiner Bio-One 
GmbH, Frickenhausen, Germany) at a density of 5700 cells/cm2 and 
incubated at 37°C, 95% relative humidity and 5% CO2 until they reached 70% 
of confluency. At this point, the harvesting procedure started. 
Harvesting procedure 
In this study, enzymatic harvesting was applied which is a technique that uses 
proteolytic enzymes to detach adherent cells from the surface of a cell culture 
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vessel. First, the growth medium in the vessel was aspirated and discarded. 
Phosphate-buffered saline (PBS) was used to wash the cells twice. 
Afterwards, the enzymatic harvesting solution was added to the vessel. After 
15±2.5 (Mean±SD) minutes the proteolytic reaction was neutralised by adding 
the serum containing culture medium. The cells in the tissue culture flasks 
(N=33) were harvested by using different enzymatic solutions composed of 
different concentrations of TrypLE (Invitrogen) and EDTA (Table 5-I). 
Different solutions were used in order to prove that the method is generic and 
applicable for different cell cultures. 
 
Table 5-I: Concentration of EDTA-TrypLE used to harvest the cells from the vessels. 
Experiment 
EDTA 
(mM) 
TrypLE (times 
dilution) 
Replication(s) 
1 3.85 5 8 
2 2.21 5.6 4 
3 2.21 4.4 4 
4 5.49 5.6 4 
5 5.49 4.4 4 
6 3.85 3.99 2 
7 6.61 5 2 
8 3.85 6.01 2 
9 1.09 5 2 
10 0.5 0 1 
 
Image processing 
During enzymatic treatment, the vessel was monitored under a Zeiss Primo 
Vert microscope (Carl Zeiss Microimaging, Oberkochen, Germany) with 4x 
magnification. Images (resolution = 2560x1920 pixels) were recorded every 4 
seconds with a Zeiss Camera AxioCam ERc 5s (Carl Zeiss Microimaging, 
Oberkochen, Germany). The software Zen 2012 Lite (Carl Zeiss 
Microimaging, Oberkochen, Germany) was used to acquire the images from 
the microscope in bitmap format. All images were processed by using Matlab 
2013b (Mathworks, Natick, MA) in order to extract the cells’ features from 
the images, following the procedure described in Figure 5.2.  
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Figure 5.2: Schematic illustration of image processing.  
The raw image was first pre-processed by background estimation using a Wiener filter with a 
window larger than the size of the cells. The estimated background was then subtracted from 
the original image. The final images were binarised by the optimal threshold. The noisy objects 
were removed by an object deletion filter. The remaining objects were reduced to a 
morphological feature describing the circularity of each cell.  
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The background was first estimated from the raw images by applying a 
Wiener filter to the original image (Wiener, 1949) with a window (W=75) 
larger than the size of the cells. The Wiener filter was used because it adapts 
to the local image variance, performing more smoothing when the variance is 
small. The estimated background was then used to compensate the 
illumination inhomogeneity by being subtracted from the original image. The 
corrected images were binarised by using an optimal threshold. The threshold 
was calculated from 10 images that had been acquired before the experiment. 
After segmentation, the detected objects still contained artefacts. These noisy 
(non-cell) objects were removed by eliminating all objects that did not meet 
specific criteria, namely area (between 100 and 3000 pixels), length (at least 5 
pixels) and width (at least 5 pixels). 
5.4.2. Bioreactor scale 
Cell line and cell culture 
The same cell type was used for the second experiment. However, at passage 
8, the cells were seeded at a density of 5700 cells/cm2 on a Pall Life Sciences 
Xpansion® multiplate bioreactor (Pall Life Sciences, Brussels, Belgium) with 
a total culture surface of 6125 cm2 (compared to 25 cm2 in the first 
experiment). The Xpansion™ bioreactor is a large scale 2D cell expansion 
system in which adherent cells can be cultured in an automatically controlled 
environment (i.e. control of pH, O2 and CO2 level) with a surface of up to 
122400 cm2. Moreover, in combination with the Ovizio iLine S microscope 
(Ovizio image technology, Brussels, Belgium), the cells on the top plates of 
the bioreactor could be visualised on-line. 
Harvesting procedure 
The harvesting performed in the bioreactor is similar to the flask-based 
process. The cell culture medium is drained from the bioreactor after which 
the bioreactor is rinsed with PBS once. Subsequently the preheated harvesting 
solution (3.85 mM EDTA/5 times diluted TrypLE) is pumped into the 
bioreactor and the whole setup is moved to the Ovizio iLine S digital 
holographic microscope for time-lapse imaging. The harvesting solution with 
the suspended cells is drained from the bioreactor upon visual confirmation of 
cell detachment. 
Image processing 
During cell detachment, the multi-layer bioreactor was monitored by using the 
Ovizio iLine S digital holographic microscope with 5x magnification. OsOne 
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3 software (Ovizio image technology, Brussels, Belgium) was used to acquire 
the image at 5 frames/second at a resolution of 1024x1024 pixels. The images 
were extracted from the OsOne system as bitmap images. The Ovizio 
microscope allows 3D cell reconstruction, but only 2D images were required 
for processing (Figure 5.3). All images were processed by using Matlab 
2013b (Mathworks, Natick, MA) in order to extract the cells’ features from 
the images. The images were filtered by using a low pass filter in order to 
correct irregular illumination. The resulting images were smoothed by using a 
Gaussian filter (W=3) and binarised by using an optimal threshold. The 
threshold was calculated from the first 10 images. After segmentation, the 
noisy (non-cell) objects were removed from the images by eliminating all 
objects that did not meet specific criteria, namely area (between 50 and 2000 
pixels), length (at least 5 pixels) and width (at least 5 pixels). 
a) 
 
b) 
 
Figure 5.3: Images acquired during the harvesting from the Xpansion® bioreactor (Pall Life 
Sciences, Brussels, Belgium).  
At the beginning, the cells had an elongated shape a) while most of the cells became round at 
the end of the harvesting procedure b). 
 
5.4.3. Features extraction 
Features extraction aims at reducing redundant information within an image to 
a few variables that retain all relevant information. These representative 
variables describe each image as a point in an N-dimensional feature vector 
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space, where N is the number of extracted features. Cell circularity was 
calculated as 4π*area/perimeter2 (Friel, 2000) for each of the segmented cells. 
The average cell circularity was used to monitor the status of the cell 
population when exposed to the harvesting solution (Figure 5.4). 
 
Figure 5.4: Cell circularity measured during harvesting. At the beginning, the adherent cells 
had an elongated shape, while they adopted a circular shape when in suspension. 
5.4.4. Modelling 
Model-based monitoring 
Model-based monitoring methods do not necessarily require a priori 
knowledge of the actual system physics in order to determine the system 
dynamics. The system is considered as an object in which different variables 
interact and produce observable signals that are the output of the system. The 
output of the system depends both on external signals that are manipulated by 
the observer (inputs) and on external signals that can only be observed by 
their influence on the output (disturbances) (Ljung, 1999). Modelling consists 
in determining the relation between input and output of the system. The 
determined relation can be used for different applications such as control, 
prediction or error detection. The purpose of the application affects the choice 
of the appropriate method for modelling the system. 
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The aim of this study was to predict the optimal time-point for cell harvesting 
by monitoring changes in the cell’s circularity (output) in response to the 
enzymatic harvesting solution (input). Cell circularity as measured by image 
analysis remained approximately constant when cells had been grown in a cell 
culture medium before the harvesting solution was added. Upon addition of 
the enzymatic harvesting solution, cell circularity changed to a new value. 
This response is described in control theory as an unitary step-response (Tay 
et al., 1998). The transient response of the system was specified by six 
attributes; namely delay time, rise time, peak time, maximum overshoot, 
maximum undershoot and settling time (Tay et al., 1998). The settling time 
was defined as the time required for the response curve to reach and stay 
within a range of certain percentage (Tay et al., 1998). In this study the 
percentage was set to 5% and the settling time was considered as the plateau 
in which the cells should be harvested. 
Off-line vs. on-line modelling 
In contrast to on-line modelling in which the model parameters are estimated 
recursively as time progresses, off-line modelling uses all data available after 
the experiment for parameter estimation. In this study, off-line modelling was 
necessary initially in order to validate the model estimation of the 
experimental data and to calculate the dynamic information used to measure 
the performance of the on-line model. 
On-line and real-time modelling, instead, was necessary in order to predict the 
optimal time for harvesting the cells while the process is still ongoing. In 
order to focus on the main system dynamics, the structure of the model was 
fixed as a first-order structure and only the input-output delay and the model 
parameters were estimated. Once the model parameters converged within a 
range of a certain percentage (5%), the model was considered stable and the 
settling time was calculated and used as the optimal time for harvesting the 
cells. Both off-line and on-line modelling approaches are described hereafter 
in more detail. 
Off-line modelling: ARX model 
In this study, the linear, discrete-time Auto Regressive model with eXternal 
input (ARX) was selected as a parametric model structure in order to describe 
the cell response to the enzymatic solution. The ARX model is most efficient 
in estimating the model parameters because it solves linear regression 
equations in analytic form. It can be used if there is a good signal-to-noise 
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ratio. The ARX model predicts the output as a linear function of measurable 
data (Ljung, 1999): 
𝒚(𝒌) =  
𝑩(𝒅)
𝑨(𝒅)
𝒖(𝒌 − 𝒏𝒌) +
𝟏
𝑨(𝒅)
𝒆(𝒌)  ( 1 ) 
where y is the output, u is the input, e is the error, A is the model denominator, 
B is the model numerator, d is the number of parameters and k is the backward 
shift operator. 
The ARX model can be solved by using Least Squares (LS) where nb and na 
are the numbers of parameters in the numerator and denominator of the 
parametric model: 
[
𝑦(𝑘)
𝑦(𝑘 + 1)
⋮
𝑦(𝑘 + 𝑛 − 1)
] =
 [
−𝑦(𝑘 − 1) ⋯ −𝑦(𝑘 − 𝑛𝑎)
−𝑦(𝑘) ⋯ −𝑦(𝑘 − 𝑛𝑎 + 1)
⋮ ⋱ ⋮
−𝑦(𝑘 + 𝑛 − 2) ⋯ −𝑦(𝑘 − 𝑛𝑎 + 𝑛)
𝑢(𝑘 − 1) ⋯ 𝑢(𝑘 − 𝑛𝑏)
𝑢(𝑘) ⋯ 𝑢(𝑘 − 𝑛𝑏 + 1)
⋮ ⋱ ⋮
 𝑢(𝑘 + 𝑛 − 2) ⋯ 𝑢(𝑘 − 𝑛𝑏 + 𝑛)
]
[
 
 
 
 
 
 
 
𝑎𝑛𝑎
𝑎𝑛𝑎−1
⋮
𝑎0
𝑏𝑛𝑏
𝑏𝑛𝑏−1
⋮
𝑏0 ]
 
 
 
 
 
 
 
+ [
𝑒(𝑘)
𝑒(𝑘 + 1)
⋮
𝑒(𝑘 + 𝑛 − 1)
] 
(2) 
Equation 2 can be written in compact format as follows: 
𝒚 = 𝒁𝝑 + 𝒆  ( 3 ) 
The LS estimation of the parameters ?̂? is used to resolve this equation: 
?̂? = (𝒁𝑻𝒁)
−𝟏
𝒁𝑻𝒚  ( 4 ) 
The input-output delay nk was estimated by using the cross-correlation 
function (CCF). The CCF is the product-moment correlation as a function of 
the input (u)-output (y)-delay (Chatfield, 2004) where N is the length of the 
time-series, ?̅? is the mean input and ?̅? the mean output: 
𝑐𝑐𝑓(𝑛𝑘) =  
1
𝑁
∑ (𝑢𝑘−𝑢)(𝑦𝑘+𝑛𝑘−?̅?)
𝑁−𝑛𝑘
𝑘=1
√
1
𝑁
∑ (𝑢𝑘−𝑢)(𝑢𝑘−𝑢)
𝑁
𝑘=1
1
𝑁
∑ (𝑦𝑘−?̅?)(𝑦𝑘−?̅?)
𝑁
𝑘=1
 ( 5 ) 
 
Off-line modelling: model identification and evaluation 
System identification requires to collect the data from the experiment and to 
select a model structure (order) that represents the system as appropriately as 
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possible based on a cost function. Different criteria exist to determine the 
structure and goodness of fit of a model from experimental data. The Young 
Information Criterion (YIC) was used to determine the degree of the 
polynomials A(d) and B(d) and the time delay nk (Young et al., 2008). The 
YIC combines the model residual variance with the parameter efficiency and 
is defined as: 
𝑌𝐼𝐶 = 𝑙𝑛
?̂?2
𝜎𝑦
2 + ln (
1
𝑛𝜗
∑
𝑝𝑖𝑖
?̂?𝑖
2
𝑛𝜗
𝑖=1 ) ( 6 ) 
where ?̂?2  is the variance of the model residuals, 𝜎𝑦
2 is the variance of the 
measured output, 𝑛𝜗 is the number of estimated parameters and ?̂?𝑖𝑖 is the i
th 
diagonal element of the covariance matrix. 
In order to quantify the goodness of fit, the coefficient of determination (R2) 
was calculated (Nash and Sutcliffe, 1970): 
𝑅2 = 1 −
𝜎𝑒
2
𝜎𝑦
2 ( 7 ) 
where 𝜎𝑒
2 is the variance of the estimated noise and 𝜎𝑦
2 the variance of the 
measured output. R2 was used to compare how the models fitted to different 
time series. 
 
On-line modelling: Kalman filter 
The Kalman filter (Kalman, 1960) was used to recursively estimate the 1st 
order ARX model parameters whenever new data was acquired. The principle 
of the Kalman filter is that the estimation of new parameters ?̂?(𝒌 + 𝟏) at time 
k+1 depends on the predicted error and on the previous parameter estimation 
?̂?(𝒌) at time k. 
Considering equation (3), when new data arrives in form of input and output, 
the new problem consists in estimating the new parameters w based on the old 
data [y Z] and the newly gathered data [?̃? ?̃?]. The problem is solved by 
minimising the 2-norm of the following equation: 
min𝒘 ‖(
𝒚
?̃?
) − ( 𝒁
?̃?𝑇
)𝒘‖
2
2
 ( 8 ) 
That resulted in: 
𝒘 = (𝒁𝑻𝒁 + ?̃??̃?𝑇)−1(𝒁𝑻𝒚 + ?̃??̃?) ( 9 ) 
The formula can be computed by using the Woodbury-Sherman-Morrison 
equation (Sherman and Morrison, 1950) and after some simplifications, the 
formula can be described as follows: 
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𝒘 = ?̂?(𝒌 + 𝟏) = ?̂?(𝒌) + 𝑮[?̃? − ?̃?𝑇?̂?(𝒌)]  ( 10 ) 
where [?̃? −  ?̃?𝑇?̂?(𝒌)] is the error of the prediction and G is the gain: 
𝑮 =
(𝒁𝑻𝒁)
−𝟏
?̃?𝑇
1+?̃?𝑇(𝒁𝑻𝒁)−𝟏?̃?
 ( 11 ) 
 
On-line modelling: model convergence  
The model parameters of ?̂?(𝒌) and the input-output delay nk were monitored 
over time (Figure 5.5). 
 
Figure 5.5: Example of parameters estimation over time.  
The a-parameter (dashed line) and b-parameter (continuous line) as well as the input-output 
delay (dotted line) converged after 350 seconds. After this moment, it was possible to predict 
the time for harvesting the cells by calculating the settling time of the model. 
A sliding window of 10 samples was used to calculate whether the parameters 
reached convergence or not. The parameters were considered converged if the 
variance of the parameters within the time window was less than 5%. 
 
5.4.5. Algorithm 
The final on-line and real-time algorithm that monitored the cell circularity in 
response to micro-environmental changes and that was used to predict the 
time when there were no more significant morphological changes (i.e. the 
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settling time) was developed in Matlab 2013b (Mathworks, Natick, MA) and 
reads as follows: 
 
1. Watch microscope acquisition folder 
2. When a new time-lapse image is detected: 
a. Load image 
b. Pre-process image 
c. Segment image 
d. Calculate mean circularity 𝑦(k+1) 
e. Calculate the predicted value ?̂?(k+1): 
?̂?(𝑘 + 1)  =  𝛼𝑇?̂?(𝑘, 𝑛𝑘)  
f. Calculate the error e(k) between the predicted and the measured 
circularity: 
𝑒(𝑘 + 1)  =  ?̂?(𝑘 + 1) − 𝑦(𝑘 + 1)  
g. Calculate the gain G: 
𝑮 =
(𝒁𝑻𝒁)
−𝟏
𝛼𝑇
1 + 𝛼𝑇(𝒁𝑻𝒁)−𝟏𝛼
 
h. Re-estimate the model parameters ?̂?𝒏𝒌(𝒌 + 𝟏) based on the new 
data for the different time delay nk: 
?̂?𝒏𝒌(𝒌 + 𝟏) = ?̂?𝒏𝒌(𝒌) + G*e 
i. Calculate the variance of the parameters in a time window of size 
10 
j. If the variance is less than 5%, calculate the settling time (ST) 
 
 Results 5.5.
5.5.1. Small scale 
10 different experiments with different levels of replication and with different 
harvesting solutions were performed. A total of 33 datasets were gathered. For 
each dataset, the cell circularity in response to the micro-environmental 
changes was modelled and the settling time was calculated (Figure 5.6). 
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Figure 5.6: Example how cell morphology was modelled as a response to the harvesting 
solution.  
The dotted line is the measured circularity, while the continuous line is the modelled one. The 
settling time is calculated as the time required for the response curve to reach and stay within 
5% range of the signal. 
The model structure, the order of the parameters and the input-output delay 
were selected by means of the YIC, a criterion that provides an indication for 
the best parsimonious model (see above). Based on the selected model, the 
coefficient of determination (R2) and the settling time were calculated. As it is 
documented in Table 2, the estimated off-line models fitted the data very well 
with a R2 ≥ 0.98. The estimated model structures were either represented by a 
first-order or by a second-order polynomial. However, while the second-order 
was estimated, the equivalent first-order model had a YIC (and R2) very close 
to the second-order one. The input-output delay varied between 0 and 10 data 
points (0 to 40 seconds), while the settling time varied between 344 and 978 
seconds, with a median of 470 seconds. The settling time was used as a 
reference for the on-line and real-time prediction of the harvesting time.  
Experiment 10 used a harvesting solution that only consisted of EDTA. Since 
this solution does not contain enzymes, it was not powerful enough to initiate 
the proteolytic reaction and was considered as negative control: no change in 
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morphology was noticed and no cells could be harvested. Therefore, no model 
was estimated for this condition since no input-output relation existed in the 
system of interest. 
The on-line model required to recursively estimate the parameters as new data 
was continuously gathered. The model was considered stable once the 
variance of the parameters was less than 5% in a time window of size 10. The 
stability of the parameters was reached after a median of 474 (Min: 238, Max: 
698) seconds. Once the model was stable, the settling time was calculated. 
The on-line modelling approach was applied to the same 33 experimental 
datasets that were used for the off-line modelling. 
Using the estimated model at the time of convergence to model the data, the 
coefficient of determination resulted in a median R2 of 0.983 (Min: 0.923, 
Max: 0.997). The absolute error between the settling time predicted at the 
time of convergence in the on-line model approach and settling time 
calculated off-line had a median of 21 seconds (Min 0 second, Max 75 
seconds) (Table 5-II). As it can be seen in Table 5-II, the on-line prediction 
tends to under-estimate the settling time. However, after the parameters 
reached convergence, the monitoring did not stop but continuously re-
estimated the settling time whenever new data was acquired. The error 
therefore decreased monotonically with new data being used for parameter 
estimation (Figure 5.7). 
 
Figure 5.7: Average estimation error (N=32) in seconds related to the elapsed time of the 
experiment. The error is monotonically decreasing with new data being used. 
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Table 5-II: Results of the small scale harvesting modelled off-line and on-line.  
For each experiment, the results of the model based on the lowest YIC are presented and 
consist of the model order (i.e. number of a parameters), the input-output delay nk¸ the YIC, the 
R2 and the calculated settling time. For the on-line experiment, the input-output delay, the R2 
and the settling time calculated at the time of parameter convergence are presented. 
Furthermore, the error between the estimated settling time (on-line) and the reference one (off-
line) is shown. aNo change in morphology was measured after the harvesting solution was 
applied. No cells were harvested at the end of the experiment. “#” stands for the model order. 
  
  
off-line on-line  
Exp Repl # nk YIC R2 
ST  
nk R2 
ST(
s) 
Error  
(s) ST (s) 
1 1 1 8 -14.964 0.994 978 10 0.943 940 -38 
1 2 1 8 -14.204 0.992 545 10 0.959 557 12 
1 3 2 1 -13.925 0.998 390 0 0.984 390 0 
1 4 2 2 -12.497 0.995 427 0 0.979 409 -18 
1 5 2 7 -13.969 0.998 597 2 0.991 597 0 
1 6 1 7 -15.965 0.998 473 7 0.997 450 -23 
1 7 2 10 -15.204 0.999 488 6 0.992 465 -23 
1 8 1 5 -14.032 0.993 390 5 0.992 375 -15 
2 1 1 1 -11.799 0.981 474 1 0.98 473 -4 
2 2 1 4 -13.82 0.993 367 4 0.993 367 0 
2 3 1 3 -14.74 0.994 469 5 0.977 394 -75 
2 4 2 7 -15.473 0.999 469 5 0.982 413 -56 
3 1 1 0 -14.316 0.993 518 3 0.923 461 -57 
3 2 1 0 -13.339 0.987 344 0 0.979 314 -30 
3 3 1 5 -13.36 0.99 689 4 0.99 715 26 
3 4 2 7 -14.023 0.998 367 3 0.991 367 0 
4 1 1 1 -12.034 0.981 344 1 0.98 344 0 
4 2 1 3 -16.442 0.998 397 4 0.995 401 4 
4 3 2 5 -14.422 0.999 454 0 0.98 428 -26 
4 4 2 2 -14.863 0.998 439 0 0.982 439 0 
5 1 1 0 -14.083 0.993 430 1 0.981 362 -68 
5 2 1 10 -14.025 0.994 499 10 0.994 503 4 
5 3 1 0 -13.003 0.984 470 0 0.977 428 -42 
5 4 2 8 -15.68 0.999 439 4 0.99 439 0 
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6 1 1 2 -14.068 0.993 428 3 0.99 394 -34 
6 2 2 7 -15.277 0.999 389 6 0.978 324 -65 
7 1 1 1 -14.137 0.992 624 1 0.992 624 0 
7 2 1 7 -14.628 0.995 473 9 0.964 473 0 
8 1 1 4 -13.534 0.99 510 6 0.973 537 27 
8 2 1 7 -15.144 0.996 526 8 0.993 481 -45 
9 1 1 4 -14.82 0.995 621 4 0.995 621 0 
9 2 1 0 -13.86 0.992 571 0 0.99 541 -30 
10a 1                   
 
5.5.2. Bioreactor scale 
The cells’ morphological response to the harvesting solution in the Xpansion® 
bioreactor was similar to the one in the flasks (Figure 5.8). The cells started to 
react to the solution and circularity increased over time.  
 
Figure 5.8: Cell circularity measured and modelled as a response to the enzymatic solution 
during the harvesting from the Xpansion® bioreactor. The dotted line is the measured 
circularity, while the continuous line is the modelled one. 
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This reaction could be quantified by measuring the average cell circularity. 
The cell response to the harvesting solution resulted in a first order-model 
with a YIC of -18.01. The model fitted the data with a R2 of 0.95. The settling 
time was calculated as 17 minutes from the start of the reaction.  
The parameters converged after 16 minutes and 20 seconds and the settling 
time at this point was estimated for 16 minutes and 40 seconds. Due to the 
higher noise in the data, the convergence of the parameters was slower 
compared to the one obtained in the T25 flasks (see 5.4.1) and the estimation 
error was around 20 seconds. 
The process dynamics were slower compared to the flasks, probably because 
the presence of more FBS containing medium residue, due to the single rinse 
(compared to double in the flasks), slowed down the reaction. Therefore, the 
harvest procedure needs be optimised to reduce the settling time to be closer 
to the time used for T25 flasks. 
 Discussion 5.6.
This work used image analysis and DB modelling techniques in order to 
develop an on-line and automatic monitoring system that measured 
morphological changes in cells during harvesting and that predicted the 
optimal time-point to stop the enzymatic reaction (i.e. harvesting). By 
measuring the cell surface it was possible to monitor the detachment status of 
the cell. The measure of circularity reflects this process as the cell changes 
from being attached to being detached. The time required for the cell to react 
varied from experiment to experiment, depending on the harvesting solution 
itself, but also on the time needed to place the vessel under the microscope, to 
focus the image and to start the recording. In fact, the input-output delay 
represented the time in which the enzymatic solution started to react with the 
substrate.  
The morphological changes in response to the harvesting solution were 
modelled as the system- response to a unitary step. The used ARX model that 
was fixed to a 1st order and was sufficiently complex to determine the input-
output relation, even though a second-order model was deemed more optimal 
in some experiments based on the YIC cost function. The chosen models 
fitted the data well, as a R2 ≥ 0.98 was determined. The dynamic information 
extracted from the model could therefore be used to interpret the physical 
information of the underlying biological process. The time constant of the 
model represented the speed of the cell response to the reaction rate, the 
steady state gain reflected the circularity level cells reach at the end of the 
reaction while the settling time was the time where no more morphological 
changes were noticeable and which was considered the optimal time for 
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harvesting the cells. Defining the plateau as the optimal time-point for 
harvesting the cells, is in accordance with literature (Wilson and Walker, 
2010) and with the empirical procedure currently followed by the operators. 
Future works will need to validate if a different percentage (in this study 5%) 
should be employed in order to calculate the settling time and how this 
percentage influences the cell yield. Future works will also need to check if 
the reaction rate (correlated with the model’s time constant) influences the 
cell quality. However, this optimisation can only be carried out if a 
quantitative measurement, as presented in this study, is available. 
By on-line monitoring cell morphology it was possible to predict the optimal 
harvesting time-point as soon as the model parameters converged with a 
prediction error of 21 seconds (Min 0 second, Max 75 seconds). A minimum 
of 60 (238 seconds) and a maximum of 174 (698 seconds) data-points were 
required to make prediction of the cell behaviour. Of course, as more data was 
collected, the increased confidence in the parameters decreased the error 
monotonically. In order to further reduce this error, a higher sampling rate 
may be used, however, this needs to be balanced in regard to the time needed 
for processing the data in real-time. 
The main challenge in automating cell culture procedures is the high cell 
variability that requires the ability to make adaptive decisions based on the 
status of the cells at each given time (Ker et al., 2011). As it was shown in the 
results, the cells responded differently even when the same harvesting 
solution was used, demonstrating the high cell variability even in controlled 
conditions. Time-lapse imaging is a non-invasive method that allows 
collecting information about the status of the cell population based on the 
morphological information and making predictions about the cell behaviour 
(Matsuoka et al., 2013). 
When using bright-field microscopy, as it was used in the small scale 
experiment of this study, image segmentation is very difficult due to the low 
contrast between the cells and the background (Ali et al., 2012b). In addition, 
the fastness of the harvesting process required efficient image processing 
algorithms. The cells morphology needed to be calculated within 4 seconds in 
order to facilitate real-time monitoring. To improve the threshold-based 
segmentation (Meijering, 2012) an estimation of the background was used in 
order to remove the shading from the images. 
A major advantage of the developed method is that it is generic and can be 
applied not only to a wide range of harvesting solutions, but also to different 
cell culture systems across different scales. This study demonstrated that the 
same procedure could be used in a large scale bioreactor, obtaining a result 
similar to the small scale cell culture flasks. The only part of the procedure 
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that is microscope specific and that needs to be adapted or tuned is the image 
segmentation because it is highly dependent on the applied microscope 
technology. Automatic monitoring tools based on live cell monitoring, as 
presented in this study, are needed to develop applications that standardise 
and optimise processes in cell culture. This becomes even more crucial in 
autologous cell-therapy applications were cell donor variability could be 
robustly dealt with by using this kind of data-based approach.  
 
 Conclusion 5.7.
This study aimed at developing a non-invasive, automatic, on-line monitoring 
system that uses microscopy, DB modelling approach and imaging technology 
in order to predict the optimal time for harvesting adherent mesenchymal stem 
cell cultures. This allowed determining in real-time the optimal time-point to 
inhibit the enzymatic reaction of the harvest. Furthermore, the quantification 
of the harvesting process will allow collecting descriptive parameters for 
further process optimisation.  
The approach was tested at two different scales, namely in flasks and in a 
large scale bioreactor, and with different microscope technologies (bright-
field and holographic). The results showed that the method is generic and 
scalable. By enabling automatic decision-making based on objective 
measurements, it will be possible to create standards and reproducibility that 
are necessary for large scale, robust and cost-effective cell cultures with 
reduced cell culture variability and consistent cell batches. 
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expansion for multiple donors in a 
monitored hollow fibre bioreactor 
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F. P, Aerts J.-M. Cytotherapy (2016) 18:1219–33. 
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 Positioning within the context of the PhD project 6.1.
This is the second ‘scale-up’ chapter in which the translation of the standard 
Prometheus flask-based cell expansion process to an automated closed-system 
bioreactor is described (see Objective 2 in Chapter 2). While Chapter 4 
evaluated the translation to a multiplate bioreactor where the cells are cultured 
on large plastic plates similar to the standard culture flasks, this chapter 
assesses a hollow fibre bioreactor where the cells grow inside perfused hollow 
fibres. The cell quality characterisation is similar to the characterisation used 
in Chapter 4, however here multiple donors were evaluated. The effect of 
donor-related variability on large-scale cell expansion and process 
comparability is discussed (Objective 3 in Chapter 2) and potential strategies 
to take this variability into account while determining the feed rate and 
harvest timing are investigated. 
 
Figure 6.1: Position of Chapter 6 in the general control scheme and the larger context of this 
work. 
 Abstract 6.2.
Background: With the increasing scale in stem cell production, a robust and 
controlled cell expansion process becomes essential for the clinical 
application of cell based therapies. The objective of this work was the 
assessment of a hollow fibre bioreactor (Quantum® Cell Expansion System 
from Terumo BCT) as a cell production unit for the clinical-scale production 
of human periosteum derived stem cells (hPDCs).  
Methods: We aimed to demonstrate comparability of bioreactor production to 
standard culture flask production based on a product characterisation in line 
with the International Society of Cell Therapy (ISCT) in vitro benchmarks 
Introduction 97 
 
and supplemented with a compelling quantitative in vivo bone-forming 
potency assay. Multiple process read-outs were implemented in order to track 
process performance and deal with donor-to-donor-related variation in 
nutrient needs and harvest timing.  
Results: The data show that the hollow fibre bioreactor is capable of robustly 
expanding autologous hPDCs on a clinical scale (yield between 316 million 
and 444 million cells starting from 20 million after ± 8 days of culture), while 
maintaining their in vitro quality attributes compared to the standard flask-
based culture. The in vivo bone-forming assay on average resulted in 10.3 ± 
3.7% and 11.0 ± 3.8% newly formed bone for the bioreactor and standard 
culture flask respectively. The analysis showed that the Quantum system 
provides a reproducible cell expansion process in terms of yields and culture 
conditions for multiple donors. 
 Introduction 6.3.
An increasing number of clinical trials (Culme-Seymour et al., 2012; 
Heathman et al., 2015a) demonstrate that cell-based therapies are becoming a 
reality, destined to revolutionize the healthcare industry. Mainly based on 
hematopoietic and mesenchymal stromal cells (MSCs), a large number of 
cell-based therapies are currently being developed for the treatment of 
multiple conditions ranging from skeletal defects (e.g. PREOB® by Bone 
Therapeutics), to oncological (Curran et al., 2015; Maus et al., 2014), to 
cardiovascular (e.g. C-CURE® by Celyad (Bartunek et al., 2013)) and liver 
disorders (e.g. HepaStem® by Promethera). However, there is growing 
awareness of the numerous bioprocessing challenges that need to be addressed 
in order to translate initial clinical successes, which were most often based on 
manual laboratory-scale cell culture processes, into an industrial process that 
can guarantee the production of cell-based therapies with manageable cost of 
goods, and robust and predictable in vivo performance (Galipeau, 2013; 
Hourd et al., 2014; Kaiser et al., 2015). 
Although clinical dose sizes vary significantly across therapeutic applications, 
most MSC- based therapies require between 107 and 109 cells for a single dose 
(Jung et al., 2012; Simaria et al., 2014a) while the number of cells that can be 
sourced from a single donor is generally much lower, e.g. approximately one 
thousand MSCs per mL of bone marrow (Beitzel et al., 2013; Fennema et al., 
2009). Therefore, a cell expansion step is required that is able to produce a 
high number of cells with a reproducible cell quality (Rowley et al., 2012; 
Sharma et al., 2011). With an increasing scale of culture volumes the choice 
to translate from manual flask-based culture to bioreactors, be it multi-plate 
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bioreactors, perfusion bioreactors or stirred vessels, is inevitable (Bovy et al., 
2015). However, the high level of automation and precision that is essential 
for the desired process reproducibility often conflicts with the complexities 
entailed in live cell-based products. As more process steps are required for 
larger numbers of cells, not only is variability introduced by the process itself 
proportional to the scale of expansion (Hanley et al., 2014), but with the use 
of large-scale automated bioreactors the monitoring and control of biological 
variability also becomes more important. Since MSCs generally possess only 
a limited expansion capacity before critical cell characteristics start to 
deteriorate (Bara et al., 2014; Siddappa et al., 2007), cells are sourced from 
multiple donors, resulting in variable process input. Especially for autologous 
(“patient-specific” compared to “universal” or allogeneic) therapies, where 
donor-to-donor variation is expected to affect each batch for example in terms 
of nutrient requirements or optimal timing of harvest, the lack of process 
reproducibility poses a significant challenge to the development of a clinical 
production process that should assure a minimal number of cells with a 
defined quality level. 
In the first phase of this work, the Quantum system was evaluated as a tool to 
scale-up a standard tissue culture flask-based expansion step for an autologous 
bone tissue engineering therapy under development in our lab. The expansion 
process should assure the maintenance of a set of MSC quality characteristics 
such as their pluripotency and differentiation potential (Dominici et al., 2006; 
Oliveira et al., 2014). But more importantly, these cells should maintain an 
unimpaired regenerative potential when implanted in an in vivo potency assay. 
Secondly, monitoring tools were implemented in order to track changes in 
bioreactor process conditions, either induced by process variations or 
biological variation. Finally, a case study on the clinical-scale expansion of 
three different donors is presented allowing to compare bioreactor process 
reproducibility. 
 Materials and methods 6.4.
6.4.1. General experimental workflow 
The evaluation of the large-scale bioreactor-based expansion step fits in the 
development of an autologous bone tissue engineering therapy, based on 
human periosteum derived stem cells (hPDCs). Only a small number of cells 
(between 1x104 and 1x105) can be obtained via a biopsy of the periosteum of 
the patient, while it is hypothesised that for a tibia defect of 3 cm wide around 
300 million cells are required (Eyckmans et al., 2010; Eyckmans and Luyten, 
2006). The general experimental workflow (Figure 6.2) consists of an initial 
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pre-culture phase (section 6.4.2 for details) in which the cells from a periost 
biopsy are expanded by standard flask-based culture to be able to seed the 
bioreactor surface with a minimum initial seeding density. The second phase 
is the bioreactor-based expansion process (section 6.4.3 for details). Three 
flask-based control conditions were included in parallel with the bioreactor 
culture in an effort to provide appropriate experimental comparators, namely 
those associated with seeding density, substrate characteristics, and fluid 
(medium) handling. The third phase consists of the post-harvest cell 
characterisation (section 6.4.6), for which an in vitro and in vivo quality 
profile was determined, starting directly after harvesting the bioreactor. 
 
Figure 6.2: General experimental work flow with an initial flask-based pre-culture phase, 
followed by the Quantum system bioreactor culture.  
During bioreactor culture the cell growth was monitored based on daily lactate measurements, 
and three tissue culture flask-based control conditions were taken along in order to investigate 
the effect of flow rate, lowered seeding density and fibronectin coating. Immediately after cell 
harvest the cell characterisation was initiated, including among others an in vivo bone-forming 
potency assay. 
In total, data from nine runs in the Quantum system are discussed in this work 
(Table 6-I). The first three runs were used to fine-tune the process based on 
the results of a pool of cells from four individual donors (Table 6-I) in order 
to compare the result of changes to the process settings, while limiting the 
biological variability. This data will be referred to as the process development 
data. For the subsequent six runs, the process parameters were fixed and three 
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other donors (2 individual runs per donor, Table 6-I) were randomly selected 
for an assessment of the process reproducibility. This data will be referred to 
as the individual donor data. 
6.4.2. Standard flask-based hPDC culture 
Human periosteum-derived stem cells (hPDCs) are a promising source of 
adult stem cells for skeletal cell therapies as they are the main contributors to 
the natural bone healing process (Roberts et al., 2014) and possess extensive 
in vitro expansion capabilities as hPDCs generally maintain linear growth 
curves for over 30 population doublings (De Bari et al., 2001a; De Bari et al., 
2006; Eyckmans and Luyten, 2006). hPDCs are able to differentiate to the 
osteogenic, chondrogenic and adipogenic lineage in vitro and generally have a 
high expression of CD105, CD90 and CD73, even after large-scale expansion 
(Lambrechts et al., 2016a). Furthermore, in comparison to stromal cells 
derived from the bone marrow or synovium, they have been shown to possess 
superior bone-forming potential when seeded on calcium phosphate carriers 
(Roberts et al., 2014).  
hPDCs were isolated by overnight enzymatic digestion (0.2% type IV 
collagenase, InvitrogenTM) of a periost biopsy that was obtained from a 
patient as described earlier (Eyckmans et al., 2010). Subsequently, periosteal 
cells were collected by centrifugation, seeded in a 6-well plate and non-
adherent cells were removed after 5 days by changing the medium. 
Procedures were approved by the ethical committee for Human Medical 
Research (KU Leuven) and informed consent was obtained from the patients. 
The isolated cells were cultured in T25 flasks for the first passage in standard 
culture medium consisting of high glucose GlutaMAXTM Dulbecco’s 
modified Eagle’s medium (Life Technologies, Merelbeke, Belgium) 
supplemented with 10% irradiated fetal bovine serum (FBS; HyClone, 
Cramlington, UK), 1% sodium pyruvate (InvitrogenTM) and 1% antibiotic–
antimycotic (100 units/ml penicillin, 100 mg/ml streptomycin, and 0.25 
mg/ml amphotericin B; Invitrogen). For the standard flask-based conditions, 
cells were further cultured in T175 flasks with a seeding density of 5 700 
cells/cm2 and sub-cultured at ± 80% confluence up to passage 7 
(approximately 12 total population doublings). For the process development 
data were a pool of cells was used, the cells from four different donors 
(average age 29 ± 11 years, Table I) were pooled together at passage 3 and 
further expanded in T175 flasks up to passage 7. At all passages, cells were 
harvested by trypsinisation for 10 min with TrypLETM Express (Invitrogen). 
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6.4.3. Bioreactor culture 
Approximately 24 h hours before seeding the bioreactor, the cell expansion 
set was loaded in the environmentally controlled housing, and the lines and 
hollow fibres were automatically primed with phosphate-buffered saline 
(PBS). Directly after priming, the lumen of the hollow fibres was coated with 
5 mg fibronectin (BD Biosciences) overnight. Before loading the cells in the 
bioreactor, the PBS and remaining fibronectin was washed out of the system 
with standard culture medium. The medium was then actively equilibrated 
with the bioreactor conditions by rapidly circulating it through the gas transfer 
module (37 °C, 20% 02, 5% CO2 and 75% N2). After an automated gas bubble 
removal step, 100 mL inoculum was transferred to a cell inlet bag, connected 
to the bioreactor and automatically loaded into the lumen of the hollow fibres 
that has 21 000 cm2 of available culture surface. The cells were allowed to 
attach for 24 h without medium circulation in the lumen, but with oxygen and 
nutrient supply through circulation in the external hollow fibre circuit. The 
system was then programmed to start feeding the cells in the internal circuit 
with fresh culture medium at a flow rate of 0.1 ml/min. The progression of the 
bioreactor feed rate was determined at-line based on lactate concentrations 
(Lactate Pro, Arkray) of medium samples taken from the external bioreactor 
circuit at least twice a day, but more often towards the end of the culture. One 
sample per day was frozen and later analysed offline for lactate and glucose 
(YSI 2950 Biochemistry Analyzer). Increases in the feed rate were aimed to 
keep the lactate concentration in the bioreactor under a level of 8 mmol/L, 
based on the maximum concentration observed in flask-based experiments. As 
the lactate concentrations approached this limit, the feed rate was doubled 
through the interface of the bioreactor system.  
As the donor-specific growth rate does not allow a fixed time point for 
harvesting of the bioreactor, the time of harvest was determined by a distinct 
shift from the exponential growth curve reflected by visual determination of a 
consecutive downward deviation of the last two lactate measurements from 
the straight line on a semilog-plot of the lactate production rate based on all 
previous measurements (n-2) (see Figure 6.6C for an example). At the time of 
harvest, the bioreactor was washed with PBS before adding 180 ml  TrypLE 
Express (Invitrogen) at 37°C to the system and incubating for 15 minutes. 
After incubation with TrypLE Express, cells were harvested by rapidly adding 
media to the system and concurrently collecting the approximately 450 mL 
cell product in the pre-attached cell harvest bag (resulting on average in a cell 
suspension of 0.8 million cells/ml directly from the bioreactor). In general, the 
harvest process, including washing, 15 min TryplE incubation time and 
spinning down the neutralised harvest suspension took around 45 minutes and 
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resulted in a single cell suspension as determined by microscopic inspection. 
A second harvest process, performed with trypsin-EDTA (0.25%, Life 
Technologies), ensured that all cells were recovered from the bioreactor, thus 
allowing an estimation of the initial harvest efficiency. Cells recovered from 
the second harvest were not used for subsequent analysis. 
6.4.4. Control conditions 
Three different flask-based cultures were taken along during the bioreactor 
culture in order to elucidate possible differences between the Quantum system 
bioreactor expansion and the current gold standard, or flask-based, expansion 
of mesenchymal stem cells. In this way, primary causes of any observed 
differences in cell quality could be more easily identified, thus providing 
opportunity to optimize future bioreactor processes in an informed manner. 
Accordingly, in addition to the bioreactor condition, the experimental design 
incorporated the following three conditions: (1) standard tissue culture flasks 
according to pre-culture protocols described above in 2.2 (CF), (2) tissue 
culture flask condition at the same initial seeding density as in the 
bioreactor (CF_Q) to account for the lower seeding density in the bioreactor, 
and (3) a tissue culture flask condition at the same initial seeding density as in 
the bioreactor with an additional fibronectin coating (1 µg/cm2) as present on 
the surface of the hollow fibres of the bioreactor (CF_Q_FIB). This last 
condition was omitted for the runs with the individual donors. For the lower 
seeding density conditions, an anticipated initial loss of 30% of the loaded 
cells in the bioreactor dead volume (according to the manufacturer’s 
information) was taken into account. A comparison of the cell characterisation 
from these culture conditions allows the assessment of the individual effect of 
seeding density (CF vs CF_Q), fibronectin coating (CF_Q vs CF_Q_FIB) and 
the effect of dynamic feed rate (CF_Q_FIB vs bioreactor) on the cell 
phenotype and in vivo potency. 
6.4.5. Growth kinetics calculations 
Growth kinetics for the bioreactor culture and control flasks were calculated 
as follows: 
𝐸𝑥𝑝𝑎𝑛𝑠𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 = 𝐸𝐹 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 ℎ𝑎𝑟𝑣𝑒𝑠𝑡𝑒𝑑
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑
  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑑𝑜𝑢𝑏𝑙𝑖𝑛𝑔𝑠 𝑝𝑒𝑟 𝑝𝑎𝑠𝑠𝑎𝑔𝑒 = 𝑃𝐷 = 𝑙𝑜𝑔2(𝐸𝐹) 
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𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑑𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 = 𝑃𝐷𝑇 =
𝑐𝑢𝑙𝑡𝑢𝑟𝑒 𝑡𝑖𝑚𝑒
𝑃𝐷
 
Note that the population doubling time is calculated based on the initial and 
final cell number and therefore includes lag phase and possible stationary 
phase of growth, because only initial and final cell numbers could be 
quantified in the bioreactor. 
Metabolite analysis 
Metabolic production and consumption rates (𝑞𝑀𝐸𝑇) were calculated between 
every two concentration measurements from the external lumen of the hollow 
fibre bioreactor. The concentration for these small molecule metabolites were 
equal between the outer side and lumen of the hollow fibre (validated by 
sampling both sides) as the hollow fibres allow diffusion of small molecules 
through the fibre. The volume of the lumen and the outer side was provided 
by the manufacturer (189.1 mL and 305.4 mL respectively). For the 𝑞𝑀𝐸𝑇 
calculation, the outgoing flow rate was assumed to be equal to the ingoing 
flow rate as specified by the user, minus an evaporation term as specified by 
the manufacturer. Metabolite ratios 𝑞𝑀𝐸𝑇1/𝑞𝑀𝐸𝑇2 were calculated between 
every measured sample. Accumulated rates were calculated by aggregating all 
quantities (mM) produced or consumed between samples. Oxygen 
consumption rates were calculated based on the slope of the measured oxygen 
concentration over the whole culture, normalised to the initial and final cell 
number. 
6.4.6. Post-harvest cell characterisation 
Post-harvest growth kinetics 
Harvested cells were re-plated at a density of 5 700 cells/cm2 in a 12-well 
plate. The growth kinetics were monitored daily by a PrestoBlue® metabolic 
assay (Life Technologies, Merelbeke, Belgium) of 10% w/w PrestoBlue 
reagent in culture medium. After 1 h of incubation the metabolic activity of 
the cells was quantified by fluorescence measurements (Bio-Tek SynergyTM 
HT, Bad Friedrichshall, Germany) with an excitation wavelength of 540 nm 
and an emission wavelength of 590 nm on 100 ml supernatant in a 96-well 
plate. A higher metabolic activity is indicated by higher fluorescent values. 
3-lineage differentiation potential 
The 3-lineage differentiation potential of the cultured hPDCs was assessed as 
described earlier (Lambrechts et al., 2016a). All experimental conditions were 
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performed in triplicate. In short, the chondrogenic differentiation cells were 
cultured for 7 days as micromasses in a 24-well plate with a chondrogenic 
medium consisting of DMEM/F12 (Life Technologies), 2% FBS, 1% 
antibiotic–antimycotic, 1% ITS pre-mic (Corning), 100nM dexamethasone 
(Sigma), 10µM Y27632 (Axon Medchem), 50µg/ml ascorbic acid, 40µg/ml 
proline and 10ng/ml recombinant human transforming growth factor-β1 
(Preprotech). After 7 days of chondrogenic induction, micromasses were fixed 
in methanol, stained with a 0.1% Alcian Blue solution in 0.1 M HCL at 
pH 1.2. After washing with Milli-Q, the micromasses were destained in 6 M 
guanidine (Sigma) and quantified by measuring the absorbance of 100 µL 
samples at 620 nm. 
The osteogenic differentiation was induced by culturing the cells for 21 days 
in standard culture medium supplemented with 100 mM dexamethasone, 
50 µg/ml ascorbic acid and 10 mM β-glycerolphosphate. Afterwards, cells 
were fixed in ice-cold methanol and stained with a 2% Alizarin Red S 
solution in Baxter water. Non-specific staining was washed away with 
distilled water. Quantification was performed by dissolving the staining with 
10% cetylpyridinium chloride in Baxter water until complete dissolution. 
Absorbance was measured at 570 nm in 100 uL samples. 
Adipogenic differentiation was assessed by culturing the harvested cells in 24-
well plates for 14 days in adipogenic medium consisting of αMEM (Life 
Technologies) supplemented with 10% FBS, 1% antibiotic–antimycotic, 
1 µM dexamethasone, 10 µg/ml human insulin (Sigma), 100 µM 
indomethacin (Sigma) and 25 µM 3-isobutyl-1-methylxanthine (Sigma). At 
day 14, cells were fixed in 10% formaldehyde, rinsed shortly with 60% 
isopropanol and stained with Oil Red O. 
MSC phenotyping 
Harvested cells were assessed based on a combined positivity for typical MSC 
cluster of differentiation (CD) markers and lack of expression for 
haematopoietic markers. The used antibody panel was CD90-FITC (clone 
DG3), CD73-APC (clone AD2), CD105-PE (clone 43A4E1), CD14 (clone 
TUK4)/CD20 (clone LT20.B4), CD34 (clone AC136), CD45 (clone 5BI)-
PerCP (all from Miltenyi Biotec). Dead cells were excluded based on a 
viability dye (Zombie AquaTM, BioLegend®) excited by the fluorescent laser 
(BD FACSCantoTM). Antibody titration was performed according to the 
protocol of Hulspas (2010). Automatic single-colour compensation was 
performed by the acquisition software (BD FACSDivaTM) using compensation 
beads (UltraComp eBeads affymetrix eBiosceince), except for the viability 
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dye as it works based on internalisation of the dye in the cell. The gating was 
based on FMO (Fluorescence Minus One) controls (Herzenberg et al., 2006), 
except for the viability dye where the gating was based on the signal of a 50-
50 mixture of healthy cells and heat/cold-killed cells. 
In vivo ectopic mouse model  
After every bioreactor run, clinical grade orthopaedic 3D matrices composed 
of calcium phosphate particles in an open collagen network (NuOssTM, ACE 
Surgical Supply Co.,Inc.) with a volume of 35 mm3 were seeded each with 
1 million cells per scaffold in a total volume of 35 µL (generally 3 to 4 
scaffolds per culture condition per experimental run). To allow cell 
attachment, the scaffolds were incubated overnight (37° C, 5% CO2, RH 95%) 
before randomised ectopic implantation on the back of nude mice (NMRI- 
nu/nu). After 8 weeks of in vivo implantation, the scaffolds were retrieved, 
fixed overnight in 4% paraformaldehyde and preserved in PBS before X-ray 
computed tomography and histology. All animal experiments and procedures 
were approved by the Animal Ethics Committee (KU Leuven) and the 
animals were housed in accordance with the guidelines of the Animal 
Research Center of KU Leuven. 
Quantification of bone formation 
The volume of newly formed bone in the explanted NuOss scaffolds was 
assessed by nanofocus X-ray computed tomography (nano-CT) on a Phoenix 
NanoTom® S (GE Measurement and Control) system equipped with a 
diamond-tungsten target and 0.5 mm aluminium filter. The scan settings 
applied were 60 kV X-ray voltage, 210 mA current, 500 ms exposure time, a 
frame averaging of 1 and image skip of 0. Images were reconstructed with 
Phoenix Datos|x CT software (GE Measurement and Control). The resulting 
reconstructed images had a 3 µm voxel size. CTAn (Bruker Micro-CT) was 
used for image processing and quantification of the bone volume based on a 
2-level automatic Otsu segmentation algorithm. Resulting segmentation was 
checked visually, and in the rare case of mismatch, manual segmentation 
levels were determined based on the greyscale histogram of the whole sample. 
3D visualisation of reconstructed CT images was done in CTvox (Bruker 
micro-CT). After nano-CT analysis, the samples were decalcified in a 0.5 M 
EDTA (ethylenediaminetetraacetic acid) solution for two weeks, dehydrated, 
embedded in paraffin and sectioned (6 µm thick at 8° angle). Hematoxylin 
and eosin staining was performed using a standard protocol and a qualitative 
assessment was done, both on bright field and fluorescent images (as in 
(Martin and Mastrogiacomo, 2002)), based on features of mature bone 
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formation (presence of osteocytes and osteoblast lining, blood vessel 
ingrowth, and onset of bone marrow compartments). 
6.4.7. Statistical analysis 
Data analysis was performed using MATLAB® 2013a (The MathWorks®). 
Independent groups were compared by unpaired Student’s t-tests, and 
considered statistically significant when P < 0.05. All error bars in figures 
show standard deviation of the mean.  
 
 Results 6.5.
6.5.1. Biological evaluation of Quantum system bioreactor 
cultured cells 
Cell yield and growth rate 
On average the total cell yield from the bioreactor was 371 ± 46 million 
hPDCs, reflecting an average cell density at harvest of 17 700 ± 2 200 
cells/cm2 (see Table 6-I for details per run). The average harvesting efficiency 
in the bioreactor was 94.5%. The average cell density at harvest of the 
standard control flasks (CF) was comparable at 16 900 ± 4 900 cells/cm2. 
However, in the control flasks at the seeding density of the bioreactor (CF_Q), 
it was noted that efficient cell growth was not always sustained for certain 
donors, resulting in a significantly lower average cell density at harvest of 
only 12 000 ± 5 600 cells/cm2. The control flasks at the seeding density of the 
bioreactor but with an additional fibronectin coating (CF_Q_FIB) show an 
average harvesting density of 18 800 ± 3 500 cells/cm2. Average population 
doubling times (Table 6-I) were not significantly different for all conditions 
with the same seeding density. 
Post-harvest growth kinetics 
Cells from all conditions showed excellent viability at time of harvest (> 95% 
determined by trypan blue exclusion), and 24 h after re-plating the harvested 
cells no apparent differences in cell morphology could be perceived. Growth 
kinetics of the harvested cells were monitored over 7 days in which all 
conditions showed a similar sigmoidal growth curve as expected (data not 
shown).  
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3-lineage in vitro differentiation potential 
For all process development runs, all conditions showed a clear maintenance 
of their in vitro differentiation potential towards the osteogenic, chondrogenic 
and adipogenic lineage (Figure 6.3 A, B, C). Both the osteogenic and 
chondrogenic assays, showed no significant difference based on Alizarin Red 
and Alcian Blue staining respectively. In a qualitative assessment of the 
adipogenic differentiation, no apparent differences could be observed between 
the bioreactor condition, the standard control flask (CF) and the control flask 
at low seeding density (CF_Q). However, cells cultured on the fibronectin-
coated flasks (CF_Q_FIB) produced notably smaller and less frequent lipid 
deposits.  
Immunophenotyping by flow cytometry 
Figure 6.3 D represents the CD-marker expression as generally cited 
according to the minimal criteria for defining multipotent MSCs (Dominici et 
al., 2006). All samples generally showed a high simultaneous expression of 
CD105, CD73 and CD90, while at the same time the combined expression for 
CD45, CD20, CD14 and CD34 is very low at this passage. When comparing 
the marker expression separately, the average CD105 expression is 
significantly lower (p = 0.03) for the bioreactor condition in a pair-wise 
comparison to the CF_Q condition, while for the other markers no difference 
could be perceived. No apparent differences could be perceived in the marker 
expression between the different donors. 
In vivo bone forming potency 
Nano-CT-based quantification of the newly formed bone was carried out and 
normalised to the available scaffold volume, i.e. not taking into account the 
space occupied by the remaining calcium phosphate grains within the 
scaffold. Figure 6.4 A-C indicates the result of the 3D segmentation of nano-
CT images of newly formed bone from the remaining calcium phosphate 
grains and shows the distribution of the newly formed bone throughout the 
whole scaffold. In the process development runs, on average the nano-CT 
quantification resulted in a relative bone volume of 10.3%, 11.0%, 10.2% and 
9.4% for the bioreactor, CF, CF_Q, and CF_Q_FIB condition respectively 
(Figure 6.5 A). For the donor-specific data (Figure 6.5 B-D), intra-donor 
results do not differ significantly either between the different culture 
conditions, or between the two different batches. However, there is a 
significant (p = 0.0006) and consistent inter-donor variability regarding bone-
forming potential, where donor 1 produces on average 8.8% ± 2.4% of newly 
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formed bone, donor 2 5.8% ± 1.7%, and donor 3 no bone at all for all 
conditions in both batches. 
 
Figure 6.3: In vitro post- harvest cell characterisation:  
(A) Alizarin red staining and quantification after 3 weeks osteogenic differentiation. (B) Alcian 
Blue staining and quantification after 1 week chondrogenic differentiation in micro-mass 
culture. (C) Oil Red O staining after 2 weeks adipogenic differentiation. Quantifications of 
staining was normalised to the negative control. (D) Percentage of viable cells with 
simultaneous expression of CD73, CD90, CD105 and combined lack of expression for CD45, 
CD20, CD14 and CD34 after immunophenotyping by flow cytometry. The data for the 
different culture conditions during the three process development runs is averaged. CF = 
Control Flask, CF_Q = Control Flask at same seeding density as the bioreactor, CF_Q_FIB= 
Control Flask at same seeding density as the bioreactor with fibronectin coating. 
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The quality of the newly formed bone was assessed based on hematoxylin and 
eosin (H&E) staining on paraffin slides of the decalcified explants. As the 
nano-CT images suggested, newly formed bone tissue was found in similar 
quantities as reported earlier (Roberts et al., 2011). The imaged sections 
(Figure 6.4D) suggest that characteristic features of mature bone (osteocytes, 
hematopoietic compartments and osteoblast lining) were generally present. 
 
 
Figure 6.4: Qualitative assessment of bone formation  
(A) Reconstructed nano-CT image of a negative control (scaffold implanted without cells). (B) 
Reconstructed nano-CT image of an implanted scaffold with cells from the bioreactor. (C) 3D 
visualisation of 200 µm thick stack of reconstructed nano-CT images where the newly formed 
bone volumes are shown in red. (D) H&E on decalcified explants after 8 weeks implantation 
with cells from the bioreactor condition. Scale bars are 250 µm. Image on the left is H&E 
staining under bright field. Image on the right show H&E staining under red fluorescent light 
where bone tissue becomes bright grey under fluorescent light as described in Martin et al. 
(2002). 
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Figure 6.5: Quantification of newly formed bone volume per available scaffold volume as 
determined by nano-CT imaging.  
Bars represent average result with standard deviations. (A) Comparison of average process 
development data per culture condition. (B-D) Comparison of the results of donor-specific runs 
per batch and per culture condition. CF = Control Flask, CF_Q = Control Flask at same seeding 
density as the bioreactor, CF_Q_FIB= Control Flask at same seeding density as the bioreactor 
with fibronectin coating. 
6.5.2. Evaluation of bioreactor process and influence of 
donor-to-donor variability 
The cell expansion process was monitored by sampling media from the 
extracapillary bioreactor circuit. In the process development runs and the first 
batch of the donor-specific runs, the medium feed rate was doubled every 
time that the measured concentration approached 8 mmol/L lactate. For the 
second batch of the donor-specific experiments, the medium feed rate as 
determined for the first batch was reproduced in the second batch. This means 
that the feed rate was equal for the same donor, but that donors with a higher 
lactate production received a more aggressive feed rate strategy, and therefore 
had a higher total medium volume spent at the end of the run (Table 6-II). For 
example, donor 2 in Figure 6.6A and 5B required around 6.2 L medium, 
compared to a less metabolically active donor such as donor 3 that required 
only 4.8 L in order to keep the lactate concentration below 8 mmol/L.  
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Additionally the at-line lactate measurements were used to provide an 
objective estimation of the optimal moment of harvest for the donor-specific 
runs (Figure 6.6C). A distinct deviation of the lactate production rate from the 
exponential lactate production curve was used as a signal for the 
determination of the time of harvest. For all donors, this moment was detected 
at comparable time points relative to the start of the culture (on average 
8.1 ± 0.14 days), however it can be seen from the decreasing lactate 
production rate that the initial process development run was unintentionally 
grown over-confluent (Figure 6.6C), which is also suggested by the lower 
harvest efficiency and higher perceived population doubling time for this run 
(Table 6-I). 
 
Figure 6.6: Lactate production, feed rates and harvest timing. 
(A) Accumulated lactate production per donor. (B) Resulting medium feed rates in bioreactor. 
(C) Semilog-plot of the lactate production rate based on all previous measurements except for 
the last 2, to determine a shift from the exponential growth in order to have a donor 
independent time for harvesting the bioreactor. (Left) Data for donor 1. (Right) Example of the 
first process development run that was grown over-confluent. 
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The bioreactor circuit was slightly modified in order to be able to measure the 
dissolved oxygen concentration (dO2) and pH by welding in an ethylene oxide 
sterilized sensor connection that was developed in-house into the waste line, 
directly after the hollow fibre. As the medium was continuously fed in the 
bioreactor, the same volume was discarded through the waste line where the 
dO2 and pH could be measured with a delay proportional to the feed rate. As 
for the metabolite measurements, it can be seen in Figure 6.7, that the dO2 and 
pH measurements followed very similar trends, for both inter- and intra-donor 
conditions. The pH followed the same slightly downward trend for all donors 
as expected for CO2-buffered culture medium at increasing cell 
concentrations, but there was a rather large difference between the average 
values across the batches for donors 2 and 3. This difference was due to the 
fact that an in situ 1-point recalibration of the pH sensor was not possible in 
this setup and the sensor had to be calibrated before sterilisation and 
implementation in the system.  
Table 6-II summarises the metabolic profile of the donor cells, as measured 
during the different bioreactor runs. While the qlac/qgluc ratios were relatively 
similar indicating a preference for aerobic glycolysis (ratio close to 2, and at 
the same time the dissolved oxygen concentration does not drop below 10%) 
as was shown earlier for proliferating hPDCs (Lambrechts et al., 2016a), it is 
clear that donor 1 and 2 were metabolically more active compared to donor 3. 
Donor 3 had a higher qlac/qgluc ratio, suggesting that the energy production 
from glucose was less efficient compared to the other donors, and potentially 
indicates a different utilisation of carbon sources.  
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Table 6-II: Overview metabolic data and medium consumption for different donors 
  Donor 1 Donor 2 Donor 3 
Batch 1 2 1 2 1 2 
Maximum lactate 
concentration in 
system (mmol/L) 
8.8 7.4 9.5 7.8 8 7.8 
Accumulated 
lactate production 
(mmol) 
21.6 19.6 26.8 23.7 15.7 15.2 
Accumulated 
glucose 
consumption 
(mmol) 
11.4 9.5 16.8 10.4 6.7 6.2 
Average daily 
ratio qLAC/qGLUC 
1.7 ± 
0.4 
1.8 ± 
0.7 
1.4 ± 
0.4 
1.9 ± 
0.6 
2.2 ± 
0.8 
2.3 ± 
0.7 
Average cell 
specific 02 
consumption rate 
(mol s
−1
 cell
−1
) 
1.03E-
15 
8.76E-
16 
1.12E-
15 
8.18E-
16 
8.59E-
16 
9.08E
-16 
Total medium 
volume used (mL) 
5 127 5 124 6 337 6 114 4 869 4 772 
mL medium 
used/100K cells 
1.14 1.27 1.96 1.73 1.45 1.46 
 
 Discussion 6.1.
In the first part, this study pursued a comparative and quantitative evaluation 
of the post-harvest quality of hPDCs expanded in the Quantum system hollow 
fibre bioreactor compared to three different tissue culture flask conditions 
(CF, CF_Q, CF_Q_FIB). This was attempted by using a pool of cells from 4 
different donors with known behaviour in 2D cultures. Secondly, it was 
attempted to integrate lactate, O2 and pH readouts that would allow to non-
invasively monitor process conditions during cell expansion, and on which 
objective donor-specific decisions for feed rates and time of harvest could be 
based. Lastly, cells derived from three different donors were cultured in the 
monitored bioreactor in order to assess process-inherent and donor-to-donor 
variability.  
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6.1.1. Cell expansion 
Regarding cell yield, the average cell density at harvest per available culture 
surface was comparable between the standard TF and bioreactor condition, 
1.69 ± 0.5 x 104 and 1.77 ± 0.2 x 104 cells/cm2 respectively. Interestingly, the 
variability on the outcome was lower for the bioreactor condition, suggesting 
a more controlled expansion process. The final cell density is very similar to 
the density obtained for hPDCs in another large-scale bioreactor (Pall® 
Xpansion®) in a recent study (Lambrechts et al., 2016a). For the CF_Q 
condition, in certain cases using the same low seeding density as in the 
bioreactor failed to initiate exponential cell growth, resulting in a significantly 
lower average final cell density at harvest (1.2 ± 0.6 x 104 cells/cm2). The 
CF_Q_FIB condition (evaluated only during the process development runs) 
on the other hand resulted on average in a final cell density that was not 
significantly different from the corresponding bioreactor runs 
(2.16 ± 0.4 x 104 cells/cm2). It is therefore hypothesised that the fibronectin 
coating of the bioreactor is able to promote more efficient cell growth 
potentially through more efficient cell attachment and cell spreading on 
fibronectin-coated surfaces as described earlier (Ogura et al., 2004).  
Clearly, as the Quantum system bioreactor culture is able to start from a low 
initial seeding density, the expansion efficiency (reflected in the expansion 
factor calculation, Table 6-I) is significantly higher in the automated process, 
16.4 on average, compared to 3.0 for the standard flask-based culture. It is 
hypothesised that the efficient culture from low seeding densities are 
facilitated in the bioreactor by improved cell-to-cell communication through 
the more 3 dimensionally-structured hollow fibres resulting in more cells per 
volume compared to the flat surface of a flask. Additionally, the load of the 
bioreactor-based culture on the down-stream processing is low, as the hollow 
fibre design allows concentrated cell suspension at harvest (in this work 
around 370 million cells in ± 450 ml neutralised harvest suspension that can 
be further processed in a benchtop centrifuge, compared to multiple litres for 
example in stacked-plate bioreactors (Lambrechts et al., 2016a)).  
hPDC population doubling times in the bioreactor were 2.0 days (leaving out 
the first run that was grown over-confluent based on the harvest efficiency 
and lactate production rates as shown in Figure 6.6C) and were generally 
faster than the ones observed in the TF_Q condition (2.3 days), however the 
difference is not significant. Jones et al. (Peters et al., 2013) and Rojewski et 
al. (Rojewski et al., 2013) experienced a slower cell growth for bone marrow-
derived hMSCs in the Quantum system bioreactor compared the standard 
culture, whereas Hanley et al. (Hanley et al., 2014) and Lechanteur et al. 
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(Lechanteur et al., 2014) reported faster cell expansion in the Quantum system 
bioreactor for bone marrow-derived hMSCs. The bioreactor process reached 
in all cases the minimum process target of 300 million cells required for the 
hypothetical tibia defect of 3 cm as introduced above, and outperformed the 
standard culture flask conditions regarding cell yield and expansion 
efficiency. We believe that there is still potential to drive the bioreactor yield 
even higher after further process optimisation, e.g. by being able to better 
monitor the confluence level in the bioreactor, or by further optimising the 
seeding homogeneity within the hollow fibres. 
6.1.2. Cell quality – In vitro assays 
The tri-lineage differentiation potential did not show significant differences in 
the osteogenic and chondrogenic differentiation. Qualitatively, the adipogenic 
differentiation of the cells harvested from CF_Q_FIB condition appeared to 
be reduced, which might be caused by the fibronectin as previously reported 
in literature (Martino et al., 2009; Ogura et al., 2004; Singh and 
Schwarzbauer, 2012; Wang et al., 2010), however this effect was not apparent 
in the bioreactor where a similar coating was used. It is plausible that the 
culture plastic has a different affinity for the coating compared to the hollow 
fibres, however it is difficult to assess the resulting fibronectin concentration 
after coating. 
Immunophenotyping by flow cytometry showed in general a high 
simultaneous expression of CD105, CD73 and CD90, while there was almost 
no expression of CD45, CD20, CD14 and CD34 for all conditions. The 
bioreactor condition showed a tendency to have a slightly lower CD105 
expression (on average 94 ± 3,4% compared to 97 ± 1.5% for the CF_Q 
condition). A loss of CD105 is regularly seen in bioreactor literature (not only 
in the specific case of the Quantum bioreactor (Hanley et al., 2014; Peters et 
al., 2013), but also in spinner flask culture (Jing et al., 2013; Dos Santos et al., 
2014)). However, no in-depth mechanisms of action are known. Dos Santos et 
al. (2014) showed that after re-plating the cells harvested from a spinner flask 
again in static culture conditions, the CD105 expression recovered to normal 
levels, and therefore hypothesised that this reversible loss was related to shear 
stress conditions. 
6.1.3. Cell quality – In vivo assay 
The in vivo bone-forming potency of the cells was assessed based on the 
ectopic implantation of harvested cells seeded on calcium-phosphate carriers 
in nude mice, which was shown previously to be a valid model for bone tissue 
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engineering (Chai et al., 2012b; Eyckmans et al., 2010; Roberts et al., 2011). 
No significant differences in the amount of bone formation and tissue 
development were perceived between cells from the bioreactor condition and 
the three control flask conditions during the process development runs, both 
quantitatively based on nano-CT imaging (Figure 6.6A), and qualitatively 
based on histology (Figure 6.7). For example, the newly formed bone per 
available scaffold volume for the bioreactor and the standard tissue culture 
flask condition was 10.3 ± 3.7% and 11.0 ± 3.8% respectively. More striking 
was the difference in bone-forming potential between the different donors 
(Figure 6.6B,C,D). While the intra-donor variability was low, i.e. the average 
percentage of newly formed bone between two different batches and between 
two different culture conditions (bioreactor and TF culture) within one donor 
was similar, the inter-donor variability on the other hand was large (8.8 ± 
2.4%, 5.8 ± 1.7% and 0% for donors 1, 2 and 3 respectively). Donor 1 
produced on average significantly more bone than donor 2 for both batches 
and both conditions, while donor 3 produced no bone at all in all conditions. It 
is clear that this lack of bone-forming potential is not due to the difference in 
culture conditions specifically, since both the standard culture flask and the 
bioreactor condition show the same behaviour. Although it is difficult to 
predict how these cells would have performed in an orthotopic in vivo model 
where more appropriate cell stimuli were provided, the example of this 
specific donor is highlighting risks entailed in autologous tissue engineering 
strategies. Thorough cell characterisation is required, ideally with a predictive 
power regarding the in vivo potency, before large-scale expansion is pursued. 
This will help prevent large sunk costs and unnecessary surgical interventions 
for the patient.  
6.1.4. Process comparability 
Apart from the practical advantage of a bioreactor-based cell expansion 
process, e.g. the reduction of open processes that requires expensive GMP 
facility resources, reduced work load, small footprint, etc., one of the main 
drivers for increased automation is to enhance the robustness and 
reproducibility of the culture process, directly leading to a more uniform cell 
quality and subsequent less variable in vitro and in vivo potency (Santoro et 
al., 2010; Trainor et al., 2014). In this study it was shown that the bioreactor 
condition is able to reduce the overall process variability by a factor of 2.5 
regarding cell yields (normalised per available surface) compared to the flask-
based condition, demonstrating therefore a much higher potential capability to 
produce cell batches within specification limits. Similar findings regarding 
automated cell expansion processes were reported earlier (Archibald et al., 
2015; Liu et al., 2010; Paull et al., 2015; Terstegge et al., 2007). 
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Controlled cell expansion methods are essential for the development of cost-
effective and robust production processes for commercial cell-based products 
(Archibald et al., 2015; Liu et al., 2010). Especially in the case of autologous 
therapies, where a decentralised multi-centre production model is almost 
inevitable, process consistency and reproducibility is a critical issue in order 
to assure uniformity of the product (Foley and Whitaker, 2012; Hourd et al., 
2014). For decentralized production of autologous cells, where cells from 
different donors might behave differently during culture (Heathman et al., 
2015b; Siddappa et al., 2007), additional process monitoring and control is 
required that is able to assess the level of similarity between two different 
runs, and ultimately facilitate the demonstration of comparability between 
different production sites and even between different donors.  
In this work, the implemented oxygen and pH measurements showed that 
culture conditions could be replicated over multiple bioreactor runs and that a 
greater process understanding can be achieved in order to better control the 
critical process parameters (EMA, 2014; FDA, 2011). Additionally, process 
read-outs were used to make consistent decisions, for example the lactate-
based feed rate strategy and harvest timing for different donors. These 
ultimately increased production efficiency by reducing medium consumption 
and optimising final cell density. Although requiring a small adaptation to the 
current bioreactor system, on-line monitoring such as done here for O2 and pH 
is preferred from a manufacturing point of view, as up-to-date information can 
be obtained from the system at any time without the manual handlings that are 
currently still required for lactate and glucose sampling. In future studies 
continuous process verification could be used as a basis for active donor-
specific process control. For example, the perceived ±10% drop in dissolved 
oxygen concentration (Figure 6.7) could be counteracted with a feedback 
control loop that would increase the medium circulation rate in the external 
space between the hollow fibres in order to increase the homogeneity in terms 
of oxygen availability over the length of the hollow fibres, without increasing 
the shear stress on the cells inside the hollow fibre lumen. 
Additionallyrecently explored oxygen-based cell number quantification 
techniques could also be applied (Lambrechts et al., 2014). 
 Conclusion 6.2.
In conclusion, these data show that hPDCs can be reproducibly expanded in 
the Quantum system bioreactor on a clinical scale. At the same time the main 
cell quality attributes, assessed with both in vitro assays based on the ISCT 
minimal criteria and an in vivo bone-forming potency assay, remained very 
consistent between the bioreactor and standard flask-based culture. 
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Additionally, it was shown that the bioreactor culture resulted in a more 
robust outcome regarding cell yield (showing a reduction of the overall 
process variability on cell yield by a factor of 2.5 compared to the standard 
flask-based culture) and showed good process reproducibility based on 
process analytics such as O2, pH, lactate etc. Although all donors reached the 
minimally required cell yield (350 million cells) and showed limited intra-
donor variability for the different batches and culture conditions, large inter-
donor differences were observed regarding for example nutrient requirements 
and in vivo potential (8.8 ± 2.4%, 5.8 ± 1.7% and 0% newly formed bone per 
available scaffold volume for donors 1, 2 and 3 respectively) that would have 
significant implications for clinical translation. 
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M. Aerts. Biotechnology and Bioengineering. (2014) 111:1982–92. 
122 Model-based cell number quantification for perfusion bioreactors 
 
 Positioning within the context of the PhD project 7.1.
In Objective 3 (Chapter 2) it was hypothesised that by making use of routine 
process data, more information on critical process parameters and critical 
quality attributes of the cells could be derived, on which in turn more 
informed process control decisions can be based. While imaging technology 
was used in Chapter 4 and 5 to assess the number of cells inside the 
bioreactor, more 3D bioreactor configurations such as the Quantum hollow 
fibre bioreactor from Chapter 6 cannot be non-invasively imaged during the 
culture. This chapter therefore focusses on the use of data from a single 
oxygen sensor in perfusion bioreactors in order to non-destructively monitor 
the amount of cells inside the bioreactor. The measured response to changes 
in the perfusion flow rate are translated by means of a data-based transfer 
function model to an estimate on the number of cells.  
 
Figure 7.1: Position of Chapter 7 in the general control scheme and the larger context of this 
work. 
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 Abstract 7.2.
On-line and non-invasive quantification of critical tissue engineering (TE) 
construct quality attributes in TE bioreactors is indispensable for the cost-
effective up-scaling and automation of cellular construct manufacturing. 
However, appropriate monitoring techniques for cellular constructs in 
bioreactors are still lacking. This study presents a generic and robust approach 
to determine cell number and metabolic activity of cell-based TE constructs in 
perfusion bioreactors based on single oxygen sensor data in dynamic 
perfusion conditions. A data-based mechanistic modelling technique was used 
that is able to correlate the number of cells within the scaffold (R2=0.80) and 
the metabolic activity of the cells (R2=0.82) to the dynamics of the oxygen 
response to step changes in the perfusion rate. This generic non-destructive 
measurement technique is effective for a large range of cells, from as low as 
1.0x105 cells to potentially multiple millions of cells, and can open-up new 
possibilities for effective bioprocess monitoring.  
 Introduction 7.3.
The translation of promising lab-scale cell based regenerative medicine and 
tissue engineering (TE) therapies to large-scale commercial production is 
hampered by a lack of robust and cost-effective manufacturing processes that 
can deliver effective, regulatory-compliant and safe cellular products 
(Brindley et al., 2012; Mason and Manzotti, 2010). Bioreactors for 3-
dimensional (3D) TE have demonstrated their potential as a cost-effective and 
highly automated production platform showing great promise for both the up 
and scale-out strategies (Martin et al., 2009; Dos Santos et al., 2013). Due to a 
combination of increased surface area per volume and improved nutrient 
transport while closer mimicking the natural niche of the cells, 3D bioreactors 
contribute to a higher productivity compared to traditional 2D cell culture  
(Martin et al., 2004; Tandon et al., 2013; Wendt et al., 2005). Additionally, in 
light of recent stringent quality control guidelines by the European Medicines 
Agency (CAT, 2010) and the US Food and Drug Administration 
(DeFrancesco, 2012), bioreactors will provide an indispensable means for 
process control as they allow a more precise physicochemical control of the 
cellular microenvironment, directly contributing to the enhancement of 
construct quality and reproducibility prerequisites for consistent clinical 
outcomes (Kirouac and Zandstra, 2008; Martin et al., 2009; Rodrigues et al., 
2011). 
Despite these advantages, the use of bioreactor systems in a clinical setting 
remains minimal (Salter et al., 2012). This is attributed to the lack of robust 
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bioprocess control in the closed system ‘black box’ bioreactor (Wendt et al., 
2009). Multiple bioprocess monitoring techniques exist, primarily originating 
in the biopharmaceutical bioreactor industry, that can quantitatively measure 
physicochemical process parameters, such as temperature, pH, dissolved O2, 
glucose concentration and metabolic activity (Bluma et al., 2011; Rolfe, 2006; 
Starly and Choubey, 2008; Ward et al., 2013; Zhou et al., 2013). However, a 
direct transfer of the biopharmaceutical monitoring and control strategies to 
TE bioreactors is not straightforward. Firstly, in the biopharmaceutical field 
the product is usually an antibody or protein expressed by cultured cells that 
are destructively harvested at the end of the culture step, while in the case of 
TE the cells will be (part of) the end product themselves (Mason and Hoare, 
2007). Secondly, contrary to the biopharmaceutical industry, the production 
process of TE constructs is more dynamic since the cell population will not 
only proliferate but will also go through a phase of differentiation. 
Furthermore, the smaller scale of TE products will require sensitive tools, 
especially in the case of autologous therapies where small cell numbers are 
cultured and a more batch-dedicated monitoring and control strategy will be 
required (Glassey et al., 2011).  
Therefore, functional bioprocess control in TE bioreactors, in the sense that it 
allows direct control over the critical quality attributes (CQAs) of the TE 
construct, such as proliferation rate, extracellular matrix production, 
differentiation stage, construct permeability, etc., remains a challenge due to 
inadequate online, non-invasive and cost-effective monitoring tools (Glassey 
et al., 2011; Koutinas et al., 2012; Placzek et al., 2009; Read et al., 2010; 
Vojinović et al., 2006). Depending on the bioreactor setup and cell carrier or 
scaffold design under consideration, this can be attributed to the high 
technicality and/or cost of direct, online and non-destructive measurement of 
TE construct CQAs. For example imaging techniques for real-time bioprocess 
control in 3D TE scaffolds are limited by the resolved depth of the sample or 
the lack of label-free techniques (Jaccard et al., 2014; Ward et al., 2013), 
surface plasmon resonance or mass spectrometry techniques needs specialized 
setups and have issues with complex culture medium samples (Jacquemart et 
al., 2008; Weber et al., 2012), while biomass probes are limited to certain cell 
carrier materials and are unable to distinguish between viable and non-viable 
cells (Kiviharju et al., 2007). 
Because the CQAs are the effectual culture parameters upon which the release 
criteria of the TE construct should be based in a clinical setting, the 
development of such monitoring tools will be indispensable for the cost-
effective production of regulatory compliant and clinically useful TE 
constructs. As a solution to the lack of direct CQA measurements some 
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studies use information on culture parameters that can conveniently be 
measured to indirectly estimate CQAs in fermentation and biopharmaceutical 
bioreactors (Dorresteijn et al., 1996; Junker and Wang, 2006; Meuwly et al., 
2006; Papas et al., 2007), but applications for TE bioreactors and especially 
for perfusion bioreactors are limited. For example Santoro et al. (2011) used 
isothermal microcalorimeters in a static culture system to correlate heat 
production caused by biological processes to cell number and proliferation 
rate. When focusing on perfusion bioreactors, Janssen et al. (2006) used the 
difference in dissolved O2 concentration in the culture medium across a 
perfused scaffold to estimate the number of cells, assuming an exponential 
cell growth rate. Santoro et al. (2012) improved this measurement by directly 
relating the difference in O2 concentration to experimental data based on DNA 
quantification. However, the main disadvantage of the latter two 
measurements is that two O2 sensors are needed. This decreases the cost-
effectiveness, but also by relying on the absolute difference between the 
sensors small measurement perturbations cause large changes in the estimated 
number of cells, resulting in a limited measurement resolution in the low cell 
number range. 
The aim of this study is to use a data-based mechanistic (DBM) modelling 
approach as a cost-effective tool to online monitor the amount of cells on a 
scaffold during 3D perfusion culture, based on single-sensor non-invasive O2 
concentration measurements in the micro-environment of the cellular 
construct under dynamic flow rate conditions. It is hypothesized that with this 
DBM approach, which is novel to the TE field, the number of cells within the 
scaffold can be estimated in a robust way based on a dynamic discrete-time 
transfer function model that describes the relation between the measured O2 
response (output) and the dynamic perfusion condition (input). 
 Materials and Methods 7.4.
7.4.1. Scaffolds 
Porous bio-inert Ti6Al4V scaffolds (Ø=6mm; h= 6mm; ±80% porosity), 
applied as geometrical backbone for 3D cell seeding and culture, were 
produced by selective laser melting as described by Van Bael et al. (2011). 
The cell-seeded volume per scaffold, taking into account a 80% porosity, is 
equal to 0.136 cm3. The scaffolds were cleaned in an ultrasonic bath 
consecutively in pure acetone, 70% ethanol and distilled water. Subsequently 
the scaffolds underwent an oxidation treatment for 24 hours in a 5M sodium 
hydroxide solution at 60°C, and were rinsed with distilled water. Before use, 
the scaffolds were autoclaved and pre-wetted with culture medium by vacuum 
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impregnation, incubated for 2 hours in a 37°C incubator at 95% humidity and 
dried overnight in a non-humidified incubator to create a customized cell 
seeding and attachment surface (Impens et al., 2010). 
7.4.2. Pre-culture of human periosteum derived stem cells 
(hPDC) and scaffold seeding 
Human periosteum derived stem cells (hPDC) were isolated as described by 
Eyckmans and Luyten (2006) after approval of the ethics committee for 
Human Medical Research (KU Leuven). The cells were pre-cultured in 
monolayer in culture medium consisting of high glucose Dulbecco’s modified 
Eagle’s medium (Invitrogen) supplemented with 10% fetal bovine serum 
(FBS; Gibco), 1% sodium pyruvate (Invitrogen) and 1% antibiotic–
antimycotic (100 units/mL penicillin, 100mg/mL strepto- mycin, and 
0.25mg/mL amphotericin B; Invitrogen). For up to 7 passages, cells were 
trypsinised for 10 minutes with Tryple Express (Invitrogen). At passage 8, 
2x105 (28 000 cells/cm²) or 4x105 (56 000 cells/cm²) cells were seeded in the 
scaffolds in 5 different batches using biphasic static drop-seeding as described 
by Impens et al. (2010) with a 45 minute incubation time during the two 
seeding steps. This seeding procedure generally results in a seeding efficiency 
of 44% ± 3.5%. The variability in cell density on the scaffolds is attributed to 
the use of two different seeding densities, the inter batch variability and the 
intrinsic variation in seeding efficiency. 
After the seeding procedure, the scaffolds were incubated under static 
conditions in 12-well plates with growth medium for up to 4 days. As part of 
the cell seeding evaluation randomly selected Live-Dead® 
viability/cytotoxicity staining (Invitrogen) was performed after seeding to 
evaluate homogeneity. 
7.4.3. Bioreactor setup 
For the O2 measurements the scaffolds were transferred to an in-house 
developed perfusion bioreactor system (Figure 7.2A) in which culture 
medium from a disposable medium reservoir (50-mL Falcon tubes; BD 
Biosciences) containing 10 ml culture medium was pumped through the 
scaffold in the perfusion chamber by a computer controlled peristaltic pump 
(PC-24; Ismatec SA). The dissolved O2 concentration in the culture medium at 
the inlet of the perfusion chamber was kept constant at incubator conditions 
(5% CO2, 37°C) with the aid of an oxygenator consisting of gas permeable 
tubing. The O2 concentration at the perfusion chamber inlet was checked with 
a Fibox3 sensor (PreSens Precision Sensing GmbH). It is important to note 
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that this data was used only as a control for a constant dissolved O2 
concentration at the inlet of the perfusion chamber and is not used in further 
analysis. A second O2 sensor (NeoFox, Ocean Optics) was placed at the outlet 
of the perfusion chamber to register the outgoing O2 concentration after 
perfusion through the cell seeded scaffold.  
 
Figure 7.2: Overview of bioreactor setup and data interpretation 
(A) Bioreactor setup in which stacks of scaffolds are dynamically perfused. The O2 sensor at 
the outlet registers the resulting fluctuations in O2 concentration in the medium, the sensor at 
the inlet is solely used as a control for the constant input conditions. (B top) The applied 
dynamic perfusion rate consisting of 4 steps of 5 hours (0.18ml/min for 2h, 0.03ml/min for 3h). 
(B) Typical examples of the resulting dynamic O2 profile for a stack of scaffolds containing 
1.0x105 and 4.0x105 cells. The box indicates the part of the data considered in the modelling 
analysis, with the perfusion flow rate as model input and resulting O2 concentration as model 
output. The bottom graph in B shows the constant O2 input conditions during the dynamic 
perfusion condition as captured by the sensor at the perfusion chamber inlet. This data is not 
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used for further analysis. .(Note that the positions of the scaffold stacks are switched compared 
to the signal that is shown in B). 
Dynamic perfusion of scaffolds 
The pump was programmed to apply a stepwise dynamic perfusion flow rate, 
consisting of 4 consecutive 5h “steps” in which a pump speed of 0.18 ml/min 
is applied for 2h, followed by 0.03 ml/min for 3h (Figure 7.2B). This dynamic 
flow rate condition is exploited as a shift or dynamic pulse experiment in 
which the cell population is subjected to a change in process parameters 
aiming at investigating culture characteristics (Sagmeister et al., 2013). By 
applying step changes in flow rate, the measured dissolved O2 concentration 
per unit volume of medium is altered due to cellular consumption proportional 
to the residence time of the medium in the scaffold. The resulting dynamic O2 
response to the perfusion rate steps can be measured by a single sensor at the 
perfusion chamber outlet (Figure 7.2B). This measurement will be used for 
further analysis with the data-based mechanistic modeling approach. The 
bottom of Figure 7.2B shows an example of a sensor measurement at the inlet 
of the perfusions chamber. This data is not used in further processing, but it 
illustrated the constant O2 input conditions during the dynamic perfusion 
conditions (i.e. the effectiveness of the oxygenator). 
The design of the steps in flow rate was based on a mathematical relation 
between the applied flow rate and resulting O2 concentration at the perfusion 
chamber outlet (Equation 6) and was chosen in this way that predicted 
variations in the measured outlet O2 concentrations would be easily perceived 
by the sensor. In a preliminary validation experiment it was shown that the 
number of cells attached to the scaffold did not significantly change (based on 
DNA content) after being exposed to the fluid flow within the perfusion 
bioreactor, irrespective of the used perfusion rate (range tested was between 
0.2 ml/min and 4 ml/min, Figure 7.3A). Additionally, to underline the non-
destructive and non-invasive nature of the step changes in the perfusion 
conditions, its effect on the metabolic activity and cell number was assessed. 
In a setup where one group of scaffolds (n=3) was subject to a constant 
perfusion rate of 0.18 ml/min for 7 days while another group of scaffolds 
(n=3) was subject to one dynamic perfusion step every 24h for 7 days (high 
flow rate 0.18 ml/min, low flow rate 0.03 ml/min for 3h), no significant 
difference in metabolic activity and DNA content between the two groups was 
observed (Figure 7.3B).  
For the O2 measurements, a total of 21 combinations of 3 seeded and/or non-
seeded scaffolds were stacked on top of each other in the bioreactor (Figure 
7.2A) and dynamically perfused for 20 h (4 steps), resulting in 21 different 
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time series of dynamic O2 measurements. By stacking combinations of 
3 seeded and non-seeded scaffolds, a large number of different cells densities 
could be measured (between 1x105 and 6.5x105 cells) without altering the 
flow profile inside the perfusion chamber. 
 
Figure 7.3: Validation experiment for the influence of the dynamic perfusion flow on the cells 
within the scaffold.  
(A) Live/dead staining after replacing the seeded scaffold from static conditions to the 
perfusion bioreactor at different flow rates. (B) The number of cells in the scaffolds 
(determined by DNA quantification) and the metabolic activity of the cells (determined by a 
PrestoBlue metabolic activity assay) after 7 days of culture in dynamic perfusion conditions did 
not significantly differ from the constant perfusion condition. 
7.4.4. Metabolic activity and DNA content analysis 
Immediately after the 20h dynamic perfusion culture period in the bioreactor, 
the stacked scaffolds were separately transferred to a 12-well plate and 
submerged in a 10% PrestoBlue (Life Technologies) metabolic activity assay 
according to the manufacturer’s instructions. After 2h incubation, the 
metabolic activity of the cells in the scaffolds was quantified by fluorescence 
measurements (Bio-Tek Synergy™ HT) with an excitation wavelength of 
540nm and an emission wavelength of 590nm on 100µL supernatant in a 96-
well plate. A higher metabolic activity is indicated by higher fluorescent 
values. Subsequent to the metabolic activity assay, the DNA content on the 
scaffolds was obtained by a highly quantitative and selective DNA assay 
(Quant- iT™dsDNA HS kit; Invitrogen) as described by Chen et al. (2012). In 
short, after rinsing the scaffolds with PBS, they were lysed in 350µL lysis 
buffer (Qiagen) supplemented with 3.5µL β-mercaptoethanol (Sigma) and 
frozen at -80°C. Afterwards the scaffolds were thawed at room temperature 
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and a Qubit® Fluorometer (Invitrogen) was used to quantify the DNA content 
for each sample in 10µl supernatant diluted in 90µl miliQ water. 
7.4.5. Data-Based Mechanistic (DBM) Modelling of single 
sensor dynamic O2 data 
A data-based mechanistic (DBM) modelling approach was used to infer 
information on cell numbers within the scaffold based on the O2 
measurements under dynamic perfusion conditions. Contrary to the often used 
mechanistic simulation models that start from a model structure as it is 
perceived based on a priori knowledge of the modeller (deductive approach), 
the data-based approach infers its model structure directly from the observed 
data (inductive approach) (Young, 1999). This approach significantly reduces 
the model complexity and facilitates parameter estimation. After the “black-
box” model identification stage, the resulting model is mechanistically 
interpreted in physically meaningful terms.  
In this study a discrete-time, linear, single-input, single-output transfer 
function (TF) model was used to describe the time series data of the response 
of the O2 sensor at the perfusion chamber output to the step variations in the 
perfusion flow rate (Young, 1984):  
𝑦𝑡 =
𝐵(𝑧−1)
𝐴(𝑧−1)
𝑢𝑡−𝛿 + 𝜉𝑡                     (1) 
where 𝑡 refers to the value of the associated variable at the 𝑡th sampling point; 
𝑦𝑡 is the model output or the observed time series from the O2 sensor (%O2); 
𝑢𝑡−𝛿 is the model input or the dynamic perfusion flow rate (ml/min) shifted 
over a time delay 𝛿; 𝜉𝑡 is the additive noise, assumed to be a zero mean, 
serially uncorrelated sequence of random variables with variance σ2 
accounting for measurement noise, modelling errors and effects of 
unmeasured process inputs. 𝐵(𝑧−1) and 𝐴(𝑧−1) are polynomials of model 
parameters that describe the influence of the exogenous input 𝑢𝑡 on the 
process: 
𝐵(𝑧−1) =  𝑏0 + 𝑏1𝑧
−1 + … + 𝑏𝑛𝑧
−𝑛               (2𝑎) 
𝐴(𝑧−1) =  1 + 𝑎1𝑧
−1 + … + 𝑎𝑚𝑧
−𝑚               (2𝑏) 
where 𝑏𝑖 and 𝑎𝑗 are the model parameters; 𝑧
−1 is the backward shift operator 
defined as 𝑧−1𝑦𝑡 = 𝑦𝑡−1; and 𝑛, 𝑚 are the orders of the respective 
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polynomials. For each data set of O2 measurements the 𝑏𝑖 and 𝑎𝑗 model 
parameters were estimated using a refined instrumental variable method 
(Young, 1984) for model orders 𝑛 and 𝑚 ranging from 1 up to 2 and time 
delays 𝛿 ranging from 0 up to 10 resulting in 44 (2 x 2 x 11) possible TF 
models. The resulting models were evaluated principally, but not solely, based 
on Young Identification Criterion (YIC) which is a combined measure for the 
goodness of fit (model residuals) and the parametric efficiency (ill-
conditioning). More negative YIC values for a certain model structure suggest 
better model fits (Pedregal et al., 2007; Young, 1984). Other criteria that were 
used in combination with YIC, were goodness of fit (expressed as the 
coefficient of determination, 𝑅𝑇
2), the model stability (quantified via the poles 
of the TF) and the reliability of the model parameter estimates (calculated 
based on the 95% confidence intervals around the parameter estimates). 
The TF model parameters or combinations thereof can be used to evaluate the 
dynamics of the model. For example the steady state gain (SSG) that will be 
used later, is a parameter describing the model dynamics that represents the 
steady level achieved by the output of the transfer function 𝑦(𝑡) following a 
sustained unit step in the input variable 𝑢(𝑡) (Figure 7.4) (Pedregal et al., 
2007). For a 1st order TF with one a- and b-parameter the SSG is calculated 
as: 
𝑆𝑆𝐺 =
𝑏0
1 + 𝑎1
               (3) 
 
Figure 7.4: Graphical interpretation of the steady state gain (SSG) and calculation for 1st order 
transfer functions. 
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7.4.6. Mechanistic model of the perceived drop in O2 
concentration 
With the goal of linking the TF model parameters to the dynamics of a 
physical system, a mechanistic model was used to describe the O2 distribution 
along the length of a perfused scaffold. In this study the perfusion setup is not 
diffusion limited (Péclet number is equal to 106 at lowest perfusion rate, 
assuming water at 37°C as the diffusion medium for O2 with a diffusivity 
constant of 3x10-9 m2/s), therefore the mass conservation law with a 
Michaelis-Menten consumption kinetics can be written like (Truscello et al., 
2011):  
𝜌𝒗
𝑑𝑝𝑂2
𝑑𝑥
=  𝑂𝐶𝑅𝑚𝑎𝑥
𝑝𝑂2
𝑘𝑚 + 𝑝𝑂2
               (4) 
where 𝜌 is the medium density; 𝒗 the flow speed; 𝑝𝑂2 the partial O2 pressure; 
𝑥 the coordinate relative to the scaffold length; 𝑂𝐶𝑅𝑚𝑎𝑥 the maximum 
volumetric O2 consumption rate of the cells and 𝑘𝑚 the Michaelis-Menten 
constant corresponding to the concentration at which the O2 consumption rate 
is equal to half of 𝑂𝐶𝑅𝑚𝑎𝑥. Assuming a near normoxic condition in the 
incubator and relatively high flow rates (𝑝𝑂2 ≫ 𝑘𝑚), the right hand side of 
the equation can be replaced by a constant consumption term equal to the 
maximum consumption rate 𝑂𝐶𝑅𝑚𝑎𝑥. In this case the equation can be solved 
analytically:  
∆𝑝𝑂2 =
  𝐿 ∙ 𝑂𝐶𝑅𝑚𝑎𝑥
𝑣
               (5) 
where L is the length of the scaffold. Substituting 𝑂𝐶𝑅𝑚𝑎𝑥 = 𝑂𝐶𝑅𝑚𝑎𝑥,𝑐𝑒𝑙𝑙 ∙
𝜌𝑐𝑒𝑙𝑙 = 𝑂𝐶𝑅𝑚𝑎𝑥,𝑐𝑒𝑙𝑙 ∙ 𝑁𝑐𝑒𝑙𝑙 𝑉⁄  and 𝑣 = 𝑄𝑚 𝜋𝑟
2⁄  results in: 
∆𝑝𝑂2 =
  𝑂𝐶𝑅𝑚𝑎𝑥,𝑐𝑒𝑙𝑙 ∙  𝑁𝑐𝑒𝑙𝑙
𝑄𝑚
               (6) 
where 𝑂𝐶𝑅𝑚𝑎𝑥,𝑐𝑒𝑙𝑙 is the maximum O2 consumption rate per cell (mol/cell
.s); 
𝜌𝑐𝑒𝑙𝑙 is the cell density (cell/m
3); 𝑁𝑐𝑒𝑙𝑙 is the total number of cells in the 
scaffold (cell), 𝑉(m3) is the scaffold volume; 𝑟 is the scaffold radius (m); 𝑄𝑚 
the medium flow rate (m3/s). A conversion between molarity (mol/L) and 
partial pressure (atm) is done with a Henry’s constant for O2 in water at 310 K 
equal to 959.3 L.atm/mol. As the mechanistic model describes the O2 gradient 
in a volume with a homogeneous cell distribution, which was not the case for 
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the scaffold stacks used in the oxygen measurements, a normalization of the 
measured oxygen drop based on the cell-seeded volume of the scaffold stack 
is required when comparing the results of the mechanistic model and the 
sensor measurements. 
7.4.7. Statistical analysis and numerical methods 
Data analysis was performed using Matlab 2011b (The MathWorks Inc.) in 
combination with the Captain toolbox (Taylor et al., 2007). Independent 
groups were compared by the unpaired Student’s t-test (two-tailed), and 
considered statistically significant in case p < 0.05.  
 Results 7.5.
A total of 21 different scaffold combinations with cumulative cell numbers 
ranging between 1.0x105 and 6.5x105 cells were dynamically perfused in the 
bioreactor. This resulted in time series data of the dynamic O2 response to the 
dynamic perfusion flow rate as shown in Figure 7.2B. Differences in the O2 
response measurements for different cell densities can already be observed 
when comparing the signal for a scaffold stack with 1 seeded scaffold and 3 
seeded scaffolds (respectively 1.0x105 and 4.0x105 cells in Figure 7.2B). 
These differences were quantified by the DBM modeling approach and the 
DBM model parameters were used to make an estimate of the number of cells 
within the scaffold. Due to the initial 1h adjustments period needed for the 
bioreactor system to reach equilibrium with the incubator conditions (37°C, 
5% CO2), data derived from the first step of the dynamic perfusion regime 
(minute 0 to minute 300) were not taken into account. Therefore, the first part 
of the second step (between minute 300 and 500 of the measurements as 
indicated by the box in Figure 7.2B) was used for the DBM model.  
The dynamic O2 response data could be accurately described by means of a 1
st 
order discrete-time, linear single-input single-output TF model, resulting in a 
𝑅𝑇
2  of 0.93 or higher for every dataset (Figure 7.5). The 1st order model 
structure with one a- and b-parameter was chosen to fit the measured data 
based on a generally lower YIC value compared to a 2nd order model structure 
with two a- and b-parameters. For the TF model parameters it was found that 
the steady state gain (SSG) showed a strong positive linear correlation 
(R2=0.80) with the number of cells inside the perfused scaffolds, with the cell 
number being based on the DNA quantification on the scaffold after the 20h 
dynamic perfusion cycle (Figure 7.6A). Additionally, the SSG also showed a 
strong positive linear combination with the total metabolic activity of the cells 
within the scaffold (R2=0.82) (Figure 7.6B) as could be expected from earlier 
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studies where a correlation between metabolic activity and the number of cells 
was found (Zhou et al., 2013).  
 
Figure 7.5: Typical example of the transfer function model resulting from the data-based 
mechanistic modeling approach (± 4.0x105 cells).  
The green dashed line represents the model input or the dynamic perfusion flow rate on the 
right axis. The red dots represent the O2 sensor time series and the blue line represents the 
resulting transfer function model of the oxygen concentration on the left axis. The arrow ΔO2 
indicates the height of the perceived drop in O2 due to the dynamic perfusion rate as will be 
used in Figure 7.7 and 7.8. 
To corroborate the data-based relation between the SSG model parameter and 
the number of cells within the scaffold, the mechanistic model describing the 
expected drop in O2 concentration (Equation 6) was used to physically 
interpret the data-based TF model. The mechanistic model showed that when 
the perfusion speed was lowered during the step change perfusion condition, 
the drop in O2 concentration was proportional to the number of cells in the 
scaffold, assuming a constant O2 consumption rate per cell (Figure 7.7). The 
drop in O2 concentration was quantified in the time series data by subtracting 
the lower steady state O2 concentration after the step in flow rate from the 
higher steady state O2 concentration before the step in flow rate (as indicated 
by the ΔO2 arrow in Figure 7.5). After normalizing this drop for the cell-
seeded volume of the scaffold stack, the mechanistic model was able to 
accurately fit (R2=0.75) the data. From the model fit a cell specific O2 
consumption rate of 1.09x10-17 mol/cell.s-1 could be calculated.  
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Figure 7.6: Correlation between Steady Sate Gain (SSG) and the number of cells in the 
scaffold, and the SSG and the metabolic activity of the cells. 
(A) Correlation between the steady state gain derived from the transfer function model 
parameters and the total number of cells within the scaffold based on DNA quantification 
(R2=0.80). (B) Correlation between the steady state gain derived from the transfer function 
model parameters and the total metabolic activity of the cell in the scaffold as determined by 
the PrestoBlue assay (R2=0.82). The graphs show the results for all 21 O2 measurement time 
series. 
 
Figure 7.7: Fit of the mechanistic model as described in Equation 6, on data from the measured 
drop oxygen concentration.  
The drop in oxygen concentration is quantified by subtracting the lower steady state O2 
concentration after the flow rate step from the higher steady state O2 concentration before the 
flow rate step and normalized for the cell-seeded volume of the scaffold stack. Based on the 
parameters of the fitted model a cell specific O2 consumption rate of 1.09x10
-17 mol/cell.s-1 
could be determined. 
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From the correlation between the number of cells in the scaffold and the SSG 
(Figure 7.6A), and the number of cells and the drop in O2 concentration 
(Figure 7.7), a linear correlation between the SSG and measured drop in O2 
concentration was obtained as can be seen in Figure 7.8A. Further, when 
looking closer to the units of the SSG (%O2/ml.min
-1
) it is possible to 
calculate the O2 drop from the value of SSG. When the O2 drop, estimated via 
the SSG as determined from the data-based model (normalized for cell-seeded 
volume as before), is compared to the O2 drop as expected from the 
mechanistic model, it can be appreciated in Figure 7.8B that the same trend is 
followed. These correlations between the SSG parameter of the TF model and 
the mechanistic model is important as it makes the purely data-based TF 
model more interpretable in a mechanistic sense. 
 
Figure 7.8: Correlation between the drop in oxygen concentration and the number of cells in 
the scaffold and the Steady State Gain. 
 (A) Correlation between the Steady State Gain derived from the transfer function model 
parameters and the drop in oxygen concentration as perceived in the time series data (R2=0.90). 
(B) Expected drop in oxygen concentration based on the prediction of the mechanistic model 
and the prediction via the Steady State Gain normalized for the cell-seeded volume of the 
scaffold stack 
 Discussion 7.6.
This study showed that a data-based mechanistic modelling approach can be 
successfully applied on O2 sensor data to accurately determine the number of 
cells in a scaffold in 3D perfusion culture in a non-invasive and on-line way. 
It can be observed (Figure 7.6A) that by combining step changes in perfusion 
flow rate with a DBM modelling approach a range of cell  numbers can be 
accurately determined. It was shown that the lowest detectable limit with this 
single sensor approach is approximately 5 times lower than reported in similar 
3D bioreactor setups in literature that make use of two O2 sensors (Janssen et 
Discussion 137 
 
al., 2006; Santoro et al., 2012) (Table 6-I). In case the absolute difference in 
O2 concentration between two sensors is taken as a measure for a certain 
amount of cells in the double sensor setup, small perturbations in the readings 
can cause relatively large deviations in the estimated number of cells. The 
single sensor approach described here, in combination with the SSG 
parameter that relatively describes the dynamics of the signal between two 
steady states, is less affected by fluctuations in the read-out. The subsequent 
increased accuracy and lower detection limit of this single sensor approach 
could open up new bioprocess control possibilities for 3D TE constructs, 
especially for autologous approaches where only a relatively small number of 
cells can be taken from patient biopsies as start of the culture (Jakob et al., 
2012; Mason and Hoare, 2007). Moreover, the principle of applying a 
dynamic perfusion flow rate to induce a dynamic O2 response that holds 
information on the number of cells in a scaffold is in theory generically 
applicable to perfusion, hollow fibre and packed bed bioreactor systems 
having at least one O2 sensor, and this for any type of cell carrier and cell 
type. 
Table 7-I: Detectable number of cells reported in literature in similar setups (however not 
necessarily targeted with the goal of determining the lowest detectable limit).  
Reference Strategy Cell type 
Lowest 
(robustly) 
detectable cell 
number 
reported 
(Janssen et al., 
2006a; Janssen et 
al., 2006b) 
Difference in 
dissolved O2 
between 2 sensors 
Goat bone 
marrow 
stromal cells 
± 20x106 cells 
seeded  
(Santoro et al., 
2012) 
Difference in 
dissolved O2 
between 2 sensors 
Human 
chondrocytes 
± 500,000 cells 
Current study 
DBM modelling of 
1 sensor in 
dynamic perfusion 
conditions 
Human 
periosteum 
derived stem 
cells 
± 100,000 cells 
The design of the dynamic perfusion flow condition is critical and will have to 
be adapted to the specific needs for every bioreactor setup, for example 
depending on the O2 consumption rate of the cells, scaffold design or the 
expected number of cells (Cioffi et al., 2008; Maes et al., 2009; McCoy et al., 
2012). The high flow rate in the step design is fairly unimportant regarding 
the measurements and will most conveniently be the functional flow rate that 
138 Model-based cell number quantification for perfusion bioreactors 
 
is used for the cell culture system. The selection of the low flow rate is more 
crucial, since it is subject to a trade-off between the non-destructiveness and 
the precision of the measurement. When the low flow rate is too low, O2 
concentrations within the TE construct might drop excessively, causing 
adverse effects on the TE construct quality due to O2 depletion and the 
development of hypoxic regions (Das et al., 2010; Malda et al., 2007; Radisic 
et al., 2006; Volkmer et al., 2008). On the other hand, the flow rate has to be 
low enough for the O2 sensor to be able to perceive the drop in O2 
concentration (constraint related to the sensor resolution). By making use of 
the cell specific oxygen consumption rate obtained from the Figure 7.7 
(1.09x10-17mol/cell.s-1, corresponding with O2 consumptions rates as found in 
literature for comparable cell types (Cochran et al., 2006; Lewis et al., 2005)) 
and Equation 6, an operating window for selecting suitable perfusion 
conditions for a range of cell numbers can be constructed as shown in Table 
7-II. The change in perfusion rate for a given number of cells that results in O2 
concentration drops from a green to a yellow zone in the table will be 
sufficient for the sensor and the data-based model to be picked up, while 
larger drops towards the red zone might result in a decreased TE construct 
quality.  
Table 7-II: Application specific operating window of the resulting drop in O2 concentration 
(%O2) for the dynamic perfusion rates. 
Changes in flow rate that result in drops in O2 concentration that go from a green to yellow 
zone are deemed optimal concerning the trade-off between measurement precision and the 
biologic quality of the TE construct. This operating window is derived from the model 
described in Equation 6 for an hPDC oxygen consumption rate of 1.09x10-17 mol/(cell*s) 
derived from the mechanistic model fit in Figure 7.7. 
 
By choosing the appropriate step change perfusion conditions, or by changing 
them over time during culture, the hypoxia risk can be mitigated and large 
ranges of cell numbers can be quantified. However, changes in flow regime 
itself have been seen to influence the cell state (Grayson et al., 2011; Jaasma 
et al., 2008; Kim and Ma, 2012; Sharp et al., 2009). Since there was no 
apparent effect of the used step change perfusion profile noticeable on the 
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metabolic activity and DNA content in the scaffolds in this dataset (Figure 
7.3B), it is hypothesized that this influence is negligible for the low frequent 
dynamics used in this case compared to the pulsatile flow rates as for example 
described in Sharp et al. (2009). Moreover, it is important to note that for 
determining the cell number within the perfusion bioreactor the application of 
a step change perfusion condition does not strictly has to proceed through 
planned experimentation. In certain processes there might anyway be 
opportunities in normal operation mode to measure O2 responses on step 
changes in perfusion rate, for example when perfusion is temporarily stopped 
during medium exchange or sample taking. 
This use of DBM modelling of O2 data in step change perfusion conditions 
has the potential to follow up 3D bioreactor cell cultures over time. However, 
temporal changes in the TE construct developmental phase (e.g. due to stem 
cell differentiation) could alter the metabolic activity of the cells (Quinn et al., 
2012; Ward et al., 2013), and therefore the O2 consumption rates of the cells 
(Zhao et al., 2005). In that case, it is expected that the linear relation between 
the SSG parameter, metabolic activity and cell number as seen in Figure 7.6 
will not be valid over the whole culture time. This may be accounted for by 
previously determining a reference curve for the evolution of the SSG 
parameter over time in relation to DNA measurements, or by implementing 
other sensing techniques that can provide information on the developmental 
phase of the cells in the TE construct (for example by the use of lactate 
measurements as described by (Zagari et al., 2013)). It should also be noted 
that the SSG reflects the dynamics caused by the oxygen consumption of all 
the cells in the system, either attached to the scaffold or growing on the 
perfusion chamber. Care should be taken during long-time culture that the cell 
number is not overestimated due to cells that might grow close to the scaffold 
while not being part of the final construct. 
Although more frequently used in other scientific domains, such as modelling 
and controlling heart rate responses of athletes (Lefever et al., 2012), energy 
transfer in buildings (Price et al., 1999), precision life stock farming (Silva et 
al., 2009), and other environmental and economic phenomena (Haredasht et 
al., 2011; Young, 1998), the DBM modelling technique is, as far as known by 
the author, unexplored in the context of bioprocess control for TE bioreactors. 
Nevertheless this data-based approach holds promise for the TE domain since 
high quality bioprocess data is often available from the bioreactor system and 
purely mechanistic models for complicated biological processes are often 
non-existent or have a significant cost of development (Koutinas et al., 2012). 
In addition, since the DBM approach results in low order, parametrically 
efficient models that describe only the dominant behaviour of the system, it 
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forms an ideal basis for controlling processes (Pedregal et al., 2007; Taylor et 
al., 2007). 
 Conclusion 7.7.
The data-based mechanistic modelling approach combined with step changes 
in the perfusion flow rate allows to accurately quantify a broad range of cell 
numbers within a scaffold in 3D perfusion bioreactors in an online and non-
destructive way. By making use of a single O2 sensor, this approach combines 
accuracy with cost-effectiveness, providing quantitative information on an 
important TE construct quality attribute. In addition to the non-invasiveness 
and relative simplicity of the setup, the approach used here is generically 
applicable for different culture applications, bioreactor designs, cell carriers 
and cell types, making it an interesting quality control tool for regulatory 
compliant clinical TE construct production. 
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 Overall discussion, future Chapter 8.
perspectives, and conclusions 
 Summary 8.1.
The development of controlled and cost-effective stem cell bioprocesses is 
imperative for the successful clinical translation and commercialization of 
cell-based therapies. In this doctoral thesis the large-scale expansion of 
mesenchymal stem cells was explored in support of an autologous cell-based 
ATMP that is currently under development at Prometheus (KU Leuven). In 
parallel, tools were developed would allow informed decision-making on 
critical process steps by making efficient use of process data in combination 
with data-based modelling techniques. 
In Chapter 3 a set of process metrics (expansion factor, final cell 
yield, concentration of protein supplement, cell density at harvest, etc) and an 
interactive tool for the comparison of cell expansion processes was provided 
based on an analysis of 73 different cell expansion processes on 7 different 
cell types in 5 different culture vessels. This tool allows the user to benchmark 
expansion processes against each other and assess their capability to support a 
certain production strategy. 
In Chapter 4 the translation of Prometheus’ standard flask-based 
production process to a large-scale bioreactor-based process was described 
specifically for a multiplate-type bioreactor (Xpansion by Pall Life Sciences). 
This chapter focused on the large-scale processes (both up- and downstream), 
with continuous monitoring and control of environmental variables, manual 
metabolite samples and image-based cell growth monitoring at discrete time 
steps. The growth dynamics and final cell density in the bioreactor were 
almost identical compared to the control flask (17 500 cells/cm2 and 17 300 
cells/cm2 respectively) and the in vivo potential of the cells remained 
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unchanged. A detailed analysis of the cell losses during the downstream 
process revealed that significant gains in efficiency can be achieved by further 
optimising the harvest procedure. 
Chapter 5 specifically focused on how the monitoring and control 
capability of the imaging setup (Ovizio iLine S) that was incorporated in the 
multiplate bioreactor could be used to optimise the harvest reaction in the 
bioreactor. An application for the on-line model-based prediction of the 
optimal time to stop the enzymatic harvest reaction was developed by means 
of real-time imaging and quantification of cell circularity in combination with 
data-based models. The tool was able to accurately estimate the inhibition 
time (median error of 21 seconds), thereby effectively reducing the exposure 
time to the harvest enzymes which are potentially influencing cell quality. 
Because the tool informs operators in real-time and in an objective way about 
the time point for the cells to be retrieved from the bioreactor vessel the 
reproducibility of harvest experiments in a 2D culture setting can be 
increased. 
Chapter 6 described another approach for the translation of the 
Prometheus flasks-based production process to a large-scale bioreactor, this 
time employing a hollow fibre perfusion configuration (Terumo BCT 
Quantum cell expansion system). The bioreactor supported efficient growth of 
the cells (cell yields between 316 million and 444 million starting from 20 
million cells over an 8 day culture period), mainly because the hollow fibre 
setup supports very low seeding densities. For these processes lactate 
production rates were used to objectively decide on the medium feed rate and 
the timing of the cell harvest for donors with different growth and metabolic 
rates. The bioreactor setup was modified slightly in order to monitor 
environmental parameters in an on-line way as was seen in Chapter 4. 
Additionally the comparability of the process outcome, both in vitro and in 
vivo was evaluated for the multiple donors. 
Finally, Chapter 7 provided another example on how on-line process read-
outs combined with data-based models are able to provide estimates of critical 
quality attributes. This was aimed at perfusion bioreactors, such as the 
Quantum bioreactor of Chapter 6, where imaging techniques as used in 
Chapter 5 are generally not applicable due to the non-transparent spatial 
configuration of the bioreactor. On-line oxygen measurements from a single 
sensor in combination with controlled changes in the perfusion flow rate and a 
data-based model with a mechanistic interpretation allowed precise estimates 
of the number of cells in the bioreactor. 
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  Overall discussion and future perspectives 8.2.
The previous chapters each contain their specific discussion and conclusion 
section, and therefore, we will focus here on three trends that are over-arching 
to all the previous chapters and which are important future consideration for 
the development of cell-based therapies: 
8.2.1. Reduction of process variability is key to assure 
robust in vivo performance  
It is advisable to strive for reduced process variability, even in the very early 
stages of process development. This will facilitate the definition of a design 
space in which the process will be under control, which in turn will ensure a 
higher chance of producing cell batches inside the specification limits and 
therefore ultimately leading to more clear-cut regulatory approval of the cell-
based therapeutic product. 
From a raw materials perspective, process variability can be reduced by 
carefully selecting the process inputs. For example, switching from highly 
batch-dependent and poorly characterised process components such as foetal 
bovine serum to chemically defined culture media is despite the high cost and 
often lower cell yields (as concluded in Chapter 3) gaining more and more 
support (Heathman et al., 2015c). While efforts are made at Prometheus 
towards chemically defined media (Bolander et al., in press), for the large-
scale experiments in this work its use was not yet considered due to the 
associated high costs that comes with this scale. Considering the cells 
themselves as a raw material in the expansion process, potentially an even 
larger impact could be made by switching from the more heterogeneous adult 
progenitor cell populations such as the hPDCs to induced Pluripotent Stem 
Cells (iPSC). These cells possess the advantage of being generated in the lab 
under standardised conditions, instead of being directly retrieved from a tissue 
biopsy. Additionally, iPSCs are able to differentiate into any cell type of the 
human body while having a phenomenal expansion capacity. This evolution 
will not only revolutionise the way we use cells for the treatment of diseases, 
but (allogeneic) iPSCs hold tremendous promise for large-scale standardised 
production processes (Baghbaderani et al., 2015; Rao and Atala, 2016). 
Apart from the variable process input as discussed in the previous paragraph, 
also from a technical point of view progress can be made in order to reduce 
process variability. By automating the critical steps of the culture procedure 
and reducing the operator induced variability, the use of bioreactors will allow 
a more robust and reproducible process (Liu et al., 2010; Williams et al., 
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2012). This could directly lead to a more uniform cell quality and subsequent 
less variable in vitro and in vivo performance (Santoro et al., 2010; Trainor et 
al., 2014). It was also shown in this work that by introducing bioreactor-based 
cell culture processes the variability on the process outcome can be 
significantly reduced. For example, in Chapter 6 it was determined that the 
variability on cell yield (normalised by culture surface) for the Quantum 
bioreactor was 2.5 times lower compared to the flask-based expansion. This 
significantly increases the chance of producing cell batches within the 
specification limits as can be seen in Figure 8.1. 
However, only standardising the input materials and automating the processes 
will not solve the process variability issue since biological systems, in the 
terminology of the M3-BIORES lab, are CITDs or “complex, individually 
different, time varying in its responses, and dynamic” (Van Loon et al., 2006). 
The implication of a CITD system is that, especially in the context of 
autologous therapies, two seemingly identical biological processes might still 
show variability given that every individual reacts differently and in a time-
variant way on a certain stimulus. In terms of bioprocess development, the 
CITD principle suggests that developing processes that are optimised for the 
average individual are still resulting in suboptimal operating conditions for a 
very large part of the population. Take for example the third donor in the 
Quantum bioreactor expansion process of Chapter 6. While the process and 
environmental conditions were nearly identical to the other 2 donors, the cells 
from the 3rd donor were not able to generate bone in the in vivo potency assay.  
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Figure 8.1 Process capability analysis based on historic harvest quantification data (cells/cm2) 
from the Prometheus lab on cell expansion processes in T-flasks and the Quantum bioreactor. 
LSL = lower specification limit, USL = upper specification limit. 
Process variability is inseparably linked to process monitoring. In the first 
place, process monitoring allows the detection of the (causes of) variability. 
Secondly, the process monitor is able to warn the operator in those case where 
process parameters exceed their allowable tolerance limits. In this way it can 
act as an early warning system able to prevent large sunken costs of processes 
that would otherwise only get rejected at the end of the process (end-point 
analysis). On-line process monitoring could eventually evolve towards on-line 
process control with self-correction, where based on the continuous process 
read-outs (and their link to the cell quality) continuous corrections to the 
process could be effectuated via the controller to better tune into the needs of 
each individual donor separately and in this way actively reduce the 
variability on the process outcome. 
While on-line monitoring has a large potential to make cell culture processes 
more robust, finding culture parameters that can be monitored on-line and 
have a direct link to the critical quality attributes of the cells are difficult to 
find as will be discussed below.  
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8.2.2. Improvements in on-line monitoring techniques for 
critical quality attributes of cells are required to make 
best use of control algorithms  
Based on concepts such as model-based (predictive) monitoring and control 
that are used in chemical plants and other process industries, automated 
control of dynamic systems has evolved enormously (Camacho and Bordons, 
2007). An example of model-based predictive monitoring can be found in 
Chapter 5 where a data-based model was able to link the on-line monitored 
feature variable (cell circularity) to a process decision (‘stop the enzymatic 
harvest reaction’) in real-time. Even better, the on-line monitoring and data-
analysis allowed to predict when to stop the process, while the process was 
still on-going (i.e. making the monitoring faster than real-time). This 
application is useful to quantitatively compare or optimise the incubation time 
for cell harvests in planar culture systems for different donors or different 
harvest solutions. However, similar approaches based on this on-line data-
based monitoring and control strategy pose tremendous potential if one would 
have access to on-line readouts of biomarkers that make up a biological 
signature of the cellular state and therefore enable the control of in vivo cell 
potency in vitro. 
However, the analysis of these type of biomarkers (if they are known for a 
specific application) require relatively complex techniques such as surface–
antigen phenotyping by flow cytometry (as described and used in Chapter 4 
and 6), or gene expression measurements by Real Time-PCR or microarrays. 
These are time consuming end-point analyses and can therefore not deliver 
the rate of data that is needed for active on-line control of the process quality. 
In other words, it is not necessarily a problem of measuring the critical quality 
attributes of the cells, the limiting factor for strictly controlled stem cell 
bioprocesses to date is the lack of non-invasive sensor systems with a 
measurement rate that allows on-line monitoring of the functional biomarkers. 
Fortunately, on-line does not necessarily mean that continuous measurements 
are required, but rather a measurements frequency that is faster (at minimum 
twice as fast) than the dynamics of the systems according to the Nyquist–
Shannon sampling theorem (Jerri, 1977) as illustrated in Figure 8.2.  
Overall discussion, future perspectives, and conclusions 147 
 
 
Figure 8.2: Illustration of the Nyquist–Shannon sampling theorem. 
Measuring dynamic data (dotted line) with a sample frequency (arrows) that is too low could 
result in perceived dynamics (solid line) that are very far away from reality. Image adapted 
from National Instruments Corporation (http://zone.ni.com/reference/en-XX/help/370592N-
01/digitizers/nyquist_theorem/). 
This means that certain (off-line) sampling methods might still provide 
sufficient data for process control, depending on the rate of change of the 
feature variable. This was for example shown by the off-line threshold-level 
control mechanism for the determination of the harvest time of the Quantum 
bioreactor in Chapter 6 that was based on manual lactate samples. Also 
Csaszar et al. (2012) developed an automated medium dilution strategy based 
on off-line ELISA read-outs on spent culture medium (via a Luminex 
platform) that was able to increase the expansion rate of hematopoietic stem 
cell cultures. A more elaborate strategy (from the controller point of view) 
was investigated during a master’s thesis project (Pauly, 2016) that was 
supervised by the author where off-line lactate samples were used in order to 
automatically refresh the medium in a perfusion bioreactor setup by 
controlling a pump (Figure 8.3A). To overcome the information gap caused 
by the off-line monitoring, a predictive data-based model was used to predict 
future lactate production values, based on which in turn an ‘on-line’ controller 
was able to contain the lactate concentration in the bioreactor within a certain 
range, ultimately providing a better controlled environment for cell growth 
(Figure 8.3B). A similar control strategy could be used for analytes that are 
currently impossible to measure on-line but that have a significant effect on 
the quality of the cells (e.g. expression level of a certain protein). 
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Figure 8.3:Setup and performance of lactate-based medium refreshment with a data-based 
model predictive control strategy. 
A) Perfusion bioreactor setup with the perfusion loop on the right side (pump 2) and the lactate-
based controller loop for  medium refreshment on the left. B) Situation at the end of day 17 in 
culture where after an initial learning period for the data-based model the lactate concentration 
within the bioreactor circuit is automatically controlled within a certain range by optimising the 
medium refreshments. The green line indicates the expected evolution of the lactate 
concentration over the next 3 days. 
Since these type of off-line measurements often still require significant 
manual sample preparation and time consuming handling, they are difficult to 
implement in cost-effective industrialised cell-based processes. However, the 
development of sensor hardware is continuously progressing and efforts are 
made to develop novel solutions for the on-line monitoring of biomarkers 
(Mandenius and Gustavsson, 2015; Polizzi and Kontoravdi, 2014; Zhao et al., 
2015). Promising non-destructive on-line sensing approaches are the 
miniaturisation of ELISA or flow cytometry techniques in combination with 
microfluidic platforms and automated sampling (Eggeling et al., 2015), or 
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high-throughput use of mass spectrometry for the analysis of metabolic 
parameters in spent culture medium, i.e. exo-metabolomics (Kell et al., 2005).  
It could be stated that having an on-line non-invasive and cost-efficient 
process read-out that is directly linked to the in vivo functionality of the cells 
is the holy grail in cell-based therapy manufacturing. It is not only critical in 
terms of optimising bioprocesses and to continuously assure the quality of the 
product during its life cycle (from development phase to the clinical 
production and potential post-approval changes), ultimately a properly 
controlled production system significantly facilitates regulatory approval.  
8.2.3. Large-scale cell expansion and product safety 
While the scientific literature is rife with reports on mouse cells that 
accumulate chromosomal instabilities during long term in vitro culture that 
lead to malignant transformation of these cells (Miura et al., 2006), there are 
conflicting reports on the spontaneous malignant transformation of human 
cells that are cultured in vitro (Bernardo et al., 2007; Røsland et al., 2009). 
However, since DNA damage might occur at any time, these transformations 
are a potential risk for any cell therapy. The risk is higher for embryonic stem 
cells and induced pluripotent (iPS) cells since these have a close to unlimited 
expansion capability and their pluripotency allows them to differentiate in any 
type of tissue. For the more adult multipotent mesenchymal stem cells 
(MSCs) or progenitor cells the risk is inherently lower since they generally 
undergo replicative senescence due to telomere shortening.  
After the first reported (Rubio et al., 2005) human mesenchymal cells that 
allegedly underwent spontaneous transformation during in vitro culture was 
retracted due to cross-contamination with a cancerous cell line (followed by 
another similar case (Torsvik et al., 2010)), there are still a couple of studies 
that seem to confirm the accumulation of DNA damage during culture. For 
example a large scale study (4 cell therapy facilities during 2 multicentre 
clinical trials) on human bone marrow derived MSCs, detected certain (donor 
dependent) chromosomal changes that, in this case, only induced cell 
senescence without malignant transformation (Tarte et al., 2010). Prockop et 
al. (2010) claim that “clinical experience so far shows that if the cells [MSCs] 
are harvested for therapy well before the cultures reach senescence, there is a 
very low probability of malignant transformation and tumour formation in 
patients”. This claim seems to be confirmed by Casiraghi et al. (2013) who 
reviewed the reported side effects (including the development of 
hematopoietic or solid tumours) after MSC administration in more than 700 
patients in clinical studies.  
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Disregarding the low chance of occurrence, in any case it has to be considered 
whether the very high number of population doublings are really beneficial 
for a certain therapy and whether it is the best strategy to push the cell 
senescence further and further. On the other hand, spontaneous malignant 
transformation of MSCs might naturally occur in the human body (Houghton 
et al., 2004) and this raises the question whether current detection assays are 
sensitive enough to detect transformations in culture above the natural 
baseline of transformations (especially if the effect of immunosuppressive 
treatment, as used in allogeneic cell therapies, on cancer is taken into 
consideration (Grulich et al., 2007)). With more sensitive detection assays it 
might be possible that new effects of extensive in vitro culture of cells 
becomes apparent. For example, only very recently an age related 
accumulation of mitochondrial genome mutations was found in in vitro 
expanded IPS cells that influenced the cell metabolism (Kang et al., 2016). 
While the risk of transformations is low for human MSCs (Prockop, 2010) 
and the benefits of most cell-based treatments far outweigh this risk, it is 
advisable to remain vigilant for unwanted cell transformations until more 
sensitive screening technology is able to provide a definitive proof of the 
absence of very small numbers of potentially malignant cells. 
8.2.4. Reduction of Cost Of Goods remains crucial for 
widespread clinical translation of cell-based therapies 
Prochymal, the mesenchymal stem cell based treatment for Graft-versus-Host 
disease as used for the introduced in Chapter 1 costs around $200K for a 
course of therapy in a paediatric setting (SCSI, 2013). This would roughly 
compare to the price of an allogeneic bone marrow transplant (including costs 
of care) (Majhail et al., 2013). Although expensive, an even more mind-
boggling price is the $1 million treatment with Glybera, a gene therapy 
developed by UniQure that uses insect cell-based manufacturing of the vector 
for the treatment of a rare disease called lipoprotein lipase deficiency, and 
which is approved by the EMA for clinical use in Europe. While such high 
prices are currently the exception, the challenging production processes and 
regulatory requirements for cell-based products lead to significant price raises 
compared to more standard treatments. Therefore, for every product that is 
being developed, the question is raised whether its costs are justifiable 
compared to the clinical added value for the patient. Especially for non-life 
threatening diseases, the cost-effectiveness of a cell-based product compared 
to a generally much cheaper standard treatment should be carefully examined. 
While trying to avoid the discussion on setting a price on a person’s life, or on 
the quality thereof, it is clear that with some of these prices widespread 
clinical translation of cell therapies is difficult to support, especially in the 
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current economic environment where large pressure is exerted to reduce 
healthcare costs. 
Particularly for autologous therapies, where the production and quality control 
costs cannot be spread over a large number of patients/clients, a significant 
reduction of the COGS (cost of goods sold) is of primary importance before a 
commercially viable therapy will be able to gain widespread clinical 
application. There are quite some examples for autologous cell-based 
therapies that struggle to translate the positive clinical results to the 
company’s bottom line (e.g. Dendreon’s Provenge). This motivates 
manufacturers of cell-based products to focus on reduction of production costs 
by introducing novel production technologies for process optimisation and 
automation for stand-alone point-of-care production of cell-based therapies 
(Rathore and Singh, 2015). A thorough evaluation of potential strategies for 
scale-up of autologous cell expansion early on in the development phase, as 
done here in Chapter 4 and 6, is a first step towards cost-efficiency. Since 
recently, strategies able to increase the cell potency are explored (Stegen et 
al., 2016), for example by cell priming steps or cell pre-selection by magnetic-
activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS). 
While these strategies are still expensive and currently still in the exploratory 
phase, these efforts might later lead to significantly more potent cells for 
autologous therapies, therefore requiring lower number of cells, and 
subsequently reducing the overall cost of the therapy. 
For allogeneic therapies the economies of scale should be exploited to a 
maximum in order to drive down the production costs. Here the challenge is 
to manufacture reproducible, clinical-grade stem cells in mass quantities for a 
reasonable cost. Process harmonisation and standardisation will eventually 
become important considerations. Again here the allogeneic use of IPSC 
technology, under the form of a master cell bank with cell lines that are able 
to differentiate to multiple cell types guided by standardised protocols, hold 
great potential (Rao and Atala, 2016), and is since recently commercially 
exploited by companies such as Cynata therapeutics (cynata.com) and an 
initiative of Lonza and the National Institutes for Health (National Institutes 
of Health, 2016). 
 
 Overall conclusion 8.3.
In the introductory chapter, two challenges were identified that hamper the 
translation of promising lab-scale strategies for cell-based treatments to 
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commercial cell therapies. First, for large-scale cultures, the gold standard 
flask-based cell expansion process should be translated to a more integrated 
bioprocess design that is able to produce cells for therapeutic products in a 
cost-effective and robust way. Secondly, novel monitoring strategies are 
needed that allow to control these bioprocesses in order to reduce process 
variability and improve in vivo potential of the cells. 
This work attempted to contribute to this scientific challenge by pursuing 
three different but closely related aims (see Figure 8.4 below for an 
overview): 
The first objective was to provide a framework for benchmarking cell 
expansion processes, so that during the development of integrated bioprocess 
designs an objective measure could be used when comparing different 
expansion processes. In Chapter 3 an interactive tool and metrics for such 
process comparison were presented that increases insight in process 
development. 
The second objective was to translate the standard flask-based 
expansion process for the autologous Prometheus ATMP to an automated and 
controlled bioreactor-based process. In this way the manual manipulations 
required for the standard flask-based culture, which are associated with an 
expensive labour force and potential introduction of operator errors and 
contamination, can be reduced. Both Chapter 4 and Chapter 6 introduce a 
comprehensive bioreactor-based cell expansion strategy for which the quality 
of the resulting cells complied with a basic reference quality profile consisting 
of both in vivo and in vitro read-outs. 
The third objective was to incorporate cost-effective data-based 
monitoring and control strategies in the large-scale production processes in 
order to deliver cells with a more robust quality profile and assure process 
comparability. Given the inherent biological variability of cell-based 
processes it is critical to be able to keep track of the critical quality attributes 
of the cells during culture in order to assure the compliance to the reference 
quality profile. The data-based approach used here, in which data from regular 
process read-outs were used to infer knowledge on the critical attributes, is 
compelling as often there are no on-line measurements available on these 
parameters. Additionally the on-line model-based control approach is able to 
take into account the time-varying donor specific cell characteristics, thus 
potentially offering a tool to deal with donor-to-donor variability. Chapter 4, 
5, 6 and 7 provide monitoring tools for cell number determination, cell 
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detachment during harvest and donor-induced variability that allow to make 
informed process decisions, while Chapter 5 and Chapter 6 provide 
exploratory examples of how on-line control can ultimately result in a cell-
based products of higher quality. 
It is clear that the development of monitored and controlled cell expansion 
processes for cell-based therapies requires innovative insights from multiple 
disciplines. It involves a challenging mixture of fundamental biology, unique 
production technologies and the appropriate data analytics that all need to 
converge into one efficient process. While there are still hurdles remaining, 
significant progress is being made to enable the wide-spread clinical use of 
cell-based therapies. 
 
 
Figure 8.4: Schematic overview of the different aspects that were addressed and the obtained 
results during this PhD project. 
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